<SEC-DOCUMENT>0001213900-17-007275.txt : 20170707
<SEC-HEADER>0001213900-17-007275.hdr.sgml : 20170707
<ACCEPTANCE-DATETIME>20170707165330
ACCESSION NUMBER:		0001213900-17-007275
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		50
CONFORMED PERIOD OF REPORT:	20170331
FILED AS OF DATE:		20170707
DATE AS OF CHANGE:		20170707

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immudyne, Inc.
		CENTRAL INDEX KEY:			0000948320
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				760238453
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-184487
		FILM NUMBER:		17955701

	BUSINESS ADDRESS:	
		STREET 1:		50 SPRING MEADOW ROAD
		CITY:			MT. KISCO
		STATE:			NY
		ZIP:			10549
		BUSINESS PHONE:		(914) 244-1777

	MAIL ADDRESS:	
		STREET 1:		50 SPRING MEADOW ROAD
		CITY:			MT. KISCO
		STATE:			NY
		ZIP:			10549

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IMMUDYNE INC
		DATE OF NAME CHANGE:	19950720
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0317_immudyneinc.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
10-Q</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#9746; <B>QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For the quarterly period ended March 31, 2017</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>OR</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
file number: 333-184487</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMUDYNE,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>76-0238453</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of <BR>
    incorporation or organization)</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer <BR>
    Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>50
    Spring Meadow Rd.</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mount
    Kisco, NY</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10549</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal
    executive offices)</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(914)
244-1777</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Registrant&rsquo;s telephone number, including area code)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the last 90 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">YES&nbsp;
&#9746;&nbsp;&nbsp; NO&nbsp; &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">YES&nbsp;
&#9746;&nbsp;&nbsp; NO&nbsp; &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large&nbsp;accelerated&nbsp;filer&nbsp;
    </FONT></TD>
    <TD STYLE="width: 28%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated&nbsp;filer&nbsp;</FONT></TD>
    <TD STYLE="width: 26%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated&nbsp;filer&nbsp;&nbsp;&nbsp;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&#9744;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller&nbsp;reporting&nbsp;company&nbsp; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(do&nbsp;not&nbsp;check&nbsp;if&nbsp;a&nbsp;smaller
    reporting&nbsp;company)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&#9746;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">YES&nbsp;
&#9744;&nbsp;&nbsp; NO&nbsp; &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,543,373
shares of common stock outstanding as of July 5, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 85%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
    about Forward-Looking Statements</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
    I. FINANCIAL INFORMATION</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s
    Discussion and Analysis of Financial Condition and Results of Operations</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and
    Qualitative Disclosures about Market Risk</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">25</TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
    II. OTHER INFORMATION</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">26</TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered Sales
    of Equity Securities and Use of Proceeds</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">26</TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults Upon Senior
    Securities</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">26</TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">26</TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">26</TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">26</TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    Index</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE&nbsp;ABOUT
FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), and Section 21E of the Securities Exchange Act of 1934, as amended, (the &ldquo;Exchange Act&rdquo;) regarding our
company that include, but are not limited to, projections of earnings, revenue or other financial items; statements of the plans,
strategies and objectives of management for future operations; statements concerning proposed new products, services or developments;
statements regarding future economic conditions or performance; statements of belief; and statements of assumptions underlying
any of the foregoing. These forward-looking statements are based on our current expectations, estimates and projections about
our industry, management&rsquo;s beliefs and certain assumptions made by us. Words such as &ldquo;anticipates,&rdquo; &ldquo;expects,&rdquo;
&ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo;
&ldquo;hopes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;should,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;with a view
to&rdquo; and variations of these words or similar expressions are intended to identify forward-looking statements. These forward-looking
statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult
to predict. Although we believe that our expectations expressed in these forward-looking statements are reasonable, our expectations
may later be found to be incorrect. Our actual results could be materially different from our expectations. Important risks and
factors that could cause our actual results to be materially different from our expectations are set forth in &ldquo;Risk Factors,&rdquo;
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; &ldquo;Our Business&rdquo;
and other sections in this report. Other sections of this report include additional factors that could adversely impact our business
and financial performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, information in this report concerning economic conditions and our industry is based on information from independent
industry analysts and publications, as well as our estimates. Except where otherwise noted, our estimates are derived from publicly
available information released by third party sources, as well as data from our internal research, and are based on such data
and our knowledge of our industry, which we believe to be reasonable. Unless otherwise indicated, none of the independent industry
publication market data cited in this report was prepared on our or our affiliates&rsquo; behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements made in this report are based only on events or information as of the date on which the statements
are made in this report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made
or to reflect the occurrence of unanticipated events. You should read this report and the documents we refer to in this report
and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially
different from what we expect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
information on the various risks and uncertainties potentially affecting our operating results are discussed in this report and
other documents we file with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). We undertake no obligation to revise
or update publicly any forward-looking statements for any reason, except as required by law. Given these risks and uncertainties,
readers are cautioned not to place undue reliance on these forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this report, &ldquo;Immudyne,&rdquo; &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; and similar terms refer
to Immudyne Inc., unless the context indicates otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
I. FINANCIAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne,
    Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Balance Sheets</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2016</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">(unaudited)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-size: 10pt; font-weight: bold">ASSETS</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Current Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-size: 10pt; padding-left: 9pt">Cash</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">381,056</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">182,561</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Trade accounts receivable, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">555,708</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">444,743</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Other receivables</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,250</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Inventory, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">136,938</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">160,270</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 4pt; padding-left: 18pt">Total Current Assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">1,073,702</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">789,824</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Accounts payable and accrued expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">562,220</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">752,930</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Derivative liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,809,890</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">192,254</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Convertible notes payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">100,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Notes payable, net of discount</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">25,000</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">106,365</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 18pt">Total Current Liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">2,397,110</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">1,151,549</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Immudyne, Inc. Stockholders&rsquo; Equity (Deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -10pt; padding-left: 18pt">Common stock, $0.01 par value; 50,000,000 shares authorized, 40,543,373 and 35,570,157 shares issued, 40,205,573 and 35,245,157 outstanding as of March 31, 2017 and&nbsp;December 31, 2016, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">405,433</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">355,701</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Additional paid-in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,363,160</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,070,064</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Accumulated (deficit)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(10,738,687</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(9,693,882</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(970,094</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(268,117</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Treasury stock, 337,800 and 325,000 shares, at cost</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(90,204</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(87,053</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 18pt">Total Immudyne, Inc. Stockholders&rsquo; (Deficit)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,060,298</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(355,170</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Non-controlling interest</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(263,110</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(6,555</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 18pt">Total Stockholders&rsquo; (Deficit)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(1,323,408</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(361,725</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 4pt; padding-left: 18pt">Total Liabilities and Stockholders&rsquo; (Deficit)</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">1,073,702</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">789,824</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne,
    Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Operations</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <BR> March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-size: 10pt; font-weight: bold; text-align: left">Net Sales</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">424,462</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">1,641,028</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">Cost of Sales</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">203,356</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">1,337,942</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Gross Profit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">221,106</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">303,086</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Compensation and related expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">358,488</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">240,455</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Professional fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">99,632</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">69,315</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Marketing expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,800</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">127,172</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">98,412</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Total operating expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">596,092</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">408,182</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Operating (Loss)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(374,986</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(105,096</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Change in fair value of derivative liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(48,192</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Interest (expense)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(649,357</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(3,063</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Net (Loss)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,072,535</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(108,159</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Net (loss) attributable to noncontrolling interests</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(27,730</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(46,110</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 4pt">Net (loss) attributable to Immudyne, Inc.</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">(1,044,805</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">(62,049</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 4pt">Basic and diluted (loss) per share attributable to Immudyne, Inc.</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">(0.03</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Average number of common shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt">Basic</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">37,581,987</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">32,010,375</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt">Diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">37,581,987</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">32,010,375</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne,
    Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statement of Stockholders&rsquo; Equity (Deficit)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Three Months Ended March 31, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="22" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immudyne,
    Inc.</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paid-in</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasury</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noncontrolling</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Deficit)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interest</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 20%; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2016</FONT></TD><TD STYLE="width: 1%; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,570,157</FONT></TD><TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">355,701</FONT></TD><TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,070,064</FONT></TD><TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,693,882</FONT></TD><TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 1%; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(87,053</FONT></TD><TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 1%; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(355,170</FONT></TD><TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 1%; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,555</FONT></TD><TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 1%; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(361,725</FONT></TD><TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock for services</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,667</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,667</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,667</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale
    of common stock and warrants</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,817,156</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,171</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">619,773</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">647,944</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">647,944</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
    of non-controlling interest equity for shares and warrants</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,183,490</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,835</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">260,368</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,203</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(272,203</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
    of note payable</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">755,179</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,552</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">737,862</FONT></P>


</TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">745,414</FONT></P>


</TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">745,414</FONT></P>


</TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock in relation to debt offering</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">217,391</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,174</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,348</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,522</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,522</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase
    of treasury stock</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,151</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,151</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,151</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of stock options for services</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">113,522</FONT></P>


</TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">113,522</FONT></P>


</TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">113,522</FONT></P>


</TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
    in subsidiary by noncontrolling interest, net of distributions</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,378</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,378</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassification
    of options, warrants and other contracts to derivative liabilities upon issuance</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,569,444</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,569,444</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,569,444</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: 0; padding-left: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    (loss)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,044,805</FONT></P>


</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,044,805</FONT></P>


</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27,730</FONT></P>


</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,072,535</FONT></P>


</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at March 31, 2017</FONT></TD><TD STYLE="padding-bottom: 4pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,543,373</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">405,433</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,363,160</FONT></P>


</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,738,687</FONT></P>


</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(90,204</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,060,298</FONT></P>


</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(263,110</FONT></P>


</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,323,408</FONT></P>


</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne,
    Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Cash Flows </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)
</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center">Three Months Ended</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid">March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-size: 10pt; text-align: left">Net (loss) attributable to Immudyne, Inc.</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">(1,044,805</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">(62,049</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Net (loss) attributable to noncontrolling interests</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(27,730</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(46,110</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Net (Loss)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,072,535</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(108,159</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Adjustments to reconcile net (loss) to net cash (used) by operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Change in fair value of derivative liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">48,192</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Bad debt recovery</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(38,027</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Amortization of debt discount</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">81,558</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Loss on settlement of notes payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">553,222</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Stock compensation expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">190,188</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">38,867</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Changes in Assets and Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Trade accounts receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(72,938</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(144,902</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Other receivables</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,250</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">Inventory</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,332</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(77,443</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Accounts payable and accrued expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(188,498</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">169,482</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash (used) by operating activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(473,256</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(122,155</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Investment in subsidiary by noncontrolling interest, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">43,378</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">92,793</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Proceeds from notes payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">235,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Repayment of convertible note payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(100,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Repayment of notes payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(151,420</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Sale of common stock and warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">647,944</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Purchase of treasury stock</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(3,151</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 18pt">Net cash provided by financing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">671,751</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">92,793</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net increase (decrease) in cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">198,495</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(29,362</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Cash at beginning of the period</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">182,561</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">232,984</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 4pt">Cash at end of the period</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">381,056</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">203,622</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-decoration: underline; text-align: left">Supplemental Disclosure of Cash Flow Information</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 4pt">Cash paid during the period for interest</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">3,612</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">3,063</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 4pt">Issuance of company stock for notes and other payables</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">192,192</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 4pt">Conversion of equity invested in subsidiary to common stock and warrants</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">272,203</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 4pt">Reclassification of options, warrants and other contracts to derivative liabilities upon issuance</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">1,569,444</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Organization and Going Concern</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Immudyne, Inc. (the &ldquo;Company&rdquo;) is a Delaware
corporation established to develop, manufacture and sell natural immune support products containing the Company&rsquo;s proprietary
yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast that have been shown through testing
and analysis to support the immune system. The Company&rsquo;s products include once a day oral intake tablets and topical creams
and gels for skin application. The Company concentrates its sales and marketing efforts on healthcare professionals, distributors
for its all-natural raw material ingredient products and direct-to-consumer sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In 2015, the Company formed a joint venture domiciled in Puerto Rico, Innate Skincare, LLC (&ldquo;Innate&rdquo;).
Under the terms of the joint venture agreement, the Company held a 33.3% equity interest, and a 51% controlling voting interest,
in Innate. On January 20, 2016, Innate amended its limited liability company operating agreement and changed its legal name to
Immudyne PR LLC (&ldquo;Immudyne PR&rdquo;). On April 1, 2016, Immudyne PR further amended its operating agreement and restated
the Company&rsquo;s ownership and voting interest in Immudyne PR increasing its ownership to 78.1667% resulting in a charge to
noncontrolling interest and additional paid-in-capital of $91,612. Immudyne PR was formed to launch a complete skin care regime
formulated using strategic ingredients provided by the Company. In the second quarter of 2017, Immudyne PR expanded their product
line and launched their in-licensed patented hair loss shampoo and conditioner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company has funded operations in the past through
the sales of its products, issuance of common stock and through loans and advances from officers and directors. The Company&rsquo;s
continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers
and directors or the issuance of additional shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The accompanying financial statements have been prepared on the basis that the Company will continue as a
going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. At
March 31, 2017, the Company has an accumulated deficit approximating $10.7 million and has incurred negative cash flows from operations.
These conditions raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Based on the Company's cash balance at March 31, 2017, and projected cash needs for 2017, management estimates
that it will need to increase sales revenue and/or raise additional capital to cover operating and capital requirements for the
remainder of the 2017 year. Management will need to raise the additional needed funds through increased sales volume, issuing additional
shares of common stock or other equity securities, or obtaining debt financing. Although management has been successful to date
in raising necessary funding, there can be no assurance that sales revenue will substantially increase or that any required future
financing can be successfully completed on a timely basis, or on terms acceptable to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary of Significant Accounting Policies</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B><I>Principles of
Consolidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company evaluates the need to consolidate affiliates
based on standards set forth in ASC 810 Consolidation (&ldquo;ASC 810&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The consolidated financial statements include the accounts
of the Company and its majority owned subsidiary, Immudyne PR and variable interest entities (VIE&rsquo;s) in which the Company
has been determined to be the primary beneficiary. The non- controlling interest in Immudyne PR represents the 21.8333% equity
interest held by other members of the joint venture. All significant consolidated transactions and balances have been eliminated
in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"><B><I>Variable Interest Entities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company follows ASC 810-10-15 guidance with respect
to accounting for variable interest entities (each, a &ldquo;VIE&rdquo;). These entities do not have sufficient equity at risk
to finance their activities without additional subordinated financial support from other parties or whose equity investors lack
any of the characteristics of a controlling financial interest. A variable interest is an investment or other interest that will
absorb portions of a VIE&rsquo;s expected losses or receive portions of its expected residual returns and are contractual, ownership,
or pecuniary in nature and that change with changes in the fair value of the entity&rsquo;s net assets. A reporting entity is the
primary beneficiary of a VIE and must consolidate it when that party has a variable interest, or combination of variable interests,
that provides it with a controlling financial interest. A party is deemed to have a controlling financial interest if it meets
both of the power and losses/benefits criteria. The power criterion is the ability to direct the activities of the VIE that most
significantly impact its economic performance. The losses/benefits criterion is the obligation to absorb losses from, or right
to receive benefits from, the VIE that could potentially be significant to the VIE. The VIE model requires an ongoing reconsideration
of whether a reporting entity is the primary beneficiary of a VIE due to changes in facts and circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">As of March 31, 2017 and December 31, 2016, the Company
consolidated nine VIEs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Immudyne PR as the primary beneficiary of Ace Account Management LLC, Innerwell Skincare LLC, MCD Merchants
LLC, One Equity Research LLC, Inate Gems LLC, Retriever Health Products LLC, Spurs 5, LLC, Salus LLC and Huntley LLC which are
qualified as VIEs. The assets and liabilities and revenues and expenses of these VIEs included in the financial statements of Immudyne
PR and further included in the consolidated financial statements. As of March 31, 2017, the VIEs had assets of $19,421, liabilities
of $5,748, revenues of $981, and operating expenses of $953. As of December 31, 2016, the VIEs had assets of $10,306, liabilities
of $5,748. The assets and liabilities include balances due from and due to the subsidiaries of Immudyne PR. Any inter-company receivables
and payables are eliminated upon consolidation of the VIE with Immudyne PR and Immudyne, Inc. No assets were pledged or given as
collateral against any borrowings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company utilizes third party entities to provide
and increase credit card processing capacity and optimize corresponding rates and fees. A majority of these entities provide this
service as independent contractors in exchange for a one percent (1%) fee of the net revenues processed and collected by such
contractors from sales initiated by the Company. The VIEs consolidated in the Company&rsquo;s financial statements are primarily
contracted to provide credit card processing through one or more merchant banks. Upon receipt of funds by each VIE, the collection
of receipts less any returns, chargeback and other fees charged by such merchant bank is transferred to Immudyne PR.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
    of Significant Accounting Policies  (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company prepares its consolidated financial statements
in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management
include the determination of reserves for accounts receivable, returns and allowances, the accounting for derivatives, the valuation
of inventory and stockholders&rsquo; equity based transactions. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Derivative Liabilities</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Under ASC 815-40-05, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in
a Company&rsquo;s Own Stock, in the event the Company does not have a sufficient number of authorized and unissued shares of common
stock to satisfy obligations for stock options, warrants and other instruments potentially convertible into common stock, the fair
value of these instruments should be reported as a liability. Pursuant to the outstanding option, warrant and convertible debt
agreements, there is currently no effective registration statement covering the shares of common stock underlying these agreements,
which are currently subject to a cashless exercise whereby the holders, at their option, may surrender their options and warrants
to the company in exchange for shares of common stock. The number of shares of common stock into which an option or a warrant would
be exchangeable in such a cashless exercise depends on both the exercise price of the options or warrant and the market price of
the common stock, each at or near the time of exercise. Because both of these factors are variable, it is possible that the Company
could have insufficient authorized shares to satisfy a cashless exercise. In this scenario, if the Company were unable to obtain
shareholder approval to increase the number of authorized shares, the Company could be obligated to settle such a cashless exercise
with cash rather than by issuing shares of common stock. Further, ASC 815-40-05 requires that the Company record the potential
settlement obligation at each reporting date using the current estimated fair value of these contracts, with any changes in fair
value being recorded through our statement of operations. The Company will continue to report the potential settlement obligation
as a liability until such time as these contracts are exercised or expire or we are otherwise able to modify the warrant agreement
to remove the provisions which require this treatment. The Company also plans to amend its Articles of Incorporation in the third
quarter of 2017 to increase the number of shares of its authorized common stock after the approval by its shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Sequencing Policy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Under ASC 815-40-35, the Company
has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is
necessary pursuant to ASC 815 due to the Company&rsquo;s inability to demonstrate it has sufficient authorized shares, shares will
be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving
the first allocation of authorized but unissued shares, and all future instruments being classified as a derivative liability,
with the exception of instruments related to share-based compensation issued to employees or directors.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Inventory&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">At March 31, 2017 and December
31, 2016, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic products. Inventory is maintained
in the Company&rsquo;s leased Kentucky warehouse and third party warehouses in Pennsylvania and Louisiana.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Inventory is valued at the lower of cost or market
with cost determined on a first-in, first-out (&ldquo;FIFO&rdquo;) basis. Management compares the cost of inventory with the net
realizable value and an allowance is made for writing down inventory to market value, if lower. At March 31, 2017 and December
31, 2016, the Company recorded an inventory reserve in the amount of $20,000. Inventory consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">March&nbsp;31,<BR> 2017</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2016</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36pt; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Raw materials</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">29,577</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">38,460</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Finished products</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">107,361</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">121,810</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">136,938</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">160,270</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary of Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company&rsquo;s policy is to record revenue as
earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably
assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer,
and for sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped, but in
limited cases if title does not pass until the product reaches the customer&rsquo;s delivery site, then recognition of revenue
is deferred until that time. Delivery is considered to have occurred when title and risk of loss have transferred to the customer.
Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company
accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates
approximated $38,000 and $517,000 in the three months ended March 31, 2017 and 2016, respectively. There are no formal sales incentives
offered to any of the Company&rsquo;s customers. Volume discounts may be offered from time to time to customers purchasing large
quantities on a per transaction basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Revenue for the three months ended March 31, 2017 consisted
of nutraceutical and cosmetic additives ($256,563) and finished cosmetic products ($167,899). Revenue for the three months ended
March 31, 2016 consists of nutraceutical and cosmetic additives ($265,910) and finished cosmetic products ($1,375,118).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Accounts receivable</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Accounts receivable are carried at original invoice
amount less an estimate made for holdbacks and doubtful receivables based on a review of all outstanding amounts. Management determines
the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&rsquo;s
financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection
is uncertain. Customers&rsquo; accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts
receivable previously written off are recorded as income when received. At March 31, 2017 and December 31, 2016 the accounts receivable
reserve was approximately $37,800 for both periods. As of March 31, 2017 and December 31, 2016, the reserve for sales returns and
allowances was approximately $12,500 and $50,500, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary of Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 36pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Segments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The guidance for disclosures about segments of an enterprise
requires that a public business enterprise report financial and descriptive information about its operating segments. Generally,
financial information is required to be reported on the basis used internally for evaluating segment performance and resource allocation.
The Company manages its operations in two reportable segments for purposes of assessing performance and making operating decisions.
Revenue is generated predominately in the United States, and all significant assets are held in the United States, or United States
territories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The accounting policies of the reportable segments
are the same as those described in the summary of significant accounting policies. The Company allocates resources and evaluates
the performance of segments based on income or loss from operations, excluding interest, corporate expenses and other income (expenses).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">A summary of the company&rsquo;s
reportable segments is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Total assets:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">March&nbsp;31,<BR> 2017</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2016</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36pt; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Nutraceutical and Cosmetic Additives</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,350,785</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">556,234</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Finished Cosmetic Products</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">385,345</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">422,288</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Eliminations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(662,428</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(188,698</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,073,702</TD><TD STYLE="padding-bottom: 4pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">789,824</TD><TD STYLE="padding-bottom: 4pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Three Months ended</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">March&nbsp;31, 2017</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">March&nbsp;31, 2016</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Net sales by segment:</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36pt; background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">Nutraceutical and Cosmetic Additives</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">256,563</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">285,160</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">Finished Cosmetic Products</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">167,899</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,375,118</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">Eliminations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(19,250</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 4pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">424,462</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,641,028</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Net (loss) income by segment:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">Nutraceutical and Cosmetic Additives</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">26,807</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">84,777</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">Finished Cosmetic Products</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(127,007</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(69,165</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Other unallocated amounts:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">Corporate expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(274,786</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(120,708</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other income (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(697,549</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,063</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Net (loss)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,072,535</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(108,159</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary of Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company files Corporate Federal and State tax returns,
while Immudyne PR, which was formed as a limited liability corporation, files a separate tax return with any tax liabilities or
benefits passing through to its members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company records current and deferred taxes in accordance
with Accounting Standards Codification (ASC) 740, &ldquo;Accounting for Income Taxes.&rdquo; This ASC requires recognition of deferred
tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they
are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected
to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to
be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a
history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold
and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return.
Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if
it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the
taxing authorities, based on the technical merits of the position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company&rsquo;s tax returns for all years since
December 31, 2013, remain open to taxing authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company follows the provisions of ASC 718, &ldquo;Share-Based
Payment&rdquo;. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized
over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option
pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents
the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility
of the Company&rsquo;s shares using weekly price observations over an observation period that approximates the expected life of
the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar
to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation
was zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Many of the assumptions require significant judgment
and any changes could have a material impact in the determination of stock-based compensation expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<BR>
<B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary of Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Earnings (Loss) Per Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Basic earnings (loss) per common share is based on
the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are
included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings
per share when the effects would be antidilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Common stock equivalents comprising shares underlying
18,295,335 options and warrants for the three months ended March 31, 2017 have not been included in the loss per share calculation
as the effects are anti-dilutive. Common stock equivalents comprising shares underlying 12,525,273 options and warrants for the
three months ended March 31, 2016 have not been included in the loss per share calculations as the effects are anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Recent Accounting Pronouncements</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In May 2017, the FASB issued ASU 2017-09, Compensation
- Stock Compensation (Topic 718): Scope of Modification Accounting. The new standard provides guidance about which changes to the
terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement
is effective for annual reporting periods beginning after December 15, 2017 but early adoption is permitted. The Company is currently
evaluating the impact of adopting this guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In August 2016, the FASB issued ASU No. 2016-15, Statement
of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (&ldquo;ASU 2016-15&rdquo;). ASU 2016-15 addresses
eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash
payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items:
(1) debt prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration
payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement
of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests
in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal
years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. Early adoption
is permitted, including adoption in an interim period. The Company is currently evaluating the impact of adoption of ASU 2016-15.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In February 2016, a pronouncement was issued that
creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets
to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless
of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement,
and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating
lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and
uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December
15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be
applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement
on its consolidated financial statements. At this time, the adoption of this pronouncement is not expected to have a material
impact on the Company&rsquo;s consolidated financial statements or related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary of Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Recent Accounting Pronouncements
(continued)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In May 2014, the Financial Accounting Standards Board (&quot;FASB&quot;) issued accounting guidance, &quot;Revenue
from Contracts with Customers.&quot; The core principle of the new standard is for companies to recognize revenue to depict the
transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects
to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue,
provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract
modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim
periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter
of fiscal year 2018. The Company does not expect it to have a material effect on the Company's consolidated financial condition,
results of operations, and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">All other accounting standards that have been issued
or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated
financial statements upon adoption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Noncontrolling Interests</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company accounts for its less than 100% interest
in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as
a component of equity on its consolidated balance sheet and reports the noncontrolling interest&rsquo;s share of the Immudyne PR
net loss attributable to noncontrolling interests in the consolidated statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"><B><I>Consolidation of Variable Interest Entities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In accordance with ASC 810-10-25-37 and as amended
by ASU 2009-17, the Company determines whether any legal entity in which the Company becomes involved is a VIE and subject to consolidation.
The Company conducts an assessment on an ongoing basis for each VIE including (1) the power to direct activities of the VIE that
most significantly impact the VIE&rsquo;s economic performance, and (2) the obligation to absorb losses or right to receive benefits
from the VIE that could potentially be significant to the VIE. As a result, the Company determined that nine (9) entities were
VIEs and subject to consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary of Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Concentration of Credit
Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company grants credit in the normal course of business
to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce
credit risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">The Company monitors its positions
with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in
various operating accounts in excess of federally insured limits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">One customer in the nutraceutical and cosmetic additives division accounted for 59% and 16% of consolidated
sales for the three months ended March 31, 2017 and 2016, respectively. This customer also accounted for 45% and 54% of accounts
receivable at March 31, 2017 and December 31, 2016, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">In the finished cosmetic products
division, two credit card processors accounted for 42% and 35% of accounts receivable at March 31, 2017. In the finished cosmetic
products division, two credit card processors accounted for 35% and 32% of accounts receivable at December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes Payable</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In November 2015, the Company borrowed $100,000 from
a commercial lender. The loan incurred interest at 11% and with a maturity date of November 1, 2016. In October 2016, the Company
repaid the entire principal balance. Interest expense related to this loan for the period ended March 31, 2016 amounted to $3,063.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In the third quarter of 2016 the Company commenced an offering pursuant to which it offered 11% subordinated
promissory notes in fifty thousand ($50,000) dollar increments combined with 62,500 shares of the Company&rsquo;s Common Stock
for a maximum offering amount of $200,000 (the &ldquo;Offering&rdquo;). In August and September 2016, the Company sold promissory
notes totaling $150,000 to three unrelated individuals. Two of the promissory notes totaling $100,000 were payable in February
2017 and one promissory note for $50,000 was payable in March 2017. In October 2016, the Company sold promissory notes totaling
$50,000 to two unrelated individuals. These promissory notes are payable in October 2017. In connection with these promissory notes
sold, pursuant to the Offering, the Company issued 250,000 shares of common stock valued at $58,750 which was recorded as a debt
discount and will be amortized over the term of these notes. Amortization of the debt discounts for the period ended March 31,
2017 was $25,035. During 2016, the Company repaid $68,600 of the principal balance. During 2017, the Company repaid $81,420 of
the principal balance and converted the remaining balance of $49,980 into 196,000 shares of common stock and 98,000 warrants. The
fair market value of the shares and warrants issued upon conversion was determined to be $179,384, of which $129,404 was included
in interest expense as loss on settlement of notes payable. Interest expense related to these notes for the three months ended
March 31, 2017 amounted to $131,117.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes Payable (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In December 2016, the Company borrowed $100,000 from
an officer and issued a convertible promissory note with a maturity date of February 28, 2017. The loan incurs no interest. This
note is convertible if not repaid by the maturity date at a conversion price of $0.23 per Unit. Each Unit shall consist of one
share of the Company&rsquo;s common stock and one three-year common-stock warrant to purchase one-half of one share of the Company&rsquo;s
common stock with an exercise price of $0.40 per share. In March 2017, the Company repaid the entire outstanding balance of this
note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In January 2017, the Company borrowed $200,000 and issued a promissory note with a 5% original issue discount
for a total principal amount of $210,000. The loan incurs 11% interest per annum and matures in various tranches from February
2017 through April 2017. In addition, the Company issued 217,391 shares of common stock related to this note. In February 2017,
the Company repaid $70,000 of the principal balance of this note. In March 2017, the Company converted the remaining $140,000 of
the principal balance of this note and accrued interest of $2,212 in exchange for 559,179 shares of common stock and 304,348 warrants.
The fair market value of the shares and warrants issued upon conversion was determined to be $566,030, of which $423,818 was included
in interest expense as loss on settlement of notes payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In February 2017, the Company borrowed $25,000 from
an American Express working capital line with 60 days maturity. The interest for this loan is a flat fee of $250. As of March 31,
2017, there were no available borrowings under the working capital line.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Interest expense related to loans from officers, directors
and other related individuals amounted to $1,713 and $312 for the three months ended March 31, 2017 and 2016, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Total interest expense on notes payable, inclusive of amortization of debt discount of $91,556 and $-0-, amounted
to $649,357 and $3,063 for the three months ended March 31, 2017 and 2016, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income Taxes</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company is not expected to have taxable income
in 2017 and incurred a loss for the year ended December 31, 2016 and accordingly, no provision for federal income tax has been
made in the accompanying financial statements. At March 31, 2017, the Company had available net operating loss carryforwards of
approximately $4,294,800, expiring during various years through 2037.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">A summary of the deferred tax
asset using an approximate 34% tax rate is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 36pt; background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-size: 10pt">Net operating loss</FONT></TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; background-color: #CCEEFF; text-align: right"><FONT STYLE="font-size: 10pt">1,699,000</FONT></TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Accounts receivable reserves</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-size: 10pt">Inventory reserves</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF; text-align: right"><FONT STYLE="font-size: 10pt">7,000</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Stock compensation</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">229,000</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-size: 10pt">Net deferred tax asset</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF; text-align: right"><FONT STYLE="font-size: 10pt">1,952,000</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Valuation allowance</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,952,000</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 4pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; background-color: #CCEEFF"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; background-color: #CCEEFF; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The net operating loss carryforwards could be subject
to limitation in any given year in the event of a change in ownership as defined by IRC Section 382.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The difference between the statutory and the effective
tax rate is primarily due to a change in valuation allowance on deferred taxes, as the Company has fully reserved the deferred
tax asset resulting from available net operating loss carryforwards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholders&rsquo; Equity</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">On April 1, 2016, the Company entered into two agreements with two consultants to provide services over a
nine-month period in exchange for 2,300,000 shares of common stock. The Company calculated a fair value of $690,000 based on the
market price of the shares on the date of the agreements. During the third quarter of 2016, the Company and the consultants renegotiated
the agreements by extending the service requirement to December 31, 2017. For the period ended March 31, 2017, the Company has
recognized expense of $76,667 in connection with these agreements. As of March 31, 2017 and December 31, 2016, the unamortized
portion of these service agreements are $230,000 and $306,667, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">During 2016, the Company purchased 325,000 shares of
outstanding Company common stock through an exchange for a price per share of $0.23 to $0.29. During 2017, the Company purchased
an additional 12,800 shares of outstanding Company common stock for a price per share of $0.24 to $0.26. As of the March 31, 2017,
a total of 337,800 shares are being held by the Company valued at cost is $90,204 and are included in treasury stock in the consolidated
balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In January 2017, the Company issued 1,183,490 shares
of common stock pursuant to a conversion of Immudyne PR equity contributions of $272,203 into equity of Immudyne, Inc. by the noncontrolling
interest.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In January 2017, the Company issued 217,391 shares
of common stock in relation to the remaining outstanding principal balance on the $210,000 note payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In the first quarter of 2017, the Company commenced
an offering to sell up to 4,000,000 shares of common stock at a price of $0.23 per share and warrants to purchase up to 2,000,000
shares of common stock excisable any time prior to the secondary anniversary of the issuance. The warrants are paired with the
stock on the basis of one warrant for every two shares of stock purchased. During the first quarter of 2017, the Company received
subscriptions in the amount of 2,817,156 shares and issued 1,408,578 warrants and proceeds in the amount of $647,944.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In March 2017, the Company issued 755,179 shares of common stock for the conversion of the outstanding balance
of three notes payable totaling $499,802 (see Note 3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholders&rsquo; Equity (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Noncontrolling Interest</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">On April 1, 2016, the Company increased its ownership
in Immudyne PR to 78.1667% decreasing the minority interest from 66.7% to 21.8333% resulting in a charge to noncontrolling interest
and additional paid-in-capital of $91,612.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">For the three months ended March 31, 2017 and 2016,
the net loss of Immudyne PR attributed to the noncontrolling interest amounted to $27,730 and $46,110, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"><B><I>Service-Based Stock Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In May 2016, the Company issued 175,000 service-based
options valued at $40,829 to two consultants at exercise prices of $0.20 per share. The options are fully vested and expire in
10 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In July 2016, the Company issued 50,000 service-based
options valued at $12,397 to a consultant with an exercise price of $0.20 per share. The options are fully vested and expire in
10 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In November 2016, the Company issued 50,000 service-based
options valued at $9,980 to a consultant with an exercise price of $0.50 per share. The options are fully vested and expire in
2 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In February 2017, the Company issued 500,000 service-based options valued at $113,522 to a director with an
exercise price of $0.20 per share. The options are fully vested and expire in 10 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Accordingly, stock based compensation for the periods ended March 31, 2017 and 2016 included $113,522 and
$-0-, respectively, related to such service-based stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">A summary of the outstanding service-based
options are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36pt; background-color: White">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2016</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,700,273</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">500,000</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at March 31, 2017</FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,200,273</FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">All outstanding options are exercisable and have a
cashless exercise provision, and certain options provide for accelerated vesting provisions and modifications, as defined, if the
Company is sold or acquired. The intrinsic value of service based options outstanding and exercisable at March 31, 2017 and December
31, 2016 amounted to $3,261,859 and $704,794, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholders&rsquo; Equity (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Service-Based Stock Options
(continued)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The significant assumptions used to determine the fair
values of options issued, using the Black-Scholes option-pricing model are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white; width: 48px">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Significant assumptions:</U></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate at grant date</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="background-color: #CCEEFF; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.49</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected stock price volatility</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">216.7</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend payout</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="background-color: #CCEEFF; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected option life-years</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">years</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average grant date fair value</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="background-color: #CCEEFF; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$0.24</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeiture rate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">The following is a summary of
outstanding service-based options at March 31, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Remaining Contractual Life</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 48px; background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.10</FONT></TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="width: 9%; background-color: #CCEEFF; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,380,273</FONT></TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 9%; background-color: #CCEEFF; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 year</FONT></TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.20 - $0.25</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,620,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.40 </FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; background-color: #CCEEFF; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,200,000</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF; text-align: center">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,200,273</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Performance-Based Stock
Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"><I><U>Vested</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company granted performance-based options to purchase
2,925,000 shares of common stock at exercise prices of $0.40. The options expire at various dates between 2021 and 2026 and are
exercisable upon the Company achieving annual sales revenue of $5,000,000. &nbsp;During the year ended December 31, 2016, the Company
cancelled 287,500 of these service-based options issued to two consultants, valued at $12,457.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The fair value of the vested performance-based options
aggregated $120,867 and was expensed over the implicit service period commencing once management believed the performance criteria
was met. During 2016, the Company met the performance criteria and accordingly, recorded stock based compensation expense of $38,867
for the three months ended March 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"><I><U>Unvested</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company granted performance-based options to purchase
1,150,000 shares of common stock at exercise prices of $0.40 and $0.80. The options expire at various dates between 2021 and 2027
and are exercisable upon the Company achieving annual sales revenue of $5,000,000 and $10,000,000. &nbsp;During the year ended
December 31, 2016, the Company cancelled 287,500 of these service-based options issued to two consultants, valued at $5,542.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The performance criteria for options exercisable upon the Company achieving annual sales revenue of $5,000,000
and $10,000,000 with an aggregate fair value of $85,608. As of March 31, 2017, no amounts have been expensed and the unearned compensation
for all the performance based options is $85,608.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholders&rsquo; Equity (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The following is a summary of outstanding and exercisable
warrants:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Weighted Average</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Exercise Price</P></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Year&nbsp;of&nbsp;<BR> Expiration</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36pt; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2016</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,954,981</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.19</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017 - 2019</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,402,671</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.40</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at March 31, 2017</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,357,562</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.31</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017 - 2019</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In September 2016, the Company issued 100,000 warrants
with an exercise price of $0.50 per share, in relation to a sale of common stock. These warrants are fully vested and expire in
two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In September 2016, the Company issued 100,000 warrants
with exercise prices between $0.20 and $0.50 per share, for consulting services. These warrants are fully vested and expire in
three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In December 2016, the Company issued 37,500 warrants
with an exercise price of $0.50 per share, in relation to a sale of common stock. These warrants are fully vested and expire in
two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In December 2016, the Company issued 217,391 warrants
with an exercise price of $0.40 per share, in relation to an issuance of common stock. These warrants are fully vested and expire
in two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In January 2017, the Company issued 591,745 warrants
with an exercise price of $0.40 per share, in relation to an issuance of common stock for the conversion of an equity contribution
into Immudyne PR by the noncontrolling interest. These warrants are fully vested and expire in two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In March 2017, the Company issued 403,348 warrants
with an exercise price of $0.40 per share, in relation to an issuance of common stock for the conversion of debt. These warrants
are fully vested and expire in two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In the first quarter of 2017, the Company issued 1,407,578
warrants with an exercise price of $0.40 per share, in relation to a sale of common stock. These warrants are fully vested and
expire in two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The fair value of warrants granted during the period
ended March 31, 2017, was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average
assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 36pt; background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</FONT></TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="width: 14%; background-color: #CCEEFF; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">181% - 211%</FONT></TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free interest rate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.03% - 2.22</FONT>%</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term (in years)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4 - 8.5</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average grant date fair value</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF; text-align: center">$<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.37 - 0.50</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">As of March 31, 2017 and December
31, 2016, certain of the Company&rsquo;s stock options, stock warrants and convertible debt instruments were accounted for as derivative
liabilities due to insufficient authorized shares of common stock to settle outstanding contracts. At March 31, 2017 and December
31, 2016, the Company estimated the fair value of these stock options, stock warrants and embedded conversion features using the
Black-Scholes option pricing model (&ldquo;Black-Scholes&rdquo;) to be $1,809,890 and $192,254, based on Level 2 valuation inputs.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholders&rsquo; Equity (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Stock Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The total stock based compensation expense related
Service-Based Stock Options, Performance-Based Stock Options and Warrants and common stock issued for service amounted to $190,189
and $38,867 for the three months ended March 31, 2017 and 2016, respectively. Such amounts are included in compensation and related
expenses in the accompanying statement of operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Royalties</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company was subject to a royalty agreement based
upon sales of certain skin care products. The agreement required the Company to pay a royalty based upon 8% of such sales, up to
$227,175. During the year ended December 31, 2015 the Company&rsquo;s sales reached the maximum amount under which the Company
was required to pay a royalty under this agreement, accordingly no royalty expense was incurred for the three month periods ended
March 31, 2017 and 2016, respectively. During December 2015, the Company&rsquo;s President who had a 60% interest in the royalties,
converted royalties payable under the agreement in the amount of $84,868 to 499,225 shares of Company stock at $0.17 cents per
share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Included in accounts payable and accrued expenses at
March 31, 2017 and December 31, 2016 was $56,579 in regards to this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commitments and Contingencies</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Leases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company leases a plant in Kentucky under an operating lease which expired on May 31, 2016. Management
is currently discussing renewal lease options for the Kentucky plant and is operating on a month-to-month lease arrangement until
a final agreement has been accepted. Monthly base rental payments are approximately $9,000. The Company&rsquo;s principal executive
offices are in office space provided to us by the Company&rsquo;s President, Mr. McLaughlin, at the rate of $2,000 per month, which
includes rents, utilities and other office related expenditures. This arrangement commenced as of January 1, 2016. In addition,
Immudyne PR utilizes office space in Puerto Rico which is subleased from Justin Schreiber (President of Immudyne PR) and incurs
expense of approximately $4,000 a month for this office space. Rent expense for the three month periods ended March 31, 2017 and
2016, was $36,061 and $16,616, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Employment and Consulting
Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company has entered into various agreements with
officers, directors, employees and consultants that expire in one to five years. The agreements provide for annual compensation
of up to $145,000 and the issuance of stock options, at exercise prices of $0.40 and $0.80, to purchase 4,400,000 shares of common
stock issuable upon the Company&rsquo;s revenue exceeding $5,000,000 and $10,000,000, as defined. In addition, the agreements provide
for bonus compensation to these individuals aggregating up to 15% (with no individual having more than 5%) of the Company&rsquo;s
pretax income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Restricted Stock and Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">The Company has entered into two agreements on April 1, 2016 with two consultants of Immudyne PR for business
development, marketing and sales related services (the &ldquo;Consultant Agreements&rdquo;). The consultants are treated as employees
for accounting purposes. Upon signing, each consultant was issued 1,000,000 restricted shares of Immudyne, Inc. common stock. In
addition, each consultant shall receive an additional 150,000 restricted shares of Immudyne, Inc. common stock for each $500,000
distributed by Immudyne PR to the Company. For each consultant, the amount of shares to be issued by the Company to the consultants
shall be capped at 1,500,000 restricted shares when Immudyne PR has transferred $5,000,000 to the Company, for a combined capped
total of 3,000,000 restricted shares. For the three months ended March 31, 2017 and 2016, -0- restricted shares of common stock
have been issued related to these agreements. During 2016, 2,300,000 restricted shares of common stock were issued related to these
agreements. The Company valued the shares at their grant date for a value of $0.30 per share for a total of $690,000 to be expensed
over the estimated service period ending December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In addition, the Consulting Agreements provided that
each consultant shall receive a bonus of an additional 750,000 restricted shares of Immudyne, Inc. common stock, plus an option
to buy 1,000,000 shares of Immudyne, Inc. common stock at $0.20/share (including a cashless exercise feature) when Immudyne PR
has transferred to the Company at each of the following three (3) thresholds: $1,250,000, $2,000,000 and $3,000,000 for a total
of 2,250,000 of restricted shares of Immudyne, Inc. common stock and options to purchase up to 3,000,000 shares of Immudyne, Inc.
common stock at $0.20/share. As of March 31, 2017, no bonus shares have been issued and no options have been granted under this
agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immudyne, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commitments and Contingencies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><B><I>Sole and Exclusive License,
Royalty, and Advisory Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">On September 1, 2016 Immudyne PR entered into a sole and exclusive license, royalty and advisory agreement
with Pilaris Laboratories, LLC (&ldquo;Pilaris&rdquo;) relating to Pilaris&rsquo; PilarisMax shampoo formulation and conditioner.
The term of the agreement will be the life of the US Patent held by Pilaris. As consideration for granting Immudyne PR this license,
Pilaris will receive on quarterly basis, 10% of the net income collected by the licensed products based on the following formula:
Net Income = total income &ndash; cost of goods sold &ndash; advertising and operating expenses directly related to the marketing
of the licensed products. In addition, Immudyne PR share pay Pilaris a performance fee of $50,000 on the 180-day anniversary of
the agreement and an additional $50,000 performance fee on the 365-day anniversary of the agreement. As of March 31, 2017, the
Company has accrued $58,333 expense related to this agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><B><I>Legal Matters</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">In the normal course of business operations, the Company
may become involved in various legal matters. At March 31, 2017, the Company&rsquo;s management does not believe that there are
any potential legal matters that could have an adverse effect on the Company&rsquo;s financial position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Related Party Transactions</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.15pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">During 2016, legal and business advisory services were
provided to the Company by one of its directors. For the three months ended March 31, 2016 this director was compensated $6,000.
No services were provided during the three months ended March 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">During the three months ended March 31, 2017 and 2016,
the Company&rsquo;s President received $8,000 and $8,000, respectively for reimbursement of home office expenditures, including
rent, utilities and other related expenses for two offices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt">Immudyne, Inc. employs the wife of the President of the
Company as an accountant and incurs $3,000 per month, plus an annual incentive bonus award equal to 0.5% of the Company&rsquo;s
pre-tax earnings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt">Immudyne PR utilizes BV Global Fulfillment, owned by the father of Immudyne PR&rsquo;s President, and incurred
$10,396 for the three months ended March 31, 2017 for these services. During the three months ended March 31, 2016, Immudyne PR
did not utilize BV Global Fulfillment.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Taggart International Trust (&ldquo;Taggart&rdquo;),
a shareholder, provides credit card processing services through one or more merchant banks. Taggart did not receive any compensation
for these services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">JLS Ventures LLC, owned by a shareholder, provides
credit card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">JSDC, Inc., owned by a shareholder, provides credit
card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Immudyne PR utilizes office space in Puerto Rico which is subleased from the President of Immudyne PR and
incurs expense of approximately $4,000 a month for this office space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsequent Events</B>&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">The Company has evaluated subsequent
events through the date these financial statements were issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">On April 24, 2017, the Company, issued 217,390 shares
of common stock pursuant to a stock subscription agreement and the Company issued 108,696 warrants with an exercise price of $0.40
per share for the stated consideration and satisfaction of obligation to pay $50,000 on the 180-day anniversary of the execution
of the Sole and Exclusive License, Royalty, and Advisory Agreement dated September 1, 2016 with Pilaris Laboratories, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * * * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We are a health and wellness company that
develops, manufactures, and markets innovative consumer products. We manufacture and market a proprietary and patent protected
Yeast Beta Glucan that has been shown in clinical studies to support and regulate the human immune system. It has broad applications
in skincare and as an immune support supplement. Our majority owned subsidiary is our digital marketing arm and is currently focused
on marketing patented products for thicker and fuller hair and a skincare line containing our proprietary Yeast Beta Glucan ingredient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We have performance based contracts with
our sales and marketing executives, which allows us to continue to maintain a relatively low overhead. Our priority is to pursue
opportunities to market our products and increase sales. We expect that a significant component of our selling, general and administration
expenses going forward will consist of equipment leasing costs relating to improving our operating efficiencies, as well as conducting
new studies which could open new markets. These aforementioned costs, along with the additional costs resulting from our operations
as a public reporting company, could adversely impact our future results of operations. Additional significant factors that we
believe will affect our operating results going forward are: (i) protection of our intellectual property rights; (ii) imposition
of more stringent government regulations of our products; and (iii) marketing expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In the 2016 fiscal year, we utilized third
party entities to provide and increase credit card processing capacity and optimize corresponding rates and fees through one or
more merchant bank accounts held by such entities. A majority of these entities providing these services are consolidated as VIEs
which received a one (1%) percent fee eliminated in consolidation of the net revenues processed and collected by such contractors
from sales initiated by the Company. The remaining entities provided such services as independent contractors, the majority of
which were considered related parties and no fee was paid. Upon receipt of funds by such contractors from their respective merchant
banks, the Company required the prompt transfer of funds to Company controlled accounts. The Company reimbursed and/or advanced
funds to such contractors for any deficit or charge related to returns, chargeback and other fees charged by such merchant bank.
Some of the entities contracted to provide these services have been determined to be variable interest entities and consolidated
in the Company&rsquo;s financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We historically have expended a significant
amount of our funds on obtaining and protecting our patents, trade secrets and proprietary products. We rely on the patent and
trademark protection laws in the U.S. to protect our intellectual property and maintain our competitive position in the marketplace.
For several years, we were involved in complex litigation regarding patents and licenses critical to our products. In 2010, we
prevailed on all major legal matters and reached favorable settlements. If additional litigation becomes necessary to protect our
intellectual property rights, such litigation may be costly, divert our management&rsquo;s attention away from our core business
and have a negative impact on our operations. Furthermore, there is no guarantee that litigation would result in an outcome favorable
to us. In addition, yeast beta glucans are designated as GRAS under current FDA regulations. Future government regulations may
prevent or delay the introduction or require the reformulation of our products. Some agencies, such as the FDA, could require us
to remove a particular product from the market, delay or prevent the import of raw materials for the manufacture of our products
or otherwise disrupt the marketing of our products. Any such government actions could result in additional costs to us, reduced
growth prospects, lost sales from products that we are required to remove from the market and potential product liability litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We have historically operated with limited capital and have funded operations in the past through the sales
of our products and loans and advances from Mark McLaughlin, our President, and other directors, as well as from debt and equity
financings. We plan on our operating business (in conjunction with proceeds from debt and equity financings completed in 2016 and
early 2017) being able to fund our operations through 2017. However, if necessary, we may raise additional capital through a private
placement of common stock, obtaining debt financing or from advances from our President and/or directors; however, no assurances
can be made that we will be successful in our endeavors to raise additional capital. For additional information regarding these
and other risks please see &ldquo;Risk Factors&rdquo; contained in our annual report for the fiscal year ended December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Three Months Ended March 31, 2017, Compared to the Three
Months Ended March 31, 2016</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following table sets forth the results of our operations
for the periods indicated as a percentage of net sales:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2016</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>$</I></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>% of Sales</I></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>$</I></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>% of Sales</I></B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Sales</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">424,462</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,641,028</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">203,356</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,337,942</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross profit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">221,106</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">303,086</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(596,092</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(140</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(408,182</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating (Loss)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(374,986</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(88</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(105,096</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value of derivative liability</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(48,192</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest (expense)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(649,357</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(153</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,063</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net (loss)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,072,535</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(253</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(108,159</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net (loss) attributable to noncontrolling interests</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27,730</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(46,110</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net (loss) attributable to Immudyne, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,044,805</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(246</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(62,049</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Overall sales for the three months ended March 31, 2017 were
$0.42 million, a decrease of 74% from $1.64 million for the same period in 2016. Our decrease in sales was due to the fact that
we invested considerable time and Company resources into the preparation for the launch of our in-licensed patented hair loss shampoo,
conditioner, and leave in foam during the first quarter of 2017, which we believe, based on initial sales numbers, will be a meaningful
contributor to our revenues during the remainder of the 2017 fiscal year. In addition, during the quarter, we shifted to an internal
marketing strategy which we believe will position the Company for long-term success. However, this shift impacted our overall sales
numbers for our finished products segment which decreased to $0.17 million for the quarter compared to $1.38 million for the three
months ended March 31, 2016. Sales in our additives segment remained relatively consistent between periods at $0.26 million for
the three months ended March 31, 2017 compared to $0.27 million for the same period in 2016, which is in-line with our expectations
and the historical performance of this segment.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Cost of sales consists primarily of material
costs, labor costs, marketing costs and related overhead directly attributable to the production of our products. Total cost of
sales decreased 85% to $0.20 million in the first quarter of 2017 compared to $1.34 million for the same period in 2016. The decrease
in our cost of sales was due to our decreased revenues and as a result of the increased advertising and marketing expenses we incurred
in the first quarter of 2016 to generate our significant increase in sales from our finished cosmetic products segment during that
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Gross profit decreased 27% to $0.22 million
in the first quarter of 2017 compared to $0.30 million for the same period in 2016. The decrease in our gross profit was a result
of our decrease in sales, which was partially offset by the fact that we did not incur the same level of advertising and marketing
expenses as we did in the first quarter of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Gross profit as a percentage of sales increased
to 52% in the first quarter of 2017 from 18% for the same period in 2016. Our increase in gross profit as a percentage of sales
for the quarter was as a result of the fact that our sales for the quarter were more heavily weighted towards our additives segment
which generally has higher margins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating expenses consisted of general and administrative expense,
compensation and related expense and professional fees. Overall operating expenses increased 46% to $0.60 million in the first
quarter of 2017 from $0.41 million for the same period in 2016. The relative consistency in our operating expenses between the
periods despite our decrease in sales was primarily attributable to our continued compensation commitments, including with respect
to our joint venture. General and administration expense increased 30% to $0.13 million in the first quarter of 2017 from $0.10
million for the same period in 2016. Compensation and related expense increased 50% to $0.36 million in the first quarter of 2017
from $0.24 million for the same period in 2016. Professional fees increased 44% to $0.10 million in the first quarter of 2017 from
approximately $0.07 million for the same period in 2016, due to increased legal and accounting fees incurred with respect to our
operations in Puerto Rico.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net loss attributable to the Company in the first quarter of
2017 was approximately $1.04 million compared to net loss of $0.06 million for the same period in 2016. We consolidated the operations
of our joint venture, Immudyne PR and reflected a non-controlling interest for 21.8333% of these operations. Net loss attributable
to the Company as a percentage of sales was 246% in the first quarter of 2017 compared to net loss as a percentage of sales of
4% for the same period in 2016. Our net loss during the period was attributable to the aforementioned decrease in our sales as
we shifted company resources in efforts to launch our in-licensed patented hair loss shampoo, conditioner, and leave in foam, and
to internal marketing strategies. It was also partially attributable to a $0.55 non-cash charge related to the settlement of a
notes payable in connection with the conversion of such note to shares of common stock and warrants. We believe these developments
will positively impact the Company&rsquo;s business during the 2017 fiscal year.</P>



<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our principal demands for liquidity are to increase sales, purchase
inventory and for sales distribution and general corporate purposes. We incurred negative operating cash flows in the 2016 and
2015 fiscal years. As a result, we have substantial doubt about our ability to continue as a going concern. Late in the 2016 fiscal
year and early in 2017, the Company issued several 11% subordinated promissory notes to accredited investors for total borrowings
of $200,000. Additionally, the Company borrowed $200,000 at 11% from an investor and borrowed $100,000 from an officer of the Company.
Each of these borrowings have since been satisfied in full with a combination of repayment in cash and conversion of certain amounts
outstanding to equity of the Company. The Company also has access to a working capital line in the amount of $25,000 with a term
of 60 days and interest at a flat fee of $250. As of March 31, 2017, there were no available borrowings under the working capital
line. Additionally, in the first quarter of 2017, the Company issued and sold 2,817,156 shares and 1,408,578 warrants to accredited
investors in an offering pursuant to Regulation D and received proceeds in the amount of $647,944. We plan on our operating business
(in conjunction with proceeds from debt and equity financings completed in 2016 and early 2017) being able to fund operations through
2017. However, if necessary, we may raise additional capital through a private placement of common stock, obtaining debt financing
or from advances from our President and/or directors; however, no assurances can be made that we will be successful in our endeavors
to raise additional capital.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">There can be no assurance that required
future financing can be successfully completed on a timely basis, or on terms acceptable to us. Any future issuance of equity securities
could cause dilution to our shareholders. Any incurrence of indebtedness would increase our debt service obligations and would
cause us to be subject to restrictive operating and financial covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We had negative net working capital of approximately $(1,323,408) at March 31, 2017, resulting in a decrease
from negative net working capital of approximately $(361,725) at December 31, 2016. The ratio of current assets to current liabilities
was .45 to 1 at March 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following is a summary of cash provided
by or used in each of the indicated types of activities during the three months ended March 31, 2017 and 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Cash provided by (used in):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">Operating activities</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(473,256</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(122,155</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">671,751</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">92,793</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Net cash flow used by operating activities
was $0.47 million for the three months ended March 31, 2017, compared to net cash flow used in operating activities of $0.12 million
for the same period in 2016. The increase in the amount of cash used by our operating activities was due primarily to our overall
net loss for the quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Net cash flows provided by financing activities
was $0.67 million for the three months ended March 31, 2017, compared to net cash flows provided by financing activities of $0.09
million for the same period in 2016. Our increase in net cash flows provided by financing activities was primarily a result of
the sale of our common stock and warrants in the first quarter of 2017 for aggregate proceeds of $0.65 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Indebtedness</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, our directors, officers and other related
individuals have made short-term advances to us for our operating needs. Late in the 2016 fiscal year and early in 2017, the Company
issued several 11% subordinated promissory notes to accredited investors for total borrowings of $200,000, borrowed $200,000 at
11% from an investor and borrowed $100,000 from an officer of the Company. Each of these borrowings have since been satisfied in
full with a combination of repayment in cash and conversion of certain amounts outstanding to equity of the Company. We also have
access to a $25,000 working capital line. As of March 31, 2017, there were no available borrowings under the working capital line.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We are subject to a royalty agreement pursuant
to which we are required to pay a monthly royalty of 8% on all sales of certain skin care products up to $227,175. During the year
ended December 31, 2015 our sales reached the maximum amount under which we are required to pay a royalty under this agreement,
accordingly no royalty expense was incurred for the three months periods ending March 31, 2017 and 2016. During 2015, our President,
who has a 60% interest in the royalties, converted all royalties payable (in the amount of $84,868) to 499,225 shares of the company&rsquo;s
stock valued at $0.17 cents a share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">There are no off-balance sheet arrangements
between us and any other entity that have, or are reasonably likely to have, a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources
that is material to shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We have not entered into any financial
guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative
contracts that are indexed to our shares and classified as stockholders&rsquo; equity or that are not reflected in our consolidated
financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated
entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated
entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development
services with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Our significant accounting policies are
described more fully in Note 2 to our financial statements, which we believe are the most critical to aid you in fully understanding
and evaluating this management discussion and analysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Quantitative and Qualitative Disclosures about Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Controls and
Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We carried out an evaluation, under the
supervision and with the participation of our Principal Executive Officer (&ldquo;PEO&rdquo;), who is also our Principal Financial
Officer (&ldquo;PFO&rdquo;), of the design and effectiveness of our &ldquo;disclosure controls and procedures&rdquo; (as defined
under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered by this report.&nbsp;Based
on this evaluation, our PEO/PFO concluded that as of the end of the period covered by this report, these disclosure controls and
procedures were not effective. The conclusion that our disclosure controls and procedures were not effective was due to the presence
of the following material weaknesses in disclosure controls and procedures which are indicative of many small companies with small
staff: (i) inadequate segregation of duties and effective risk assessment as the Company had only one officer; (ii) insufficient
written policies and procedures for accounting and financial reporting with respect to the requirements and application of both
US GAAP and SEC Guidelines; and (iii) inadequate security and restricted access to computer systems including insufficient disaster
recovery plans; and (iv) no written whistleblower policy. If and when sufficient funds are available, our PEO/PFO plans to implement
appropriate disclosure controls and procedures to remediate these material weaknesses, including (i) appointing additional qualified
personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopt sufficient written policies and
procedures for accounting and financial reporting and a whistle blower policy; and (iii) implement sufficient security and restricted
access measures regarding our computer systems and implement a disaster recovery plan. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Changes in Internal Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">There were no changes in our internal control
over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the
quarter ended March 31, 2017, that have materially affected, or are reasonably likely to materially affect, our internal control
over financial reporting. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls
and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control
objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints
and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to
their costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II. OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We may become involved in various lawsuits
and legal proceedings arising in the ordinary course of business. Litigation is subject to inherent uncertainties and an adverse
result in these or other matters may arise from time to time that may have an adverse effect on our business, financial conditions
or operating results. We are currently not aware of any such legal proceedings or claims that will have, individually or in the
aggregate, a material adverse effect on our business, financial condition or operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 1A.&nbsp;&nbsp;&nbsp;&nbsp; Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">You should consider carefully the factors
discussed in the &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unregistered
Sales of Equity Securities and Use of Proceeds</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In the first quarter of 2017, the Company
commenced a private placement to sell up to 4,000,000 shares of its common stock, coupled with warrants to purchase 2,000,000 shares
of the Company&rsquo;s common stock (with an exercise price of $0.40 per share), at a price per unit of $0.23. The Company has
received subscriptions in the amount of 2,817,156 shares and 1,408,578 warrants for aggregate proceeds of $647,944. The Company
issued the shares and warrants to accredited investors only pursuant to Rule 506 of Regulation D promulgated under the Securities
Act of 1933, as amended. The securities offered in the private placement have not been registered under the Securities Act, or
any state securities laws, and unless so registered, may not be sold in the United States except pursuant to an exemption from,
or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Defaults Upon
Senior Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mine Safety Disclosures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">See the Exhibit Index following the signature
page to this Quarterly Report on Form 10-Q for a list of exhibits filed or furnished with this report, which Exhibit Index is incorporated
herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMUDYNE INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 36%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: July 7, 2017</FONT></P>
</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Mark McLaughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark McLaughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Document Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1 &dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10q0317ex31i_immudyneinc.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1 &Dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10q0317ex32i_immudyneinc.htm">Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Instance Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Schema Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Calculation Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Definition Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Label Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Presentation Linkbase Document</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&dagger; Filed herewith</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&Dagger; Furnished herewith</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">28</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>f10q0317ex31i_immudyneinc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 302(a)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Mark McLaughlin, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed
    this Quarterly Report on Form 10-Q for the period ended March 31, 2017, of Immudyne, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge,
    this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
    statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
    covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge,
    the financial statements, and other financial information included in this report, fairly present in all material respects
    the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
    report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s
    other certifying officer(s) and I&nbsp;are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure
    controls and procedures, or caused such disclosure controls and procedures to be designed under&nbsp;our supervision, to ensure
    that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under&nbsp;our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness
    of the registrant&rsquo;s disclosure controls and procedures and presented in this report&nbsp;our conclusions about the effectiveness
    of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this
    report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report)&nbsp;that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s
    other certifying officer(s) and I have disclosed, based on&nbsp;our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
    performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant
    deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
    likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether
    or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
    control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    July 7, 2017</FONT></TD>
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Mark McLaughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark McLaughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer and <BR>
    Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>3
<FILENAME>f10q0317ex32i_immudyneinc.htm
<DESCRIPTION>CERTIFICATIONS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATIONS OF PRESIDENT AND PRINCIPAL
FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">I, Mark McLaughlin, hereby certify that,
to the best of my knowledge, the Quarterly Report on Form 10-Q of Immudyne, Inc. for the quarterly period ended March 31, 2017,
fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained
in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations
of Immudyne Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: July 7, 2017</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Mark McLaughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mark McLaughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer and </FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>4
<FILENAME>immd-20170331.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 8.0.0.0 [07/07/2017 09:57:14 PM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Friday, July 07, 2017 09:57:37 PM -->
<xbrli:xbrl xmlns:immd="http://www.immudyne.com/20170331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="immd-20170331.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_As_Of_30_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-11-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-11-02
</xbrli:startDate>
<xbrli:endDate>
2015-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfFinancingReceivableTypeOfBorrowerAxis">immd:CommercialLenderMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-11-02
</xbrli:startDate>
<xbrli:endDate>
2015-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PresidentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_InnateScientificLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:InnateScientificLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PresidentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-12-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:NutraceuticalAndCosmeticMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:CosmeticGoodsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="immd:ConcentrationRiskNumberOfCustomersAxis">immd:OneCustomerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:NutraceuticalAndCosmeticMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_TitleOfIndividualAxis_OfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:OfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_TitleOfIndividualAxis_PresidentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:PresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_RestrictedStockOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:RestrictedStockOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShortTermDebtTypeAxis_NotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">immd:NotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_VestedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">immd:VestedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-04-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ImmudynePrLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-04-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-04-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-04-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-03-25
</xbrli:startDate>
<xbrli:endDate>
2016-04-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_AwardTypeAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-03-25
</xbrli:startDate>
<xbrli:endDate>
2016-04-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ConsultantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-03-25
</xbrli:startDate>
<xbrli:endDate>
2016-04-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-03-25
</xbrli:startDate>
<xbrli:endDate>
2016-04-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ConsultantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-05-01
</xbrli:startDate>
<xbrli:endDate>
2016-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2016T00_00_00_TO_31_Jul_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ConsultantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Aug_2016T00_00_00_TO_31_Aug_2016T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-08-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_26_Aug_2016T00_00_00_TO_01_Sep_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-08-26
</xbrli:startDate>
<xbrli:endDate>
2016-09-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:ConsultingServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_RangeAxis_MinimumMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:ConsultingServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:ConsultingServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-09-02
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:ConsultingServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-09-02
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_20_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-20
</xbrli:startDate>
<xbrli:endDate>
2016-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ConsultantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-11-01
</xbrli:startDate>
<xbrli:endDate>
2016-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_OfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:OfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_VestedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">immd:VestedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="immd:ConcentrationRiskNumberOfCustomersAxis">immd:OneCustomerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:IssuanceOfCommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_OneCreditCardProcessorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis">immd:OneCreditCardProcessorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_TwoCreditCardProcessorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis">immd:TwoCreditCardProcessorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_UnvestedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">immd:UnvestedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:NutraceuticalAndCosmeticMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:CosmeticGoodsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_OfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:OfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:IssuanceOfCommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">immd:SummationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_LegalEntityAxis_ImmudynePrLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:IssuanceOfCommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_LegalEntityAxis_ImmudynePrLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:IssuanceOfCommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-02-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">immd:CommercialPaperTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-02-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-02-01
</xbrli:startDate>
<xbrli:endDate>
2017-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_DirectorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-02-01
</xbrli:startDate>
<xbrli:endDate>
2017-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:NutraceuticalAndCosmeticMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:CosmeticGoodsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="immd:ConcentrationRiskNumberOfCustomersAxis">immd:OneCustomerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:NutraceuticalAndCosmeticMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_TitleOfIndividualAxis_OfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:OfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_TitleOfIndividualAxis_PresidentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:PresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_RestrictedStockOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:RestrictedStockOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShortTermDebtTypeAxis_NotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">immd:NotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_VestedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">immd:VestedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_LegalEntityAxis_ImmudynePrLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="immd:ConcentrationRiskNumberOfCustomersAxis">immd:OneCustomerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:IssuanceOfCommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_OneCreditCardProcessorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis">immd:OneCreditCardProcessorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_TwoCreditCardProcessorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis">immd:TwoCreditCardProcessorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_UnvestedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">immd:UnvestedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_SummationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">immd:SummationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_RestrictedStockTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:RestrictedStockTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_RestrictedStockThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:RestrictedStockThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_RangeAxis_MinimumMember_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_UnvestedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">immd:UnvestedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_RangeAxis_MaximumMember_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_UnvestedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">immd:UnvestedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_RangeAxis_MinimumMember_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_VestedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">immd:VestedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_RangeAxis_MaximumMember_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_VestedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">immd:VestedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_WarrantOneMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:WarrantOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:IssuanceOfCommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:NutraceuticalAndCosmeticMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:CosmeticGoodsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:IssuanceOfCommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_SummationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">immd:SummationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_WarrantOneMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:WarrantOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:IssuanceOfCommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">immd:CommercialPaperOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-03-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-03-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-03-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_24_Apr_2017T00_00_00_TO_24_Apr_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-04-24
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2017T00_00_00_TO_24_Apr_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-04-01
</xbrli:startDate>
<xbrli:endDate>
2017-04-24
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_05_Jul_2017T00_00_00_TO_05_Jul_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-07-05
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevEkirxw;=c444c555cT{h>HGGG<FJJ1IJ=7184II1F=671<H97G=6H95:4 -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Consultants"><xbrli:measure>immd:Consultants</xbrli:measure></xbrli:unit>
<xbrli:unit id="Thresholds"><xbrli:measure>immd:Thresholds</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">Immudyne, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">0000948320</dei:EntityCentralIndexKey>
<dei:TradingSymbol contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">IMMD</dei:TradingSymbol>
<dei:AmendmentFlag contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">false</dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
<dei:DocumentType contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">10-Q</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">2017-03-31</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">2017</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">Q1</dei:DocumentFiscalPeriodFocus>
<dei:EntityFilerCategory contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_05_Jul_2017T00_00_00_TO_05_Jul_2017T00_00_00" unitRef="shares" decimals="INF">40543373</dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">232984</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">203622</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">182561</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">381056</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">444743</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">555708</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:OtherReceivablesNetCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">2250</us-gaap:OtherReceivablesNetCurrent>
<us-gaap:OtherReceivablesNetCurrent contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InventoryNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">160270</us-gaap:InventoryNet>
<us-gaap:InventoryNet contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">136938</us-gaap:InventoryNet>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">789824</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">1073702</us-gaap:AssetsCurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">752930</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">562220</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">192254</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">1809890</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">106365</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">25000</us-gaap:NotesPayableCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1151549</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">2397110</us-gaap:LiabilitiesCurrent>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">355701</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">405433</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">9070064</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">9363160</us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-9693882</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-10738687</us-gaap:RetainedEarningsAccumulatedDeficit>
<immd:Equity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-268117</immd:Equity>
<immd:Equity contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-970094</immd:Equity>
<us-gaap:TreasuryStockValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">87053</us-gaap:TreasuryStockValue>
<us-gaap:TreasuryStockValue contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">90204</us-gaap:TreasuryStockValue>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-355170</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-1060298</us-gaap:StockholdersEquity>
<us-gaap:MinorityInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-6555</us-gaap:MinorityInterest>
<us-gaap:MinorityInterest contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-263110</us-gaap:MinorityInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-361725</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9070064</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">355701</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-9693882</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">-355170</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">-6555</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">-87053</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-1323408</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9363160</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">405433</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-10738687</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">-1060298</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">-263110</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">-90204</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">789824</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">1073702</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">35570157</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00" unitRef="shares" decimals="INF">217391</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="shares" decimals="INF">1183490</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="INF">40543373</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">35245157</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="INF">40205573</us-gaap:CommonStockSharesOutstanding>
<us-gaap:TreasuryStockCommonShares contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">325000</us-gaap:TreasuryStockCommonShares>
<us-gaap:TreasuryStockCommonShares contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="INF">337800</us-gaap:TreasuryStockCommonShares>
<us-gaap:Revenues contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">1641028</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="USD" decimals="0">265910</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember" unitRef="USD" decimals="0">1375118</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="USD" decimals="0">-19250</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">424462</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="USD" decimals="0">256563</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember" unitRef="USD" decimals="0">167899</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:CostOfRevenue contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">1337942</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">203356</us-gaap:CostOfRevenue>
<us-gaap:GrossProfit contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">303086</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">221106</us-gaap:GrossProfit>
<immd:CompensationAndRelatedExpenses contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">240455</immd:CompensationAndRelatedExpenses>
<immd:CompensationAndRelatedExpenses contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">358488</immd:CompensationAndRelatedExpenses>
<us-gaap:ProfessionalFees contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">69315</us-gaap:ProfessionalFees>
<us-gaap:ProfessionalFees contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">99632</us-gaap:ProfessionalFees>
<us-gaap:ProfessionalFees contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="USD" decimals="0">3000</us-gaap:ProfessionalFees>
<us-gaap:MarketingExpense contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:MarketingExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">10800</us-gaap:MarketingExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">98412</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">127172</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">408182</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">596092</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-105096</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-374986</us-gaap:OperatingIncomeLoss>
<immd:ChangeInFairValueOfDerivativeLiability contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<immd:ChangeInFairValueOfDerivativeLiability contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">48192</immd:ChangeInFairValueOfDerivativeLiability>
<us-gaap:InterestExpense contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">3063</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_TitleOfIndividualAxis_OfficerMember" unitRef="USD" decimals="0">312</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">649357</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_TitleOfIndividualAxis_OfficerMember" unitRef="USD" decimals="0">1713</us-gaap:InterestExpense>
<us-gaap:ProfitLoss contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-108159</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="USD" decimals="0">84777</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember" unitRef="USD" decimals="0">-69165</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="USD" decimals="0">46110</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-1072535</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="USD" decimals="0">26807</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember" unitRef="USD" decimals="0">-127007</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="USD" decimals="0">27730</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProfitLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProfitLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-1044805</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">-1044805</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">-27730</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-46110</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-27730</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-62049</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-1044805</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD_per_Share" decimals="2">-0.03</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="0">32010375</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="0">37581987</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="shares" decimals="0">32010375</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="0">37581987</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">35570157</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">40543373</us-gaap:SharesOutstanding>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_RestrictedStockOneMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="USD" decimals="0">500000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD" decimals="0">690000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD" decimals="INF">2300000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">76667</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_RestrictedStockOneMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">76667</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">76667</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="shares" decimals="INF">2300000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">647944</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">619773</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">28171</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">647944</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PresidentMember" unitRef="shares" decimals="INF">499225</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">2817156</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">260368</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">11835</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">272203</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">-272203</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1183490</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">745414</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">737862</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">7552</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">745414</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">755179</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_Custom_20_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00" unitRef="USD" decimals="0">58750</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">56522</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">54348</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">2174</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">56522</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">62500</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Context_Custom_20_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00" unitRef="shares" decimals="INF">250000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">217391</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-3151</us-gaap:TreasuryStockValueAcquiredCostMethod>
<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">-3151</us-gaap:TreasuryStockValueAcquiredCostMethod>
<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">-3151</us-gaap:TreasuryStockValueAcquiredCostMethod>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">113522</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">113522</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">113522</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">43378</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">43378</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-1569444</immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities>
<immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-1569444</immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities>
<immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">-1569444</immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities>
<immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">48192</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
<us-gaap:ProvisionForDoubtfulAccounts contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProvisionForDoubtfulAccounts contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-38027</us-gaap:ProvisionForDoubtfulAccounts>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_ShortTermDebtTypeAxis_NotesPayableMember" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">81558</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShortTermDebtTypeAxis_NotesPayableMember" unitRef="USD" decimals="0">91556</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-553222</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">38867</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="USD" decimals="0">38867</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_VestedMember" unitRef="USD" decimals="0">38867</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">190188</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">113522</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="USD" decimals="0">190189</us-gaap:ShareBasedCompensation>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">144902</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">72938</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-2250</us-gaap:IncreaseDecreaseInOtherReceivables>
<us-gaap:IncreaseDecreaseInInventories contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">77443</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-23332</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">169482</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-188498</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-122155</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-473256</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">92793</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
<us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">43378</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_Custom_02_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember" unitRef="USD" decimals="0">100000</us-gaap:ProceedsFromNotesPayable>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">235000</us-gaap:ProceedsFromNotesPayable>
<us-gaap:RepaymentsOfConvertibleDebt contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:RepaymentsOfConvertibleDebt contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:RepaymentsOfConvertibleDebt>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">151420</us-gaap:RepaymentsOfNotesPayable>
<immd:IssuanceOfCommonStockAndWarrants contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<immd:IssuanceOfCommonStockAndWarrants contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">647944</immd:IssuanceOfCommonStockAndWarrants>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-3151</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">92793</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">671751</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-29362</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">198495</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:InterestPaid contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">3063</us-gaap:InterestPaid>
<us-gaap:InterestPaid contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">3612</us-gaap:InterestPaid>
<us-gaap:ConversionOfStockAmountIssued1 contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ConversionOfStockAmountIssued1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">192192</us-gaap:ConversionOfStockAmountIssued1>
<immd:ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<immd:ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">272203</immd:ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants>
<immd:ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<immd:ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">1569444</immd:ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Organization and Going Concern&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Immudyne, Inc. (the &amp;#8220;Company&amp;#8221;) is a Delaware corporation established to develop, manufacture and sell natural immune support products containing the Company&amp;#8217;s proprietary yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast that have been shown through testing and analysis to support the immune system. The Company&amp;#8217;s products include once a day oral intake tablets and topical creams and gels for skin application. The Company concentrates its sales and marketing efforts on healthcare professionals, distributors for its all-natural raw material ingredient products and direct-to-consumer sales.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In 2015, the Company formed a joint venture domiciled in Puerto Rico, Innate Skincare, LLC (&amp;#8220;Innate&amp;#8221;). Under the terms of the joint venture agreement, the Company held a 33.3% equity interest, and a 51% controlling voting interest, in Innate. On January 20, 2016, Innate amended its limited liability company operating agreement and changed its legal name to Immudyne PR LLC (&amp;#8220;Immudyne PR&amp;#8221;). On April 1, 2016, Immudyne PR further amended its operating agreement and restated the Company&amp;#8217;s ownership and voting interest in Immudyne PR increasing its ownership to 78.1667% resulting in a charge to noncontrolling interest and additional paid-in-capital of $91,612. Immudyne PR was formed to launch a complete skin care regime formulated using strategic ingredients provided by the Company. In the second quarter of 2017, Immudyne PR expanded their product line and launched their in-licensed patented hair loss shampoo and conditioner.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has funded operations in the past through the sales of its products, issuance of common stock and through loans and advances from officers and directors. The Company&amp;#8217;s continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers and directors or the issuance of additional shares of common stock.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. At March 31, 2017, the Company has an accumulated deficit approximating $10.7 million and has incurred negative cash flows from operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Based on the Company's cash balance at March 31, 2017, and projected cash needs for 2017, management estimates that it will need to increase sales revenue and/or raise additional capital to cover operating and capital requirements for the remainder of the 2017 year. Management will need to raise the additional needed funds through increased sales volume, issuing additional shares of common stock or other equity securities, or obtaining debt financing. Although management has been successful to date in raising necessary funding, there can be no assurance that sales revenue will substantially increase or that any required future financing can be successfully completed on a timely
 basis, or on terms
 acceptable to the Company.&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;
&lt;table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 36pt; text-align: justify; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (&amp;#8220;ASC 810&amp;#8221;).&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Immudyne PR and variable interest entities (VIE&amp;#8217;s) in which the Company has been determined to be the primary beneficiary. The non- controlling interest in Immudyne PR represents the 21.8333% equity interest held by other members of the joint venture. All significant consolidated transactions and balances have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Variable Interest Entities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company follows ASC 810-10-15 guidance with respect to accounting for variable interest entities (each, a &amp;#8220;VIE&amp;#8221;). These entities do not have sufficient equity at risk to finance their activities without additional subordinated financial support from other parties or whose equity investors lack any of the characteristics of a controlling financial interest. A variable interest is an investment or other interest that will absorb portions of a VIE&amp;#8217;s expected losses or receive portions of its expected residual returns and are contractual, ownership, or pecuniary in nature and that change with changes in the fair value of the entity&amp;#8217;s net assets. A reporting entity is the primary beneficiary of a VIE and must consolidate it when that party has a variable interest, or combination of variable interests, that provides it with a controlling financial interest. A party is deemed to have a controlling financial interest if it meets both of the power and losses/benefits criteria. The power criterion is the ability to direct the activities of the VIE that most significantly impact its economic performance. The losses/benefits criterion is the obligation to absorb losses from, or right to receive benefits from, the VIE that could potentially be significant to the VIE. The VIE model requires an ongoing reconsideration of whether a reporting entity is the primary beneficiary of a VIE due to changes in facts and circumstances.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;As of March 31, 2017 and December 31, 2016, the Company consolidated nine VIEs.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Immudyne PR as the primary beneficiary of Ace Account Management LLC, Innerwell Skincare LLC, MCD Merchants LLC, One Equity Research
 LLC, Inate Gems LLC, Retriever Health Products LLC, Spurs 5, LLC, Salus LLC and Huntley LLC which are qualified as VIEs. The assets and liabilities and revenues and expenses of these VIEs included in the financial statements of Immudyne PR and further included in the consolidated financial statements. As of March 31, 2017, the VIEs had assets of $19,421, liabilities of $5,748, revenues of $981, and operating expenses of $953. As of December 31, 2016, the VIEs had assets of $10,306, liabilities of $5,748. The assets and liabilities include balances due from and due to the subsidiaries of Immudyne PR. Any inter-company receivables and payables are eliminated upon consolidation of the VIE with Immudyne PR and Immudyne, Inc. No assets were pledged or given as collateral against any borrowings.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company utilizes third party entities to provide and increase credit card processing capacity and optimize corresponding rates and fees. A majority of these entities provide this service as independent contractors in exchange for a one percent (1%) fee of the net revenues processed and collected by such contractors from sales initiated by the Company. The VIEs consolidated in the Company&amp;#8217;s financial statements are primarily contracted to provide credit card processing through one or more merchant banks. Upon receipt of funds by each VIE, the collection of receipts less any returns, chargeback and other fees charged by such merchant bank is transferred to Immudyne PR.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&lt;br /&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the determination of reserves for accounts receivable, returns and allowances, the accounting for derivatives, the valuation of inventory and stockholders&amp;#8217; equity based transactions. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Derivative Liabilities&lt;/i&gt;&lt;/b&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Under ASC 815-40-05, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in a Company&amp;#8217;s Own Stock, in the event the Company does not have a sufficient number of authorized and unissued shares of common stock to satisfy obligations for stock options, warrants and other instruments potentially convertible into common stock, the fair value of these instruments should be reported as a liability. Pursuant to the outstanding option, warrant and convertible debt agreements, there is currently no effective registration statement covering the shares of common stock underlying these agreements, which are currently subject to a cashless exercise whereby the holders, at their option, may surrender their options and warrants to the company in exchange for shares of common stock. The number of shares of common stock into which an option or a warrant would be exchangeable in such a cashless exercise depends on both the exercise price of the options or warrant and the market price of the common stock, each at or near the time of exercise. Because both of these factors are variable, it is possible that the Company could have insufficient authorized shares to satisfy a cashless exercise. In this scenario, if the Company were unable to obtain shareholder approval to increase the number of authorized shares, the Company could be obligated to settle such a cashless exercise with cash rather than by issuing shares of common stock. Further, ASC 815-40-05 requires that the Company record the potential settlement obligation at each reporting date using the current estimated fair value of these contracts, with any changes in fair value being recorded through our statement of operations. The Company will continue to report the potential settlement obligation as a liability until such time as these contracts are
 exercised or expire or we are otherwise able to modify the warrant agreement to remove the provisions which require this treatment. The Company also plans to amend its Articles of Incorporation in the third quarter of 2017 to increase the number of shares of its authorized common stock after the approval by its shareholders.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Sequencing Policy&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Under ASC 815-40-35, the Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company&amp;#8217;s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of authorized but unissued shares, and all future instruments being classified as a derivative liability, with the exception of instruments related to share-based compensation issued to employees or directors.&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Inventory&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;At March 31, 2017 and December 31, 2016, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic products. Inventory is maintained in the Company&amp;#8217;s leased Kentucky warehouse and third party warehouses in Pennsylvania and Louisiana.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Inventory is valued at the lower of cost or market with cost determined on a first-in, first-out (&amp;#8220;FIFO&amp;#8221;) basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to market value, if lower. At March 31, 2017 and December 31, 2016, the Company recorded an inventory reserve in the amount of $20,000. Inventory consists of the following:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;March&amp;#160;31,&lt;br /&gt;2017&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;December&amp;#160;31,&lt;br /&gt;2016&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman',
 times, serif; text-align: left; font-stretch: normal;"&gt;Raw materials&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 100px; text-align: right; font-stretch: normal;"&gt;29,577&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 100px; text-align: right; font-stretch: normal;"&gt;38,460&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;Finished products&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;107,361&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;121,810&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;136,938&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;160,270&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer, and for sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped, but in limited cases if title does not pass until the product reaches the customer&amp;#8217;s delivery site, then recognition of revenue is deferred until that time. Delivery is considered to have occurred when title and risk of loss have transferred to the customer. Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates approximated $38,000 and $517,000 in the three months ended March 31, 2017 and 2016, respectively. There are no formal sales incentives offered to any of the Company&amp;#8217;s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Revenue for the three months ended March 31, 2017 consisted of nutraceutical and cosmetic additives ($256,563) and finished cosmetic products ($167,899). Revenue for the three months ended March 31, 2016 consists of nutraceutical and cosmetic additives ($265,910) and finished cosmetic products ($1,375,118).&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Accounts receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Accounts receivable are carried at original invoice amount less an estimate made for holdbacks and doubtful receivables based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&amp;#8217;s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers&amp;#8217; accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. At March 31, 2017 and December 31, 2016 the accounts receivable reserve was approximately $37,800 for both periods. As of March 31, 2017 and December 31, 2016, the reserve for sales returns and allowances was approximately $12,500 and $50,500, respectively.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The guidance for disclosures about segments of an enterprise requires that a public business enterprise report financial and descriptive information about its operating segments. Generally, financial information is required to be reported on the basis used internally for evaluating segment performance and resource allocation. The Company manages its operations in two reportable segments for purposes of assessing performance and making operating decisions. Revenue is generated predominately in the United States, and all significant assets are held in the United States, or United States territories.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company allocates resources and evaluates the performance of segments based on income or loss from operations, excluding interest, corporate expenses and other income (expenses).&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;A summary of the company&amp;#8217;s reportable segments is as follows:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;Total assets:&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times,
 serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;March&amp;#160;31,&lt;br /&gt;2017&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;December&amp;#160;31,&lt;br /&gt;2016&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Nutraceutical and Cosmetic Additives&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 100px; text-align: right; font-stretch: normal;"&gt;1,350,785&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 100px; text-align: right; font-stretch: normal;"&gt;556,234&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Finished Cosmetic Products&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;385,345&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;422,288&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;Eliminations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(662,428&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(188,698&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;Total&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;1,073,702&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;789,824&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1250.4px;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;Three Months ended&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;March&amp;#160;31, 2017&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;March&amp;#160;31, 2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Net sales by segment:&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Nutraceutical and Cosmetic Additives&lt;/td&gt;
&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 100px; text-align: right;"&gt;256,563&lt;/td&gt;
&lt;td style="width: 12px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 100px; text-align: right;"&gt;285,160&lt;/td&gt;
&lt;td style="width: 12px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Finished Cosmetic Products&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;167,899&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,375,118&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;Eliminations&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(19,250&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;424,462&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,641,028&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; text-decoration: underline;"&gt;Net (loss) income by segment:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Nutraceutical and Cosmetic Additives&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;26,807&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;84,777&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Finished Cosmetic Products&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(127,007&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(69,165&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align:
 left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; text-decoration: underline;"&gt;Other unallocated amounts:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Corporate expenses&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(274,786&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(120,708&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Other income (expense)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(697,549&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(3,063&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;Net (loss)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(1,072,535&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(108,159&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;br class="apple-interchange-newline" /&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company files Corporate Federal and State tax returns, while Immudyne PR, which was formed as a limited liability corporation, files a separate tax return with any tax liabilities or benefits passing through to its members.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company records current and deferred taxes in accordance with Accounting Standards Codification (ASC) 740, &amp;#8220;Accounting for Income Taxes.&amp;#8221; This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s tax returns for all years since December 31, 2013, remain open to taxing authorities.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company follows the provisions of ASC 718, &amp;#8220;Share-Based Payment&amp;#8221;. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company&amp;#8217;s shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&lt;br /&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Earnings (Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Common stock equivalents comprising shares underlying 18,295,335 options and warrants for the three months ended March 31, 2017 have not been included in the loss per share calculation as the effects are anti-dilutive. Common stock equivalents comprising shares underlying 12,525,273 options and warrants for the three months ended March 31, 2016 have not been included in the loss per share calculations as the effects are anti-dilutive.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017 but early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times,
 serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (&amp;#8220;ASU 2016-15&amp;#8221;). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of adoption of ASU 2016-15.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement on its consolidated financial statements. At this time, the adoption of this pronouncement is not expected to have a material impact on the Company&amp;#8217;s consolidated financial statements or related disclosures.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In May 2014, the Financial Accounting Standards Board ("FASB") issued accounting guidance, "Revenue from Contracts with Customers." The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal year 2018. The Company does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Noncontrolling Interests&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px
 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest&amp;#8217;s share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Consolidation of Variable Interest Entities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In accordance with ASC 810-10-25-37 and as amended by ASU 2009-17, the Company determines whether any legal entity in which the Company becomes involved is a VIE and subject to consolidation. The Company conducts an assessment on an ongoing basis for each VIE including (1) the power to direct activities of the VIE that most significantly impact the VIE&amp;#8217;s economic performance, and (2) the obligation to absorb losses or right to receive benefits from the VIE that could potentially be significant to the VIE. As a result, the Company determined that nine (9) entities were VIEs and subject to consolidation.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;One customer in the nutraceutical and cosmetic additives division accounted for 59% and 16% of consolidated sales for the three months ended March 31, 2017 and 2016, respectively. This customer also accounted for 45% and 54% of accounts receivable at March 31, 2017 and December 31, 2016, respectively.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In the finished cosmetic products division, two credit card processors accounted for 42% and 35% of accounts receivable at March 31, 2017. In the finished cosmetic products division, two credit card processors accounted for 35% and 32% of accounts receivable at December 31, 2016.&lt;/p&gt;
&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;
&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 36pt; text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Notes Payable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In November 2015, the Company borrowed $100,000 from a commercial lender. The loan incurred interest at 11% and with a maturity date of November 1, 2016. In October 2016, the Company repaid the entire principal balance. Interest expense related to this loan for the period ended March 31, 2016 amounted to $3,063.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In the third quarter of 2016 the Company commenced an offering pursuant to which it offered 11% subordinated promissory notes in fifty thousand ($50,000) dollar increments combined with 62,500 shares of the Company&amp;#8217;s Common Stock for a maximum offering amount of $200,000 (the &amp;#8220;Offering&amp;#8221;). In August and September 2016, the Company sold promissory notes totaling $150,000 to three unrelated individuals. Two of the promissory notes totaling $100,000 were payable in February 2017 and one promissory note for $50,000 was payable in March 2017. In October 2016, the Company sold promissory notes totaling $50,000 to two unrelated individuals. These promissory notes are payable in October 2017. In connection with these promissory notes sold, pursuant to the Offering, the Company issued 250,000 shares of common stock valued at $58,750 which was recorded as a debt discount and will be amortized over the term of these notes. Amortization of the debt discounts for the period ended March 31, 2017 was $25,035. During 2016, the Company repaid $68,600 of the principal balance. During 2017, the Company repaid $81,420 of the principal balance and converted the remaining balance of $49,980 into 196,000 shares of common stock and 98,000 warrants. The fair market value of the shares and warrants issued upon conversion was determined to be $179,384, of which $129,404 was included in interest expense as loss on settlement of notes payable. Interest expense related to these notes for the three months ended March 31, 2017 amounted to $131,117.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In December 2016, the Company borrowed $100,000 from an officer and issued a convertible promissory note with a maturity date of February 28, 2017. The loan incurs no interest. This note is convertible if not repaid by the maturity date at a conversion price of $0.23 per Unit. Each Unit shall consist of one share of the Company&amp;#8217;s common stock and one three-year common-stock warrant to purchase one-half of one share of the Company&amp;#8217;s common stock with an exercise price of $0.40 per share. In March 2017, the Company repaid the entire outstanding balance of this note.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January 2017, the Company borrowed $200,000 and issued a promissory note with a 5% original issue discount for a total principal amount of $210,000. The loan incurs 11% interest per annum and matures in various tranches from February 2017 through April 2017. In addition, the Company issued 217,391 shares of common stock related to this note. In February 2017, the Company repaid $70,000 of the principal balance of this note. In March 2017, the Company converted the remaining $140,000 of the principal balance of this note and accrued interest of $2,212 in exchange for 559,179 shares of common stock and 304,348 warrants. The fair market value of the shares and warrants issued upon conversion was determined to be $566,030, of which $423,818 was included in interest expense as loss on settlement of notes payable.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal;
 word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In February 2017, the Company borrowed $25,000 from an American Express working capital line with 60 days maturity. The interest for this loan is a flat fee of $250. As of March 31, 2017, there were no available borrowings under the working capital line.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Interest expense related to loans from officers, directors and other related individuals amounted to $1,713 and $312 for the three months ended March 31, 2017 and 2016, respectively.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Total interest expense on notes payable, inclusive of amortization of debt discount of $91,556 and $-0-, amounted to $649,357 and $3,063 for the three months ended March 31, 2017 and 2016, respectively.&lt;/p&gt;
&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;table style="width: 888.57px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company is not expected to have taxable income in 2017 and incurred a loss for the year ended December 31, 2016 and accordingly, no provision for federal income tax has been made in the accompanying financial statements. At March 31, 2017, the Company had available net operating loss carryforwards of approximately $4,294,800, expiring during various years through 2037.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;A summary of the deferred tax asset using an approximate 34% tax rate is as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 888.57px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Net operating loss&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8.57px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8.57px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 70.85px; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;1,699,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8.57px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Accounts receivable reserves&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;17,000&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Inventory reserves&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;7,000&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Stock compensation&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-size: 10pt;"&gt;229,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Net deferred tax asset&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;1,952,000&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-size: 10pt;"&gt;(1,952,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 10pt; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The net operating loss carryforwards could be
 subject to limitation in any given year in the event of a change in
 ownership as defined by IRC Section 382.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The difference between the statutory and the effective tax rate is primarily due to a change in valuation allowance on deferred taxes, as the Company has fully reserved the deferred tax asset resulting from available net operating loss carryforwards.&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;
&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 36pt; text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Stockholders&amp;#8217; Equity&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On April 1, 2016, the Company entered into two agreements with two consultants to provide services over a nine-month period in exchange for 2,300,000 shares of common stock. The Company calculated a fair value of $690,000 based on the market price of the shares on the date of the agreements. During the third quarter of 2016, the Company and the consultants renegotiated the agreements by extending the service requirement to December 31, 2017. For the period ended March 31, 2017, the Company has recognized expense of $76,667 in connection with these agreements. As of March 31, 2017 and December 31, 2016, the unamortized portion of these service agreements are $230,000 and $306,667, respectively.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;During 2016, the Company purchased 325,000 shares of outstanding Company common stock through an exchange for a price per share of $0.23 to $0.29. During 2017, the Company purchased an additional 12,800 shares of outstanding Company common stock for a price per share of $0.24 to $0.26. As of the March 31, 2017, a total of 337,800 shares are being held by the Company valued at cost is $90,204 and are included in treasury stock in the consolidated balance sheet.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January 2017, the Company issued 1,183,490 shares of common stock pursuant to a conversion of Immudyne PR equity contributions of $272,203 into equity of Immudyne, Inc. by the noncontrolling interest.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January 2017, the Company issued 217,391 shares of common stock in relation to the remaining outstanding principal balance on the $210,000 note payable.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In the first quarter of 2017, the Company commenced an offering to sell up to 4,000,000 shares of common stock at a price of $0.23 per share and warrants to purchase up to 2,000,000 shares of common stock excisable any time prior to the secondary anniversary of the issuance. The warrants are paired with the stock on the basis of one warrant for every two shares of stock purchased. During the first quarter of 2017, the Company received subscriptions in the amount of 2,817,156 shares and issued 1,408,578 warrants and proceeds in the amount of $647,944.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In March 2017, the Company issued 755,179 shares of common stock for the conversion of the outstanding balance of three notes payable totaling $499,802 (see Note 3).&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Noncontrolling Interest&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On April 1, 2016, the Company increased its ownership in Immudyne PR to 78.1667% decreasing the minority interest from 66.7% to 21.8333% resulting in a charge to noncontrolling interest and additional paid-in-capital of $91,612.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the three months ended March 31, 2017 and 2016, the net loss of Immudyne PR attributed to the noncontrolling interest amounted to $27,730 and $46,110, respectively.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Service-Based Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In May 2016, the Company issued 175,000 service-based options valued at $40,829 to two consultants at exercise prices of $0.20 per share. The options are fully vested and expire in 10 years.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style:
 initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In July 2016, the Company issued 50,000 service-based options valued at $12,397 to a consultant with an exercise price of $0.20 per share. The options are fully vested and expire in 10 years.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In November 2016, the Company issued 50,000 service-based options valued at $9,980 to a consultant with an exercise price of $0.50 per share. The options are fully vested and expire in 2 years.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In February 2017, the Company issued 500,000 service-based options valued at $113,522 to a director with an exercise price of $0.20 per share. The options are fully vested and expire in 10 years.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Accordingly, stock based compensation for the periods ended March 31, 2017 and 2016 included $113,522 and $-0-, respectively, related to such service-based stock options.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;A summary of the outstanding service-based options are as follows:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Number of&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Options&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 156px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;10,700,273&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Issued&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;500,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Balance at March 31, 2017&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom:
 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;11,200,273&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;All outstanding options are exercisable and have a cashless exercise provision, and certain options provide for accelerated vesting provisions and modifications, as defined, if the Company is sold or acquired. The intrinsic value of service based options outstanding and exercisable at March 31, 2017 and December 31, 2016 amounted to $3,261,859 and $704,794, respectively.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The significant assumptions used to determine the fair values of options issued, using the Black-Scholes option-pricing model are as follows:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="width: 48px; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Significant assumptions:&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="width: 141px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Risk-free interest rate at grant date&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; background-color: #cceeff;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;1.49&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected stock price volatility&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;216.7&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected dividend payout&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; background-color: #cceeff;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected option life-years&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;3&lt;/font&gt;&amp;#160;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Weighted average grant date fair value&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center; background-color: #cceeff;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;$0.24&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Forfeiture rate&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;0&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt;
 text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following is a summary of outstanding service-based options at March 31, 2017:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Exercise Price&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Number of&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Options&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Weighted Average Remaining Contractual Life&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="width: 48px; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$0.10&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,380,273&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: center; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: center; background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1 year&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$0.20 - $0.25&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;8,620,000&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;5 years&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$0.40&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,200,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;5 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-left: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Total&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;11,200,273&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Performance-Based Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal;
 orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;&lt;u&gt;Vested&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company granted performance-based options to purchase 2,925,000 shares of common stock at exercise prices of $0.40. The options expire at various dates between 2021 and 2026 and are exercisable upon the Company achieving annual sales revenue of $5,000,000. &amp;#160;During the year ended December 31, 2016, the Company cancelled 287,500 of these service-based options issued to two consultants, valued at $12,457.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The fair value of the vested performance-based options aggregated $120,867 and was expensed over the implicit service period commencing once management believed the performance criteria was met. During 2016, the Company met the performance criteria and accordingly, recorded stock based compensation expense of $38,867 for the three months ended March 31, 2016.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;&lt;u&gt;Unvested&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company granted performance-based options to purchase 1,150,000 shares of common stock at exercise prices of $0.40 and $0.80. The options expire at various dates between 2021 and 2027 and are exercisable upon the Company achieving annual sales revenue of $5,000,000 and $10,000,000. &amp;#160;During the year ended December 31, 2016, the Company cancelled 287,500 of these service-based options issued to two consultants, valued at $5,542.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The performance criteria for options exercisable upon the Company achieving annual sales revenue of $5,000,000 and $10,000,000 with an aggregate fair value of $85,608. As of March 31, 2017, no amounts have been expensed and the unearned compensation for all the performance based options is $85,608.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following is a summary of outstanding and exercisable warrants:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal;
 word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;Number of Shares&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Weighted Average&lt;/p&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Exercise Price&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;Year&amp;#160;of&amp;#160;&lt;br /&gt;Expiration&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"&gt;1,954,981&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"&gt;0.19&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 235px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2017 - 2019&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Issued&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;2,402,671&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;0.40&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"&gt;2019&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;
 font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Balance at March 31, 2017&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;4,357,562&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;0.31&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2017 - 2019&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In September 2016, the Company issued 100,000 warrants with an exercise price of $0.50 per share, in relation to a sale of common stock. These warrants are fully vested and expire in two years.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In September 2016, the Company issued 100,000 warrants with exercise prices between $0.20 and $0.50 per share, for consulting services. These warrants are fully vested and expire in three years.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In December 2016, the Company issued 37,500 warrants with an exercise price of $0.50 per share, in relation to a sale of common stock. These warrants are fully vested and expire in two years.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In December 2016, the Company issued 217,391 warrants with an exercise price of $0.40 per share, in relation to an issuance of common stock. These warrants are fully vested and expire in two years.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2;
 font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January 2017, the Company issued 591,745 warrants with an exercise price of $0.40 per share, in relation to an issuance of common stock for the conversion of an equity contribution into Immudyne PR by the noncontrolling interest. These warrants are fully vested and expire in two years.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In March 2017, the Company issued 403,348 warrants with an exercise price of $0.40 per share, in relation to an issuance of common stock for the conversion of debt. These warrants are fully vested and expire in two years.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In the first quarter of 2017, the Company issued 1,407,578 warrants with an exercise price of $0.40 per share, in relation to a sale of common stock. These warrants are fully vested and expire in two years.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The fair value of warrants granted during the period ended March 31, 2017, was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 219px; text-align: center; background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;181% - 211%&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1.03% - 2.22&lt;/font&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1.4 - 8.5&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Weighted average grant date fair value&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; background-color: #cceeff;"&gt;$&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.37 - 0.50&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt
 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of March 31, 2017 and December 31, 2016, certain of the Company&amp;#8217;s stock options, stock warrants and convertible debt instruments were accounted for as derivative liabilities due to insufficient authorized shares of common stock to settle outstanding contracts. At March 31, 2017 and December 31, 2016, the Company estimated the fair value of these stock options, stock warrants and embedded conversion features using the Black-Scholes option pricing model (&amp;#8220;Black-Scholes&amp;#8221;) to be $1,809,890 and $192,254, based on Level 2 valuation inputs.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Stock Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The total stock based compensation expense related Service-Based Stock Options, Performance-Based Stock Options and Warrants and common stock issued for service amounted to $190,189 and $38,867 for the three months ended March 31, 2017 and 2016, respectively. Such amounts are included in compensation and related expenses in the accompanying statement of operations.&lt;/p&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<immd:RoyaltiesDisclosureTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Royalties&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company was subject to a royalty agreement based upon sales of certain skin care products. The agreement required the Company to pay a royalty based upon 8% of such sales, up to $227,175. During the year ended December 31, 2015 the Company&amp;#8217;s sales reached the maximum amount under which the Company was required to pay a royalty under this agreement, accordingly no royalty expense was incurred for the three month periods ended March 31, 2017 and 2016, respectively. During December 2015, the Company&amp;#8217;s President who had a 60% interest in the royalties, converted royalties payable under the agreement in the amount of $84,868 to 499,225 shares of Company stock at $0.17 cents per share.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Included in accounts payable and accrued expenses at March 31, 2017 and December 31, 2016 was $56,579 in regards to this agreement.&lt;/p&gt;&lt;/div&gt;</immd:RoyaltiesDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;table style="width: 888.57px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Commitments and Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company leases a plant in Kentucky under an operating lease which expired on May 31, 2016. Management is currently discussing renewal lease options for the Kentucky plant and is operating on a month-to-month lease arrangement until a final agreement has been accepted. Monthly base rental payments are approximately $9,000. The Company&amp;#8217;s principal executive offices are in office space provided to us by the Company&amp;#8217;s President, Mr. McLaughlin, at the rate of $2,000 per month, which includes rents, utilities and other office related expenditures. This arrangement commenced as of January 1, 2016. In addition, Immudyne PR utilizes office space in Puerto Rico which is subleased from Justin Schreiber (President of Immudyne PR) and incurs expense of approximately $4,000 a month for this office space. Rent expense for the three month periods ended March 31, 2017 and 2016, was $36,061 and $16,616, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Employment and Consulting Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has entered into various agreements with officers, directors, employees and consultants that expire in one to five years. The agreements provide for annual compensation of up to $145,000 and the issuance of stock options, at exercise prices of $0.40 and $0.80, to purchase 4,400,000 shares of common stock issuable upon the Company&amp;#8217;s revenue exceeding $5,000,000 and $10,000,000, as defined. In addition, the agreements provide for bonus compensation to these individuals aggregating up to 15% (with no individual having more than 5%) of the Company&amp;#8217;s pretax income.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock and Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has entered into two agreements on April 1, 2016 with two consultants of Immudyne PR for business development, marketing and sales related services (the &amp;#8220;Consultant Agreements&amp;#8221;). The consultants are treated as employees for accounting purposes. Upon signing, each consultant was issued 1,000,000 restricted shares of Immudyne, Inc. common stock. In addition, each consultant shall receive an additional 150,000 restricted shares of Immudyne, Inc. common stock for each $500,000 distributed by Immudyne PR to the Company. For each consultant, the amount of shares to be issued by the Company to the consultants shall be capped at 1,500,000 restricted shares when Immudyne PR has transferred $5,000,000 to the Company, for a combined capped total of 3,000,000 restricted shares. For the three months ended March 31, 2017 and 2016, -0- restricted shares of common stock have been issued related to these agreements. During 2016, 2,300,000 restricted shares of common stock were issued related to these agreements. The Company valued the shares at their grant date for a value of $0.30 per share for a total of $690,000 to be expensed over the estimated service period ending December 31, 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman',
 times, serif; margin:
 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In addition, the Consulting Agreements provided that each consultant shall receive a bonus of an additional 750,000 restricted shares of Immudyne, Inc. common stock, plus an option to buy 1,000,000 shares of Immudyne, Inc. common stock at $0.20/share (including a cashless exercise feature) when Immudyne PR has transferred to the Company at each of the following three (3) thresholds: $1,250,000, $2,000,000 and $3,000,000 for a total of 2,250,000 of restricted shares of Immudyne, Inc. common stock and options to purchase up to 3,000,000 shares of Immudyne, Inc. common stock at $0.20/share. As of March 31, 2017, no bonus shares have been issued and no options have been granted under this agreement.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Sole and Exclusive License, Royalty, and Advisory Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On September 1, 2016 Immudyne PR entered into a sole and exclusive license, royalty and advisory agreement with Pilaris Laboratories, LLC (&amp;#8220;Pilaris&amp;#8221;) relating to Pilaris&amp;#8217; PilarisMax shampoo formulation and conditioner. The term of the agreement will be the life of the US Patent held by Pilaris. As consideration for granting Immudyne PR this license, Pilaris will receive on quarterly basis, 10% of the net income collected by the licensed products based on the following formula: Net Income = total income &amp;#8211; cost of goods sold &amp;#8211; advertising and operating expenses directly related to the marketing of the licensed products. In addition, Immudyne PR share pay Pilaris a performance fee of $50,000 on the 180-day anniversary of the agreement and an additional $50,000 performance fee on the 365-day anniversary of the agreement. As of March 31, 2017, the Company has accrued $58,333 expense related to this agreement.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Legal Matters&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In the normal course of business operations, the Company may become involved in various legal matters. At March 31, 2017, the Company&amp;#8217;s management does not believe that there are any potential legal matters that could have an adverse effect on the Company&amp;#8217;s financial position.&lt;/p&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;table style="width: 888.57px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Related Party Transactions&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;During 2016, legal and business advisory services were provided to the Company by one of its directors. For the three months ended March 31, 2016 this director was compensated $6,000. No services were provided during the three months ended March 31, 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;During the three months ended March 31, 2017 and 2016, the Company&amp;#8217;s President received $8,000 and $8,000, respectively for reimbursement of home office expenditures, including rent, utilities and other related expenses for two offices.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Immudyne, Inc. employs the wife of the President of the Company as an accountant and incurs $3,000 per month, plus an annual incentive bonus award equal to 0.5% of the Company&amp;#8217;s pre-tax earnings.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Immudyne PR utilizes BV Global Fulfillment, owned by the father of Immudyne PR&amp;#8217;s President, and incurred $10,396 for the three months ended March 31, 2017 for these services. During the three months ended March 31, 2016, Immudyne PR did not utilize BV Global Fulfillment.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Taggart International Trust (&amp;#8220;Taggart&amp;#8221;), a shareholder, provides credit card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;JLS Ventures LLC, owned by a shareholder, provides credit card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;JSDC, Inc., owned by a shareholder, provides credit card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Immudyne PR utilizes office space in Puerto Rico which
 is subleased from the
 President of Immudyne PR and incurs expense of approximately $4,000 a month for this office space.&lt;/p&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has evaluated subsequent events through the date these financial statements were issued.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On April 24, 2017, the Company, issued 217,390 shares of common stock pursuant to a stock subscription agreement and the Company issued 108,696 warrants with an exercise price of $0.40 per share for the stated consideration and satisfaction of obligation to pay $50,000 on the 180-day anniversary of the execution of the Sole and Exclusive License, Royalty, and Advisory Agreement dated September 1, 2016 with Pilaris Laboratories, LLC.&lt;/p&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (&amp;#8220;ASC 810&amp;#8221;).&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Immudyne PR and variable interest entities (VIE&amp;#8217;s) in which the Company has been determined to be the primary beneficiary. The non- controlling interest in Immudyne PR represents the 21.8333% equity interest held by other members of the joint venture. All significant consolidated transactions and balances have been eliminated in consolidation.&lt;/p&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
<immd:VariableInterestEntitiesPolicyTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Variable Interest Entities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company follows ASC 810-10-15 guidance with respect to accounting for variable interest entities (each, a &amp;#8220;VIE&amp;#8221;). These entities do not have sufficient equity at risk to finance their activities without additional subordinated financial support from other parties or whose equity investors lack any of the characteristics of a controlling financial interest. A variable interest is an investment or other interest that will absorb portions of a VIE&amp;#8217;s expected losses or receive portions of its expected residual returns and are contractual, ownership, or pecuniary in nature and that change with changes in the fair value of the entity&amp;#8217;s net assets. A reporting entity is the primary beneficiary of a VIE and must consolidate it when that party has a variable interest, or combination of variable interests, that provides it with a controlling financial interest. A party is deemed to have a controlling financial interest if it meets both of the power and losses/benefits criteria. The power criterion is the ability to direct the activities of the VIE that most significantly impact its economic performance. The losses/benefits criterion is the obligation to absorb losses from, or right to receive benefits from, the VIE that could potentially be significant to the VIE. The VIE model requires an ongoing reconsideration of whether a reporting entity is the primary beneficiary of a VIE due to changes in facts and circumstances.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;As of March 31, 2017 and December 31, 2016, the Company consolidated nine VIEs.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Immudyne PR as the primary beneficiary of Ace Account Management LLC, Innerwell Skincare LLC, MCD Merchants LLC, One Equity Research LLC, Inate Gems LLC, Retriever Health Products LLC, Spurs 5, LLC, Salus LLC and Huntley LLC which are qualified as VIEs. The assets and liabilities and revenues and expenses of these VIEs included in the financial statements of Immudyne PR and further included in the consolidated financial statements. As of March 31, 2017, the VIEs had assets of $19,421, liabilities of $5,748, revenues of $981, and operating expenses of $953. As of December 31, 2016, the VIEs had assets of $10,306, liabilities of $5,748. The assets and liabilities include balances due from and due to the subsidiaries of Immudyne PR. Any inter-company receivables and payables are eliminated upon consolidation of the VIE with Immudyne PR and Immudyne, Inc. No assets were pledged or given as collateral against any borrowings.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company utilizes third party entities to provide and increase credit card processing capacity and optimize corresponding rates and fees. A majority of these entities provide this service as independent contractors in exchange for a one percent (1%) fee of the net revenues processed and collected by such contractors from sales initiated by the Company. The VIEs consolidated in the Company&amp;#8217;s financial statements are primarily contracted to provide credit card processing through one or more merchant banks. Upon receipt of funds by each VIE, the collection of receipts less any returns, chargeback and other fees charged by such merchant bank is transferred to Immudyne PR.&lt;/p&gt;&lt;/div&gt;</immd:VariableInterestEntitiesPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the determination of reserves for accounts receivable, returns and allowances, the accounting for derivatives, the valuation of inventory and stockholders&amp;#8217; equity based transactions. Actual results could differ from those estimates.&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
<us-gaap:DerivativesPolicyTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Derivative Liabilities&lt;/i&gt;&lt;/b&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Under ASC 815-40-05, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in a Company&amp;#8217;s Own Stock, in the event the Company does not have a sufficient number of authorized and unissued shares of common stock to satisfy obligations for stock options, warrants and other instruments potentially convertible into common stock, the fair value of these instruments should be reported as a liability. Pursuant to the outstanding option, warrant and convertible debt agreements, there is currently no effective registration statement covering the shares of common stock underlying these agreements, which are currently subject to a cashless exercise whereby the holders, at their option, may surrender their options and warrants to the company in exchange for shares of common stock. The number of shares of common stock into which an option or a warrant would be exchangeable in such a cashless exercise depends on both the exercise price of the options or warrant and the market price of the common stock, each at or near the time of exercise. Because both of these factors are variable, it is possible that the Company could have insufficient authorized shares to satisfy a cashless exercise. In this scenario, if the Company were unable to obtain shareholder approval to increase the number of authorized shares, the Company could be obligated to settle such a cashless exercise with cash rather than by issuing shares of common stock. Further, ASC 815-40-05 requires that the Company record the potential settlement obligation at each reporting date using the current estimated fair value of these contracts, with any changes in fair value being recorded through our statement of operations. The Company will continue to report the potential settlement obligation as a liability until such time as these contracts are exercised or expire or we are otherwise able to modify the warrant agreement to remove the provisions which require this treatment. The Company also plans to amend its Articles of Incorporation in the third quarter of 2017 to increase the number of shares of its authorized common stock after the approval by its shareholders.&lt;/p&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
<immd:SequencingPolicyPolicyTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Sequencing Policy&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Under ASC 815-40-35, the Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company&amp;#8217;s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of authorized but unissued shares, and all future instruments being classified as a derivative liability, with the exception of instruments related to share-based compensation issued to employees or directors.&lt;/p&gt;&lt;/div&gt;</immd:SequencingPolicyPolicyTextBlock>
<us-gaap:InventoryPolicyTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Inventory&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;At March 31, 2017 and December 31, 2016, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic products. Inventory is maintained in the Company&amp;#8217;s leased Kentucky warehouse and third party warehouses in Pennsylvania and Louisiana.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Inventory is valued at the lower of cost or market with cost determined on a first-in, first-out (&amp;#8220;FIFO&amp;#8221;) basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to market value, if lower. At March 31, 2017 and December 31, 2016, the Company recorded an inventory reserve in the amount of $20,000. Inventory consists of the following:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;March&amp;#160;31,&lt;br /&gt;2017&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;December&amp;#160;31,&lt;br /&gt;2016&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Raw materials&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 113.63px; text-align: right; font-stretch: normal;"&gt;29,577&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 113.63px; text-align: right; font-stretch: normal;"&gt;38,460&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;Finished products&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;107,361&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;121,810&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman',
 times,
 serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;136,938&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;160,270&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer, and for sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped, but in limited cases if title does not pass until the product reaches the customer&amp;#8217;s delivery site, then recognition of revenue is deferred until that time. Delivery is considered to have occurred when title and risk of loss have transferred to the customer. Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates approximated $38,000 and $517,000 in the three months ended March 31, 2017 and 2016, respectively. There are no formal sales incentives offered to any of the Company&amp;#8217;s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Revenue for the three months ended March 31, 2017 consisted of nutraceutical and cosmetic additives ($256,563) and finished cosmetic products ($167,899). Revenue for the three months ended March 31, 2016 consists of nutraceutical and cosmetic additives ($265,910) and finished cosmetic products ($1,375,118).&lt;/p&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Accounts receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Accounts receivable are carried at original invoice amount less an estimate made for holdbacks and doubtful receivables based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&amp;#8217;s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers&amp;#8217; accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. At March 31, 2017 and December 31, 2016 the accounts receivable reserve was approximately $37,800 for both periods. As of March 31, 2017 and December 31, 2016, the reserve for sales returns and allowances was approximately $12,500 and $50,500, respectively.&lt;/p&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The guidance for disclosures about segments of an enterprise requires that a public business enterprise report financial and descriptive information about its operating segments. Generally, financial information is required to be reported on the basis used internally for evaluating segment performance and resource allocation. The Company manages its operations in two reportable segments for purposes of assessing performance and making operating decisions. Revenue is generated predominately in the United States, and all significant assets are held in the United States, or United States territories.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company allocates resources and evaluates the performance of segments based on income or loss from operations, excluding interest, corporate expenses and other income (expenses).&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;A summary of the company&amp;#8217;s reportable segments is as follows:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;Total assets:&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;March&amp;#160;31,&lt;br /&gt;2017&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;December&amp;#160;31,&lt;br /&gt;2016&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Nutraceutical and Cosmetic Additives&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"&gt;1,350,785&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"&gt;556,234&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch:
 normal;"&gt;Finished Cosmetic Products&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;385,345&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;422,288&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;Eliminations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(662,428&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(188,698&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;Total&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;1,073,702&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;789,824&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;Three Months ended&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;March&amp;#160;31, 2017&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;March&amp;#160;31, 2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Net sales by segment:&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Nutraceutical and Cosmetic Additives&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 125px;
 text-align: right;"&gt;256,563&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 125px; text-align: right;"&gt;285,160&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Finished Cosmetic Products&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;167,899&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,375,118&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;Eliminations&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(19,250&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;424,462&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,641,028&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; text-decoration: underline;"&gt;Net (loss) income by segment:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Nutraceutical and Cosmetic Additives&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;26,807&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;84,777&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Finished Cosmetic Products&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(127,007&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(69,165&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; text-decoration: underline;"&gt;Other unallocated amounts:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Corporate expenses&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(274,786&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(120,708&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Other income (expense)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(697,549&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(3,063&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;Net (loss)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(1,072,535&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(108,159&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company files Corporate Federal and State tax returns, while Immudyne PR, which was formed as a limited liability corporation, files a separate tax return with any tax liabilities or benefits passing through to its members.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company records current and deferred taxes in accordance with Accounting Standards Codification (ASC) 740, &amp;#8220;Accounting for Income Taxes.&amp;#8221; This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s tax returns for all years since December 31, 2013, remain open to taxing authorities.&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company follows the provisions of ASC 718, &amp;#8220;Share-Based Payment&amp;#8221;. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company&amp;#8217;s shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.&lt;/p&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Earnings (Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Common stock equivalents comprising shares underlying 18,295,335 options and warrants for the three months ended March 31, 2017 have not been included in the loss per share calculation as the effects are anti-dilutive. Common stock equivalents comprising shares underlying 12,525,273 options and warrants for the three months ended March 31, 2016 have not been included in the loss per share calculations as the effects are anti-dilutive.&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017 but early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (&amp;#8220;ASU 2016-15&amp;#8221;). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of adoption of ASU 2016-15.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement on its consolidated financial statements. At this time, the adoption of this pronouncement is not expected to have a material impact on the Company&amp;#8217;s consolidated financial statements or related disclosures.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In May 2014, the Financial Accounting Standards Board ("FASB") issued accounting guidance, "Revenue from Contracts with Customers." The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal year 2018. The Company does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt
 0px 0pt
 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<immd:MinorityInterestPolicyTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Noncontrolling Interests&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest&amp;#8217;s share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.&lt;/p&gt;&lt;/div&gt;</immd:MinorityInterestPolicyTextBlock>
<us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Consolidation of Variable Interest Entities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In accordance with ASC 810-10-25-37 and as amended by ASU 2009-17, the Company determines whether any legal entity in which the Company becomes involved is a VIE and subject to consolidation. The Company conducts an assessment on an ongoing basis for each VIE including (1) the power to direct activities of the VIE that most significantly impact the VIE&amp;#8217;s economic performance, and (2) the obligation to absorb losses or right to receive benefits from the VIE that could potentially be significant to the VIE. As a result, the Company determined that nine (9) entities were VIEs and subject to consolidation.&lt;/p&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
<us-gaap:ConcentrationRiskCreditRisk contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;One customer in the nutraceutical and cosmetic additives division accounted for 59% and 16% of consolidated sales for the three months ended March 31, 2017 and 2016, respectively. This customer also accounted for 45% and 54% of accounts receivable at March 31, 2017 and December 31, 2016, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In the finished cosmetic products division, two credit card processors accounted for 42% and 35% of accounts receivable at March 31, 2017. In the finished cosmetic products division, two credit card processors accounted for 35% and 32% of accounts receivable at December 31, 2016.&lt;/p&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;div&gt;&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;March&amp;#160;31,&lt;br /&gt;2017&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;December&amp;#160;31,&lt;br /&gt;2016&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Raw materials&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 113.63px; text-align: right; font-stretch: normal;"&gt;29,577&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 113.63px; text-align: right; font-stretch: normal;"&gt;38,460&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;Finished products&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;107,361&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;121,810&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;136,938&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;160,270&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
<us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;Total assets:&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2"&gt;March&amp;#160;31,&lt;br /&gt;2017&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2"&gt;December&amp;#160;31,&lt;br /&gt;2016&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;Nutraceutical and Cosmetic Additives&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;1,350,785&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;556,234&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;Finished Cosmetic Products&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;385,345&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;422,288&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;Eliminations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;(662,428&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;(188,698&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;Total&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal
 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;1,073,702&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;789,824&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;Three Months ended&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;March&amp;#160;31, 2017&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;March&amp;#160;31, 2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Net sales by segment:&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Nutraceutical and Cosmetic Additives&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 125px; text-align: right;"&gt;256,563&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 125px; text-align: right;"&gt;285,160&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Finished Cosmetic Products&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;167,899&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,375,118&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;Eliminations&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(19,250&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;424,462&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,641,028&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align:
 left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; text-decoration: underline;"&gt;Net (loss) income by segment:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Nutraceutical and Cosmetic Additives&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;26,807&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;84,777&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Finished Cosmetic Products&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(127,007&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(69,165&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; text-decoration: underline;"&gt;Other unallocated amounts:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Corporate expenses&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(274,786&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(120,708&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Other income (expense)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(697,549&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(3,063&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;Net (loss)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(1,072,535&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(108,159&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">&lt;table style="width: 888px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Net operating loss&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 70px; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;1,699,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Accounts receivable reserves&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;17,000&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Inventory reserves&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;7,000&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Stock compensation&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-size: 10pt;"&gt;229,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Net deferred tax asset&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;1,952,000&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-size: 10pt;"&gt;(1,952,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 10pt; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; background-color: #cceeff;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">&lt;div&gt;&lt;table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Number of&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Options&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 124.8px; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;10,700,273&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Issued&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;500,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Balance at March 31, 2017&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;11,200,273&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">&lt;div&gt;&lt;table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;Number of Shares&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Weighted Average&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;Year&amp;#160;of&amp;#160;&lt;br /&gt;Expiration&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 112px; text-align: right; font-stretch: normal;"&gt;1,954,981&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 112px; text-align: right; font-stretch: normal;"&gt;0.19&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 187.2px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2017 - 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Issued&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;2,402,671&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;0.40&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"&gt;2019&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size:
 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Balance at March 31, 2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;4,357,562&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;0.31&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2017 - 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">&lt;div&gt;&lt;table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 48px; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Significant assumptions:&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="width: 112px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Risk-free interest rate at grant date&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; background-color: #cceeff;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;1.49&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected stock price volatility&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;216.7&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected dividend payout&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; background-color: #cceeff;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected option life-years&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;3&lt;/font&gt;&amp;#160;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Weighted average grant date fair value&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; background-color: #cceeff;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;$0.24&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Forfeiture rate&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;0&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
<us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">&lt;div&gt;&lt;table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 36pt; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 174.4px; text-align: center; background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;181% - 211%&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1.03% - 2.22&lt;/font&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1.4 - 8.5&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Weighted average grant date fair value&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; background-color: #cceeff;"&gt;$&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.37 - 0.50&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">&lt;div&gt;&lt;table style="width: 888px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Exercise Price&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Number of&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Options&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Weighted Average Remaining Contractual Life&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 48px; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$0.10&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 79px; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,380,273&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8px; text-align: center; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 79px; text-align: center; background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1 year&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$0.20 - $0.25&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;8,620,000&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;5 years&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$0.40&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,200,000&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; background-color: #cceeff;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;5 years&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;11,200,273&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_InnateScientificLlcMember" unitRef="pure" decimals="3">0.333</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ImmudynePrLlcMember" unitRef="pure" decimals="6">0.781667</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_InnateScientificLlcMember" unitRef="pure" decimals="2">0.51</us-gaap:MinorityInterestOwnershipPercentageByParent>
<us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="USD" decimals="0">91612</us-gaap:MinorityInterestPeriodIncreaseDecrease>
<us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">91612</us-gaap:MinorityInterestPeriodIncreaseDecrease>
<us-gaap:InventoryRawMaterials contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">38460</us-gaap:InventoryRawMaterials>
<us-gaap:InventoryRawMaterials contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">29577</us-gaap:InventoryRawMaterials>
<us-gaap:InventoryFinishedGoods contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">121810</us-gaap:InventoryFinishedGoods>
<us-gaap:InventoryFinishedGoods contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">107361</us-gaap:InventoryFinishedGoods>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">789824</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="USD" decimals="0">556234</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember" unitRef="USD" decimals="0">422288</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="USD" decimals="0">-188698</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">1073702</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="USD" decimals="0">1350785</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember" unitRef="USD" decimals="0">385345</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="USD" decimals="0">-662428</us-gaap:Assets>
<immd:CorporateExpenses contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">120708</immd:CorporateExpenses>
<immd:CorporateExpenses contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">274786</immd:CorporateExpenses>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-3063</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-697549</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">-108159</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-1072535</us-gaap:NonoperatingIncomeExpense>
<immd:MinorityInterestRate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="pure" decimals="6">0.218333</immd:MinorityInterestRate>
<us-gaap:InventoryLIFOReserve contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">20000</us-gaap:InventoryLIFOReserve>
<us-gaap:InventoryLIFOReserve contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">20000</us-gaap:InventoryLIFOReserve>
<us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">517000</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
<us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">38000</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">12525273</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">18295335</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="pure" decimals="2">0.16</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember" unitRef="pure" decimals="2">0.54</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_OneCreditCardProcessorsMember" unitRef="pure" decimals="2">0.35</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_TwoCreditCardProcessorsMember" unitRef="pure" decimals="2">0.32</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="pure" decimals="2">0.59</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember" unitRef="pure" decimals="2">0.45</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_OneCreditCardProcessorsMember" unitRef="pure" decimals="2">0.42</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_TwoCreditCardProcessorsMember" unitRef="pure" decimals="2">0.35</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:AccountsReceivableNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">37800</us-gaap:AccountsReceivableNet>
<us-gaap:AccountsReceivableNet contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">37800</us-gaap:AccountsReceivableNet>
<immd:NonControllingInterestDescription contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">100000</immd:NonControllingInterestDescription>
<us-gaap:SalesReturnsAndAllowancesGoods contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">50500</us-gaap:SalesReturnsAndAllowancesGoods>
<us-gaap:SalesReturnsAndAllowancesGoods contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">12500</us-gaap:SalesReturnsAndAllowancesGoods>
<us-gaap:VariableInterestEntityConclusionToConsolidate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">Company consolidated nine VIEs.</us-gaap:VariableInterestEntityConclusionToConsolidate>
<us-gaap:VariableInterestEntityConclusionToConsolidate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">Company consolidated nine VIEs.</us-gaap:VariableInterestEntityConclusionToConsolidate>
<us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">10306</us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets>
<us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">19421</us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets>
<us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">5748</us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities>
<us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">5748</us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities>
<us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityRevenues contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">981</us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityRevenues>
<us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">953</us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss>
<immd:NoncontrollingInterestsDescription contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest's share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.</immd:NoncontrollingInterestsDescription>
<us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">More than 50</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_30_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00" unitRef="pure" decimals="2">0.11</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="pure" decimals="2">0.11</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_Custom_02_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00">2016-11-01</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_OfficerMember">2017-02-28</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="pure" decimals="2">0.11</us-gaap:DebtInstrumentInterestRateDuringPeriod>
<us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">68600</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of_28_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00" unitRef="USD" decimals="0">70000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">81420</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">200000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:ConvertibleDebt contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_OfficerMember" unitRef="USD" decimals="0">100000</us-gaap:ConvertibleDebt>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.23</us-gaap:DebtInstrumentConvertibleConversionPrice1>
<invest:InvestmentOptionsExercisePrice contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.40</invest:InvestmentOptionsExercisePrice>
<immd:TermOfWarrant contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">P3Y</immd:TermOfWarrant>
<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="pure" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
<us-gaap:DebtConversionOriginalDebtAmount1 contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="USD" decimals="0">210000</us-gaap:DebtConversionOriginalDebtAmount1>
<immd:CommonStockSharesIssuedRelatedPromissoryNote contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00" unitRef="shares" decimals="INF">217391</immd:CommonStockSharesIssuedRelatedPromissoryNote>
<us-gaap:InterestExpenseDebt contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">131117</us-gaap:InterestExpenseDebt>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Aug_2016T00_00_00_TO_31_Aug_2016T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="USD" decimals="0">150000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">50000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="USD" decimals="0">150000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="USD" decimals="0">50000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00" unitRef="USD" decimals="0">210000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="USD" decimals="0">200000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_28_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00" unitRef="USD" decimals="0">25000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_28_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperTwoMember" unitRef="USD" decimals="0">100000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">499802</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperOneMember" unitRef="USD" decimals="0">50000</us-gaap:NotesPayable>
<immd:FlatFee contextRef="Context_Custom_01_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00" unitRef="USD" decimals="0">250</immd:FlatFee>
<us-gaap:DebtInstrumentTerm contextRef="Context_Custom_01_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00">P60D</us-gaap:DebtInstrumentTerm>
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">49980</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">140000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">196000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">98000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">559179</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">304348</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<immd:ConversionOfFairMarketValueSharesAndWarrantsIssued contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00" unitRef="USD" decimals="0">566030</immd:ConversionOfFairMarketValueSharesAndWarrantsIssued>
<immd:ConversionOfFairMarketValueSharesAndWarrantsIssued contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">179384</immd:ConversionOfFairMarketValueSharesAndWarrantsIssued>
<us-gaap:LitigationSettlementInterest contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00" unitRef="USD" decimals="0">423818</us-gaap:LitigationSettlementInterest>
<us-gaap:LitigationSettlementInterest contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">129404</us-gaap:LitigationSettlementInterest>
<us-gaap:InterestReceivable contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">2212</us-gaap:InterestReceivable>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">1699000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">17000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
<us-gaap:DeferredTaxAssetsInventory contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">7000</us-gaap:DeferredTaxAssetsInventory>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">229000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">1952000</us-gaap:DeferredTaxAssetsGross>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">1952000</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">4294800</us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">2037-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="pure" decimals="2">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">10700273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">1954981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">11200273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">4357562</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember" unitRef="shares" decimals="0">1380273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember" unitRef="shares" decimals="INF">8620000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember" unitRef="shares" decimals="INF">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="shares" decimals="INF">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_Jul_2016T00_00_00_TO_31_Jul_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_DirectorMember" unitRef="shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_VestedMember" unitRef="shares" decimals="INF">2925000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_UnvestedMember" unitRef="shares" decimals="INF">1150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">2402671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">0.0149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.0222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="3">2.167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember" unitRef="pure" decimals="2">2.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember" unitRef="pure" decimals="2">1.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember">P8Y6M0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember">P1Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
<immd:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.00</immd:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_01_Jul_2016T00_00_00_TO_31_Jul_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_01_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD_per_Share" decimals="2">0.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_01_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_DirectorMember" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_VestedMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_RangeAxis_MinimumMember_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_UnvestedMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_RangeAxis_MaximumMember_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_UnvestedMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<immd:ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">2017-2019</immd:ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration>
<immd:ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">2019</immd:ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued>
<immd:ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">2017-2019</immd:ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration>
<us-gaap:CommonStockOtherSharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">325000</us-gaap:CommonStockOtherSharesOutstanding>
<us-gaap:CommonStockOtherSharesOutstanding contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="INF">12800</us-gaap:CommonStockOtherSharesOutstanding>
<immd:PurchaseOfCommonStockDescriptionOfTransaction contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;Common stock through an exchange for a price per share of $0.23 to $0.29.&lt;/div&gt;</immd:PurchaseOfCommonStockDescriptionOfTransaction>
<immd:PurchaseOfCommonStockDescriptionOfTransaction contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">Common stock for a price per share of $0.24 to $0.26.</immd:PurchaseOfCommonStockDescriptionOfTransaction>
<us-gaap:ConversionOfStockAmountConverted1 contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="USD" decimals="0">272203</us-gaap:ConversionOfStockAmountConverted1>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">76667</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="INF">4000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD_per_Share" decimals="2">0.23</us-gaap:SaleOfStockPricePerShare>
<immd:WarrantsToPurchaseOfCommonStock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="INF">2000000</immd:WarrantsToPurchaseOfCommonStock>
<us-gaap:CommonStockSharesSubscribedButUnissued contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="INF">2817156</us-gaap:CommonStockSharesSubscribedButUnissued>
<us-gaap:CommonStockSharesSubscribedButUnissued contextRef="Context_As_Of_24_Apr_2017T00_00_00_TO_24_Apr_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">217390</us-gaap:CommonStockSharesSubscribedButUnissued>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="INF">1408578</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_Custom_01_Apr_2017T00_00_00_TO_24_Apr_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">108696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:CommonStockSharesSubscriptions contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">647944</us-gaap:CommonStockSharesSubscriptions>
<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="INF">755179</us-gaap:ConversionOfStockSharesIssued1>
<us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="pure" decimals="6">0.781667</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
<us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember_RangeAxis_MaximumMember" unitRef="pure" decimals="3">0.667</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
<us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember_RangeAxis_MinimumMember" unitRef="pure" decimals="6">0.218333</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD" decimals="0">40829</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="Context_Custom_01_Jul_2016T00_00_00_TO_31_Jul_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD" decimals="0">12397</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="Context_Custom_01_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD" decimals="0">9980</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="Context_Custom_01_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_DirectorMember" unitRef="USD" decimals="0">113522</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Context_Custom_01_Jul_2016T00_00_00_TO_31_Jul_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Context_Custom_01_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Context_Custom_01_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_DirectorMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<immd:NumberOfConsultant contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="Consultants" decimals="INF">2</immd:NumberOfConsultant>
<immd:NumberOfConsultant contextRef="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="Consultants" decimals="INF">2</immd:NumberOfConsultant>
<immd:NumberOfConsultant contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_VestedMember" unitRef="Consultants" decimals="INF">2</immd:NumberOfConsultant>
<immd:NumberOfConsultant contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_UnvestedMember" unitRef="Consultants" decimals="INF">2</immd:NumberOfConsultant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">704794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">3261859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">2017-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_RangeAxis_MinimumMember_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_UnvestedMember">2021-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_RangeAxis_MaximumMember_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_UnvestedMember">2027-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_RangeAxis_MinimumMember_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_VestedMember">2021-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_RangeAxis_MaximumMember_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_VestedMember">2026-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
<immd:AnnualSalesRevenueTarget contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_VestedMember" unitRef="USD" decimals="0">5000000</immd:AnnualSalesRevenueTarget>
<immd:AnnualSalesRevenueTarget contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_RangeAxis_MinimumMember" unitRef="USD" decimals="0">5000000</immd:AnnualSalesRevenueTarget>
<immd:AnnualSalesRevenueTarget contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_RangeAxis_MaximumMember" unitRef="USD" decimals="0">10000000</immd:AnnualSalesRevenueTarget>
<immd:AnnualSalesRevenueTarget contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_RangeAxis_MinimumMember_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_UnvestedMember" unitRef="USD" decimals="0">5000000</immd:AnnualSalesRevenueTarget>
<immd:AnnualSalesRevenueTarget contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_RangeAxis_MaximumMember_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_UnvestedMember" unitRef="USD" decimals="0">10000000</immd:AnnualSalesRevenueTarget>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_VestedMember" unitRef="shares" decimals="INF">287500</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_UnvestedMember" unitRef="shares" decimals="INF">287500</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_VestedMember" unitRef="USD" decimals="0">12457</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_UnvestedMember" unitRef="USD" decimals="0">5542</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
<immd:FairValueOfPerformanceBasedStockOptions contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">192254</immd:FairValueOfPerformanceBasedStockOptions>
<immd:FairValueOfPerformanceBasedStockOptions contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">1809890</immd:FairValueOfPerformanceBasedStockOptions>
<immd:FairValueOfPerformanceBasedStockOptions contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_VestingAxis_VestedMember" unitRef="USD" decimals="0">120867</immd:FairValueOfPerformanceBasedStockOptions>
<immd:AggregateOfFairValue contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="USD" decimals="0">85608</immd:AggregateOfFairValue>
<us-gaap:DeferredCompensationEquity contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="USD" decimals="0">85608</us-gaap:DeferredCompensationEquity>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember" unitRef="shares" decimals="INF">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember" unitRef="shares" decimals="INF">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember" unitRef="shares" decimals="INF">37500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember" unitRef="shares" decimals="INF">217391</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember" unitRef="shares" decimals="INF">591745</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember" unitRef="shares" decimals="INF">403348</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_WarrantOneMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember" unitRef="shares" decimals="INF">1407578</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD_per_Share" decimals="2">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_RangeAxis_MinimumMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember" unitRef="USD_per_Share" decimals="2">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD_per_Share" decimals="2">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.19</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_WarrantOneMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_24_Apr_2017T00_00_00_TO_24_Apr_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_02_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_02_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_WarrantOneMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<immd:UnamortizedOfServiceAgreements contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">306667</immd:UnamortizedOfServiceAgreements>
<immd:UnamortizedOfServiceAgreements contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">230000</immd:UnamortizedOfServiceAgreements>
<immd:PercentageOfRoyaltyBasedUponSales contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="pure" decimals="2">0.08</immd:PercentageOfRoyaltyBasedUponSales>
<immd:RoyaltyBasedUponSalesAmount contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">227175</immd:RoyaltyBasedUponSalesAmount>
<us-gaap:RoyaltyExpense contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:RoyaltyExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<immd:InterestInRoyalty contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PresidentMember" unitRef="pure" decimals="2">0.60</immd:InterestInRoyalty>
<us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PresidentMember" unitRef="USD" decimals="0">84868</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PresidentMember" unitRef="USD_per_Share" decimals="2">0.17</us-gaap:SharesIssuedPricePerShare>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">56579</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">56579</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:LeaseExpirationDate1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">2016-05-31</us-gaap:LeaseExpirationDate1>
<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">9000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
<us-gaap:LeaseAndRentalExpense contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">16616</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseAndRentalExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">36061</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseAndRentalExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_TitleOfIndividualAxis_PresidentMember" unitRef="USD" decimals="0">2000</us-gaap:LeaseAndRentalExpense>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="USD" decimals="0">4000</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:SalariesWagesAndOfficersCompensation contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">145000</us-gaap:SalariesWagesAndOfficersCompensation>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
<immd:StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="INF">4400000</immd:StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock>
<us-gaap:SalesRevenueNet contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">5000000</us-gaap:SalesRevenueNet>
<immd:SalesRevenueIncreased contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">10000000</immd:SalesRevenueIncreased>
<immd:BonusPercentageOfCompensationForPretaxIncome contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="pure" decimals="2">0.15</immd:BonusPercentageOfCompensationForPretaxIncome>
<immd:PertaxIncomePercentage contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="pure" decimals="2">0.05</immd:PertaxIncomePercentage>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="shares" decimals="INF">150000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="shares" decimals="INF">1000000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="INF">2250000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="USD" decimals="0">5000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_RestrictedStockOneMember" unitRef="USD" decimals="0">1250000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_RestrictedStockTwoMember" unitRef="USD" decimals="0">2000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_RestrictedStockThreeMember" unitRef="USD" decimals="0">3000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<immd:DebtLongTermAndShortTermCombinedAmountShares contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="shares" decimals="INF">3000000</immd:DebtLongTermAndShortTermCombinedAmountShares>
<immd:DebtLongTermAndShortTermCombinedAmountShares contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="shares" decimals="0">1500000</immd:DebtLongTermAndShortTermCombinedAmountShares>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.30</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:SharePrice>
<us-gaap:RestrictedStockExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD" decimals="0">690000</us-gaap:RestrictedStockExpense>
<immd:BonusShares contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_RestrictedStockOneMember" unitRef="shares" decimals="INF">750000</immd:BonusShares>
<immd:OptionToBuyShares contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_RestrictedStockOneMember" unitRef="shares" decimals="INF">1000000</immd:OptionToBuyShares>
<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="INF">3000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
<immd:NumerOfThresholds contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="Thresholds" decimals="INF">3</immd:NumerOfThresholds>
<us-gaap:IntercompanyAgreementsDescription contextRef="Context_Custom_26_Aug_2016T00_00_00_TO_01_Sep_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember">In addition, Immudyne PR share pay Pilaris a performance fee of $50,000 on the 180-day anniversary of the agreement and an additional $50,000 performance fee on the 365-day anniversary of the agreement. As of March 31, 2017, the Company has accrued $58,333 expense related to this agreement.</us-gaap:IntercompanyAgreementsDescription>
<us-gaap:PremiumsPercentageAssumedToNet contextRef="Context_Custom_26_Aug_2016T00_00_00_TO_01_Sep_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="pure" decimals="2">0.10</us-gaap:PremiumsPercentageAssumedToNet>
<us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">58333</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
<immd:ReimbursementOfHomeOfficeExpenditures contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00_TitleOfIndividualAxis_PresidentMember" unitRef="USD" decimals="0">8000</immd:ReimbursementOfHomeOfficeExpenditures>
<immd:ReimbursementOfHomeOfficeExpenditures contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_TitleOfIndividualAxis_PresidentMember" unitRef="USD" decimals="0">8000</immd:ReimbursementOfHomeOfficeExpenditures>
<immd:CompensationForLegalServices contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="-3">6000000</immd:CompensationForLegalServices>
<immd:CompensationForLegalServices contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="USD" decimals="0">10396</immd:CompensationForLegalServices>
<immd:AnnualIncentiveBonusAwardPercentage contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="pure" decimals="3">0.005</immd:AnnualIncentiveBonusAwardPercentage>
<us-gaap:ContractualObligation contextRef="Context_As_Of_24_Apr_2017T00_00_00_TO_24_Apr_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">50000</us-gaap:ContractualObligation>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>immd-20170331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Friday, July 07, 2017 09:57:37 PM -->
<schema targetNamespace="http://www.immudyne.com/20170331" elementFormDefault="qualified" xmlns:immd="http://www.immudyne.com/20170331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation><appinfo>
<link:roleType roleURI="http://www.immudyne.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/Consolidatedbalancesheets" id="Consolidatedbalancesheets">
<link:definition>002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/ConsolidatedStatementsOfOperationsUnaudited" id="ConsolidatedStatementsOfOperationsUnaudited">
<link:definition>004 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/ConsolidatedStatementOfStockholdersEquityDeficitUnaudited" id="ConsolidatedStatementOfStockholdersEquityDeficitUnaudited">
<link:definition>005 - Statement - Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" id="ConsolidatedStatementsOfCashFlowsUnaudited">
<link:definition>006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/OrganizationAndGoingConcern" id="OrganizationAndGoingConcern">
<link:definition>007 - Disclosure - Organization and Going Concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/NotesPayable" id="NotesPayable">
<link:definition>009 - Disclosure - Notes Payable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>010 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>011 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/Royalties" id="Royalties">
<link:definition>012 - Disclosure - Royalties</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>013 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>014 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>015 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>016 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>017 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>018 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
<link:definition>019 - Disclosure - Stockholders' Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/OrganizationAndGoingConcernDetails" id="OrganizationAndGoingConcernDetails">
<link:definition>020 - Disclosure - Organization and Going Concern (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
<link:definition>021 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails1" id="SummaryOfSignificantAccountingPoliciesDetails1">
<link:definition>022 - Disclosure - Summary of Significant Accounting Policies (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/Summaryofsignificantaccountingpoliciesdetailstextual" id="Summaryofsignificantaccountingpoliciesdetailstextual">
<link:definition>023 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/NotesPayableDetails" id="NotesPayableDetails">
<link:definition>024 - Disclosure - Notes Payable (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
<link:definition>025 - Disclosure - Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/IncomeTaxesDetailsTextual" id="IncomeTaxesDetailsTextual">
<link:definition>026 - Disclosure - Income Taxes (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
<link:definition>027 - Disclosure - Stockholders' Equity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
<link:definition>028 - Disclosure - Stockholders' Equity (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
<link:definition>029 - Disclosure - Stockholders' Equity (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityDetails4" id="StockholdersEquityDetails4">
<link:definition>030 - Disclosure - Stockholders' Equity (Details 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityDetails5" id="StockholdersEquityDetails5">
<link:definition>031 - Disclosure - Stockholders' Equity (Details 4)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityDetailsTextual" id="StockholdersEquityDetailsTextual">
<link:definition>032 - Disclosure - Stockholders' Equity (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/RoyaltiesDetails" id="RoyaltiesDetails">
<link:definition>033 - Disclosure - Royalties (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
<link:definition>034 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
<link:definition>035 - Disclosure - Related Party Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>036 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="immd-20170331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="immd-20170331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="immd-20170331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="immd-20170331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="immd_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="Equity" id="immd_Equity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CompensationAndRelatedExpenses" id="immd_CompensationAndRelatedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ChangeInFairValueOfDerivativeLiability" id="immd_ChangeInFairValueOfDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SummationMember" id="immd_SummationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" id="immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfCommonStockAndWarrants" id="immd_IssuanceOfCommonStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" id="immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities" id="immd_ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RoyaltiesAbstract" id="immd_RoyaltiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RoyaltiesDisclosureTextBlock" id="immd_RoyaltiesDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="VariableInterestEntitiesPolicyTextBlock" id="immd_VariableInterestEntitiesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SequencingPolicyPolicyTextBlock" id="immd_SequencingPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MinorityInterestPolicyTextBlock" id="immd_MinorityInterestPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ImmudynePrLlcMember" id="immd_ImmudynePrLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InnateScientificLlcMember" id="immd_InnateScientificLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OrganizationAndGoingConcernTextualAbstract" id="immd_OrganizationAndGoingConcernTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NutraceuticalAndCosmeticMember" id="immd_NutraceuticalAndCosmeticMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CosmeticGoodsMember" id="immd_CosmeticGoodsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OtherUnallocatedAmountsAbstract" id="immd_OtherUnallocatedAmountsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CorporateExpenses" id="immd_CorporateExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConcentrationRiskNumberOfCustomersAxis" id="immd_ConcentrationRiskNumberOfCustomersAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="ConcentrationRiskNumberOfCustomersDomain" id="immd_ConcentrationRiskNumberOfCustomersDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OneCustomerMember" id="immd_OneCustomerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SecondCustomerMember" id="immd_SecondCustomerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OneCreditCardProcessorsMember" id="immd_OneCreditCardProcessorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoCreditCardProcessorsMember" id="immd_TwoCreditCardProcessorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SummaryOfSignificantAccountingPoliciesTextualAbstract" id="immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MinorityInterestRate" id="immd_MinorityInterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NonControllingInterestDescription" id="immd_NonControllingInterestDescription" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NoncontrollingInterestsDescription" id="immd_NoncontrollingInterestsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommercialLenderMember" id="immd_CommercialLenderMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommercialPaperOneMember" id="immd_CommercialPaperOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommercialPaperTwoMember" id="immd_CommercialPaperTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NotesPayableMember" id="immd_NotesPayableMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NotesPayableTextualAbstract" id="immd_NotesPayableTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TermOfWarrant" id="immd_TermOfWarrant" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockSharesIssuedRelatedPromissoryNote" id="immd_CommonStockSharesIssuedRelatedPromissoryNote" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FlatFee" id="immd_FlatFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConversionOfFairMarketValueSharesAndWarrantsIssued" id="immd_ConversionOfFairMarketValueSharesAndWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncomeTaxesTextualAbstract" id="immd_IncomeTaxesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" id="immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExercisePriceRangeOneMember" id="immd_ExercisePriceRangeOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExercisePriceRangeTwoMember" id="immd_ExercisePriceRangeTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExercisePriceRangeThreeMember" id="immd_ExercisePriceRangeThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" id="immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" id="immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" id="immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConsultantMember" id="immd_ConsultantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PerformanceBasedStockOptionsMember" id="immd_PerformanceBasedStockOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantOneMember" id="immd_WarrantOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="VestedMember" id="immd_VestedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UnvestedMember" id="immd_UnvestedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConsultingServicesMember" id="immd_ConsultingServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfCommonStockMember" id="immd_IssuanceOfCommonStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockholdersEquityTextualAbstract" id="immd_StockholdersEquityTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PurchaseOfCommonStockDescriptionOfTransaction" id="immd_PurchaseOfCommonStockDescriptionOfTransaction" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsToPurchaseOfCommonStock" id="immd_WarrantsToPurchaseOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfConsultant" id="immd_NumberOfConsultant" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AnnualSalesRevenueTarget" id="immd_AnnualSalesRevenueTarget" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfPerformanceBasedStockOptions" id="immd_FairValueOfPerformanceBasedStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AggregateOfFairValue" id="immd_AggregateOfFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UnamortizedOfServiceAgreements" id="immd_UnamortizedOfServiceAgreements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RoyaltiesTextualAbstract" id="immd_RoyaltiesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfRoyaltyBasedUponSales" id="immd_PercentageOfRoyaltyBasedUponSales" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RoyaltyBasedUponSalesAmount" id="immd_RoyaltyBasedUponSalesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InterestInRoyalty" id="immd_InterestInRoyalty" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommitmentsAndContingenciesTable" id="immd_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="RestrictedStockOneMember" id="immd_RestrictedStockOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RestrictedStockTwoMember" id="immd_RestrictedStockTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RestrictedStockThreeMember" id="immd_RestrictedStockThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommitmentsAndContingenciesLineItems" id="immd_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommitmentsAndContingenciesTextualAbstract" id="immd_CommitmentsAndContingenciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" id="immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SalesRevenueIncreased" id="immd_SalesRevenueIncreased" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BonusPercentageOfCompensationForPretaxIncome" id="immd_BonusPercentageOfCompensationForPretaxIncome" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PertaxIncomePercentage" id="immd_PertaxIncomePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DebtLongTermAndShortTermCombinedAmountShares" id="immd_DebtLongTermAndShortTermCombinedAmountShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BonusShares" id="immd_BonusShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionToBuyShares" id="immd_OptionToBuyShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumerOfThresholds" id="immd_NumerOfThresholds" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RelatedPartyTransactionsTextualAbstract" id="immd_RelatedPartyTransactionsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReimbursementOfHomeOfficeExpenditures" id="immd_ReimbursementOfHomeOfficeExpenditures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CompensationForLegalServices" id="immd_CompensationForLegalServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AnnualIncentiveBonusAwardPercentage" id="immd_AnnualIncentiveBonusAwardPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SubsequentEventsTextualAbstract" id="immd_SubsequentEventsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>immd-20170331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Friday, July 07, 2017 09:57:37 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#Consolidatedbalancesheets" roleURI="http://www.immudyne.com/role/Consolidatedbalancesheets"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Consolidatedbalancesheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_NotesPayableCurrent" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_Equity" xlink:label="loc_immd_Equity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_immd_Equity" xlink:to="loc_us-gaap_CommonStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_immd_Equity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_immd_Equity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_immd_Equity" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_TreasuryStockValue" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="20" use="optional" weight="1"/></calculationLink>





<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.immudyne.com/role/ConsolidatedStatementsOfOperationsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_Revenues" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_CostOfRevenue" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/><loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CompensationAndRelatedExpenses" xlink:label="loc_immd_CompensationAndRelatedExpenses"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_immd_CompensationAndRelatedExpenses" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ProfessionalFees" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_MarketingExpense" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GrossProfit" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_immd_ChangeInFairValueOfDerivativeLiability"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_immd_ChangeInFairValueOfDerivativeLiability" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_InterestExpense" order="30" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_ProfitLoss" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="20" use="optional" weight="-1"/></calculationLink>




<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" order="50" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" order="70" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables" order="80" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" order="90" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="100" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromNotesPayable" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt" order="30" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable" order="40" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_IssuanceOfCommonStockAndWarrants" xlink:label="loc_immd_IssuanceOfCommonStockAndWarrants"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_immd_IssuanceOfCommonStockAndWarrants" order="50" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" order="60" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="20" use="optional" weight="1"/></calculationLink>


<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryRawMaterials" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryFinishedGoods" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#IncomeTaxesDetails" roleURI="http://www.immudyne.com/role/IncomeTaxesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" order="10" use="optional" weight="-1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" order="20" use="optional" weight="1"/></calculationLink>

</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>immd-20170331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Friday, July 07, 2017 09:57:38 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#ConsolidatedStatementOfStockholdersEquityDeficitUnaudited" roleURI="http://www.immudyne.com/role/ConsolidatedStatementOfStockholdersEquityDeficitUnaudited"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#StockholdersEquityTables" roleURI="http://www.immudyne.com/role/StockholdersEquityTables"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#OrganizationAndGoingConcernDetails" roleURI="http://www.immudyne.com/role/OrganizationAndGoingConcernDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#Summaryofsignificantaccountingpoliciesdetailstextual" roleURI="http://www.immudyne.com/role/Summaryofsignificantaccountingpoliciesdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#NotesPayableDetails" roleURI="http://www.immudyne.com/role/NotesPayableDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#StockholdersEquityDetails" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#StockholdersEquityDetails1" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails1"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#StockholdersEquityDetails2" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails2"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#StockholdersEquityDetails4" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails4"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#StockholdersEquityDetails5" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails5"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.immudyne.com/role/StockholdersEquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#RoyaltiesDetails" roleURI="http://www.immudyne.com/role/RoyaltiesDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.immudyne.com/role/CommitmentsAndContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.immudyne.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#SubsequentEventsDetails" roleURI="http://www.immudyne.com/role/SubsequentEventsDetails"/>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementOfStockholdersEquityDeficitUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_TreasuryStockMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SummationMember" xlink:label="loc_immd_SummationMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_immd_SummationMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_13" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_14" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_15" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_16" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_17" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_18" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_19" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_20" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_21" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_22" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_23" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_24" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xlink:label="loc_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities_25" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProfitLoss_26" order="170" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_10" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/OrganizationAndGoingConcernDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_immd_ImmudynePrLlcMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_InnateScientificLlcMember" xlink:label="loc_immd_InnateScientificLlcMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_immd_InnateScientificLlcMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6" xlink:to="loc_us-gaap_EquityComponentDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6" xlink:to="loc_us-gaap_EquityComponentDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_OrganizationAndGoingConcernTextualAbstract" xlink:label="loc_immd_OrganizationAndGoingConcernTextualAbstract_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_immd_OrganizationAndGoingConcernTextualAbstract_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_9" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_9" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_9" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_13" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_ConsolidationItemsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidationItemsAxis_2" xlink:to="loc_us-gaap_ConsolidationItemsDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidationItemsAxis_2" xlink:to="loc_us-gaap_ConsolidationItemsDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NutraceuticalAndCosmeticMember" xlink:label="loc_immd_NutraceuticalAndCosmeticMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_3" xlink:to="loc_immd_NutraceuticalAndCosmeticMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CosmeticGoodsMember" xlink:label="loc_immd_CosmeticGoodsMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_3" xlink:to="loc_immd_CosmeticGoodsMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="loc_us-gaap_IntersegmentEliminationMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_3" xlink:to="loc_us-gaap_IntersegmentEliminationMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_us-gaap_Assets_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_us-gaap_Revenues_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_us-gaap_ProfitLoss_9" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_OtherUnallocatedAmountsAbstract" xlink:label="loc_immd_OtherUnallocatedAmountsAbstract_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_immd_OtherUnallocatedAmountsAbstract_10" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CorporateExpenses" xlink:label="loc_immd_CorporateExpenses_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_OtherUnallocatedAmountsAbstract_10" xlink:to="loc_immd_CorporateExpenses_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_OtherUnallocatedAmountsAbstract_10" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_OtherUnallocatedAmountsAbstract_10" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_13" order="20" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Summaryofsignificantaccountingpoliciesdetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTable" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9" xlink:to="loc_us-gaap_SalesMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9" xlink:to="loc_us-gaap_AccountsReceivableMember_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConcentrationRiskNumberOfCustomersAxis" xlink:label="loc_immd_ConcentrationRiskNumberOfCustomersAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_immd_ConcentrationRiskNumberOfCustomersAxis_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConcentrationRiskNumberOfCustomersDomain" xlink:label="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_immd_ConcentrationRiskNumberOfCustomersAxis_12" xlink:to="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConcentrationRiskNumberOfCustomersDomain" xlink:label="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_immd_ConcentrationRiskNumberOfCustomersAxis_12" xlink:to="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_OneCustomerMember" xlink:label="loc_immd_OneCustomerMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13" xlink:to="loc_immd_OneCustomerMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SecondCustomerMember" xlink:label="loc_immd_SecondCustomerMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13" xlink:to="loc_immd_SecondCustomerMember_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_ConsolidationItemsAxis_16" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidationItemsAxis_16" xlink:to="loc_us-gaap_ConsolidationItemsDomain_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_17_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidationItemsAxis_16" xlink:to="loc_us-gaap_ConsolidationItemsDomain_17_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NutraceuticalAndCosmeticMember" xlink:label="loc_immd_NutraceuticalAndCosmeticMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_17" xlink:to="loc_immd_NutraceuticalAndCosmeticMember_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CosmeticGoodsMember" xlink:label="loc_immd_CosmeticGoodsMember_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_17" xlink:to="loc_immd_CosmeticGoodsMember_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_20" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndustryOfCounterpartyDomain" xlink:label="loc_us-gaap_IndustryOfCounterpartyDomain_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_20" xlink:to="loc_us-gaap_IndustryOfCounterpartyDomain_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndustryOfCounterpartyDomain" xlink:label="loc_us-gaap_IndustryOfCounterpartyDomain_21_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_20" xlink:to="loc_us-gaap_IndustryOfCounterpartyDomain_21_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_OneCreditCardProcessorsMember" xlink:label="loc_immd_OneCreditCardProcessorsMember_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndustryOfCounterpartyDomain_21" xlink:to="loc_immd_OneCreditCardProcessorsMember_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_TwoCreditCardProcessorsMember" xlink:label="loc_immd_TwoCreditCardProcessorsMember_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndustryOfCounterpartyDomain_21" xlink:to="loc_immd_TwoCreditCardProcessorsMember_23" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_MinorityInterestRate" xlink:label="loc_immd_MinorityInterestRate_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_immd_MinorityInterestRate_25" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLIFOReserve" xlink:label="loc_us-gaap_InventoryLIFOReserve_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_InventoryLIFOReserve_26" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_27" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_28" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_29" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_Revenues_30" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_AccountsReceivableNet_31" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NonControllingInterestDescription" xlink:label="loc_immd_NonControllingInterestDescription_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_immd_NonControllingInterestDescription_32" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesReturnsAndAllowancesGoods" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesGoods_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesGoods_33" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConclusionToConsolidate" xlink:label="loc_us-gaap_VariableInterestEntityConclusionToConsolidate_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_VariableInterestEntityConclusionToConsolidate_34" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xlink:label="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_35" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities" xlink:label="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_36" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues" xlink:label="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues_37" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss" xlink:label="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss_38" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NoncontrollingInterestsDescription" xlink:label="loc_immd_NoncontrollingInterestsDescription_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_immd_NoncontrollingInterestsDescription_39" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="loc_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_40" order="150" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/NotesPayableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis" xlink:label="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" xlink:label="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_2" xlink:to="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" xlink:label="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_2" xlink:to="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommercialLenderMember" xlink:label="loc_immd_CommercialLenderMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3" xlink:to="loc_immd_CommercialLenderMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficerMember" xlink:label="loc_us-gaap_OfficerMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_us-gaap_OfficerMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9" xlink:to="loc_us-gaap_CommercialPaperMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommercialPaperOneMember" xlink:label="loc_immd_CommercialPaperOneMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9" xlink:to="loc_immd_CommercialPaperOneMember_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommercialPaperTwoMember" xlink:label="loc_immd_CommercialPaperTwoMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9" xlink:to="loc_immd_CommercialPaperTwoMember_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_13" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_14_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_13" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_14_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_14" xlink:to="loc_us-gaap_SubsequentEventMember_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_16" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_16" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_17_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_16" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_17_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NotesPayableMember" xlink:label="loc_immd_NotesPayableMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_17" xlink:to="loc_immd_NotesPayableMember_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_19" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_19" xlink:to="loc_us-gaap_EquityComponentDomain_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_20_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_19" xlink:to="loc_us-gaap_EquityComponentDomain_20_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_20" xlink:to="loc_us-gaap_CommonStockMember_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_20" xlink:to="loc_us-gaap_WarrantMember_22" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NotesPayableTextualAbstract" xlink:label="loc_immd_NotesPayableTextualAbstract_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_immd_NotesPayableTextualAbstract_23" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_24" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_25" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_26" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_InterestExpense_27" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_28" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_29" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_30" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_31" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_32" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_33" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_ConvertibleDebt_34" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_35" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="loc_invest_InvestmentOptionsExercisePrice_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_invest_InvestmentOptionsExercisePrice_36" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_TermOfWarrant" xlink:label="loc_immd_TermOfWarrant_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_immd_TermOfWarrant_37" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_38" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_39" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommonStockSharesIssuedRelatedPromissoryNote" xlink:label="loc_immd_CommonStockSharesIssuedRelatedPromissoryNote_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_immd_CommonStockSharesIssuedRelatedPromissoryNote_40" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_InterestExpenseDebt_41" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_NotesPayable_42" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_FlatFee" xlink:label="loc_immd_FlatFee_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_immd_FlatFee_43" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_DebtInstrumentTerm_44" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_45" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_46" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConversionOfFairMarketValueSharesAndWarrantsIssued" xlink:label="loc_immd_ConversionOfFairMarketValueSharesAndWarrantsIssued_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_immd_ConversionOfFairMarketValueSharesAndWarrantsIssued_47" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementInterest" xlink:label="loc_us-gaap_LitigationSettlementInterest_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_LitigationSettlementInterest_48" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable_49"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_23" xlink:to="loc_us-gaap_InterestReceivable_49" order="250" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6" order="20" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_14" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate_15" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ExercisePriceRangeOneMember" xlink:label="loc_immd_ExercisePriceRangeOneMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_immd_ExercisePriceRangeOneMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ExercisePriceRangeTwoMember" xlink:label="loc_immd_ExercisePriceRangeTwoMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_immd_ExercisePriceRangeTwoMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ExercisePriceRangeThreeMember" xlink:label="loc_immd_ExercisePriceRangeThreeMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_immd_ExercisePriceRangeThreeMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_RangeAxis_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_7" xlink:to="loc_us-gaap_RangeMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_7" xlink:to="loc_us-gaap_RangeMember_8_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MinimumMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MaximumMember_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12" xlink:to="loc_us-gaap_EmployeeStockOptionMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_14" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17" order="20" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration_11" order="70" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails5">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_14" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConsultantMember" xlink:label="loc_immd_ConsultantMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_immd_ConsultantMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_immd_ImmudynePrLlcMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MinimumMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13" xlink:to="loc_us-gaap_EmployeeStockOptionMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_PerformanceBasedStockOptionsMember" xlink:label="loc_immd_PerformanceBasedStockOptionsMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13" xlink:to="loc_immd_PerformanceBasedStockOptionsMember_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13" xlink:to="loc_us-gaap_WarrantMember_16" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_WarrantOneMember" xlink:label="loc_immd_WarrantOneMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13" xlink:to="loc_immd_WarrantOneMember_17" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_18" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_18" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_18" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19" xlink:to="loc_us-gaap_DirectorMember_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_VestingAxis_21" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_21" xlink:to="loc_us-gaap_VestingDomain_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_22_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_21" xlink:to="loc_us-gaap_VestingDomain_22_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_VestedMember" xlink:label="loc_immd_VestedMember_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_22" xlink:to="loc_immd_VestedMember_23" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_UnvestedMember" xlink:label="loc_immd_UnvestedMember_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_22" xlink:to="loc_immd_UnvestedMember_24" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_25" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_25" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_25" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26" xlink:to="loc_us-gaap_IPOMember_27" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConsultingServicesMember" xlink:label="loc_immd_ConsultingServicesMember_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26" xlink:to="loc_immd_ConsultingServicesMember_28" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_IssuanceOfCommonStockMember" xlink:label="loc_immd_IssuanceOfCommonStockMember_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26" xlink:to="loc_immd_IssuanceOfCommonStockMember_29" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_StockholdersEquityTextualAbstract" xlink:label="loc_immd_StockholdersEquityTextualAbstract_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_0" xlink:to="loc_immd_StockholdersEquityTextualAbstract_30" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_31" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_32" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_33" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_PurchaseOfCommonStockDescriptionOfTransaction" xlink:label="loc_immd_PurchaseOfCommonStockDescriptionOfTransaction_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_immd_PurchaseOfCommonStockDescriptionOfTransaction_34" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_TreasuryStockValue_35" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_TreasuryStockCommonShares_36" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_CommonStockSharesIssued_37" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_38" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_NotesPayable_39" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_40" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_41" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_42" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_WarrantsToPurchaseOfCommonStock" xlink:label="loc_immd_WarrantsToPurchaseOfCommonStock_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_immd_WarrantsToPurchaseOfCommonStock_43" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_44" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_45" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_46" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_47" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_48" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_49"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_49" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_50"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_ProfitLoss_50" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_51"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_51" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_52"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_52" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_53"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_53" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_54"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_54" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NumberOfConsultant" xlink:label="loc_immd_NumberOfConsultant_55"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_immd_NumberOfConsultant_55" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_56"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_56" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_57"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_ShareBasedCompensation_57" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_58"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_58" order="270" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_59"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_59" order="280" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_AnnualSalesRevenueTarget" xlink:label="loc_immd_AnnualSalesRevenueTarget_60"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_immd_AnnualSalesRevenueTarget_60" order="290" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_61"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_61" order="300" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_62"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_62" order="310" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_FairValueOfPerformanceBasedStockOptions" xlink:label="loc_immd_FairValueOfPerformanceBasedStockOptions_63"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_immd_FairValueOfPerformanceBasedStockOptions_63" order="320" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_AggregateOfFairValue" xlink:label="loc_immd_AggregateOfFairValue_64"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_immd_AggregateOfFairValue_64" order="330" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_us-gaap_DeferredCompensationEquity_65"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_DeferredCompensationEquity_65" order="340" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_66"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_66" order="350" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_67"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_67" order="360" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_68"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_68" order="370" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_UnamortizedOfServiceAgreements" xlink:label="loc_immd_UnamortizedOfServiceAgreements_69"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_30" xlink:to="loc_immd_UnamortizedOfServiceAgreements_69" order="380" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/RoyaltiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_us-gaap_PresidentMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RoyaltiesTextualAbstract" xlink:label="loc_immd_RoyaltiesTextualAbstract_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_immd_RoyaltiesTextualAbstract_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_PercentageOfRoyaltyBasedUponSales" xlink:label="loc_immd_PercentageOfRoyaltyBasedUponSales_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_immd_PercentageOfRoyaltyBasedUponSales_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RoyaltyBasedUponSalesAmount" xlink:label="loc_immd_RoyaltyBasedUponSalesAmount_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_immd_RoyaltyBasedUponSalesAmount_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_us-gaap_RoyaltyExpense_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_InterestInRoyalty" xlink:label="loc_immd_InterestInRoyalty_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_immd_InterestInRoyalty_9" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_10" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_12" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_13" order="70" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommitmentsAndContingenciesLineItems" xlink:label="loc_immd_CommitmentsAndContingenciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommitmentsAndContingenciesTable" xlink:label="loc_immd_CommitmentsAndContingenciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_immd_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_immd_CommitmentsAndContingenciesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_RestrictedStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RestrictedStockOneMember" xlink:label="loc_immd_RestrictedStockOneMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_RestrictedStockOneMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RestrictedStockTwoMember" xlink:label="loc_immd_RestrictedStockTwoMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_RestrictedStockTwoMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RestrictedStockThreeMember" xlink:label="loc_immd_RestrictedStockThreeMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_RestrictedStockThreeMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" xlink:to="loc_us-gaap_RelatedPartyDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" xlink:to="loc_us-gaap_RelatedPartyDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConsultantMember" xlink:label="loc_immd_ConsultantMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9" xlink:to="loc_immd_ConsultantMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_dei_LegalEntityAxis_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_11" xlink:to="loc_dei_EntityDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_11" xlink:to="loc_dei_EntityDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_12" xlink:to="loc_immd_ImmudynePrLlcMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_14" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_14" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" xlink:to="loc_us-gaap_PresidentMember_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_immd_CommitmentsAndContingenciesTextualAbstract_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_LeaseExpirationDate1_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_LeaseAndRentalExpense_20" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_21" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_SalariesWagesAndOfficersCompensation_22" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_23" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_24" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" xlink:label="loc_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock_25" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_SalesRevenueNet_26" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SalesRevenueIncreased" xlink:label="loc_immd_SalesRevenueIncreased_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_SalesRevenueIncreased_27" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_BonusPercentageOfCompensationForPretaxIncome" xlink:label="loc_immd_BonusPercentageOfCompensationForPretaxIncome_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_BonusPercentageOfCompensationForPretaxIncome_28" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_PertaxIncomePercentage" xlink:label="loc_immd_PertaxIncomePercentage_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_PertaxIncomePercentage_29" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_30" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_31" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_32" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_DebtLongTermAndShortTermCombinedAmountShares" xlink:label="loc_immd_DebtLongTermAndShortTermCombinedAmountShares_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_DebtLongTermAndShortTermCombinedAmountShares_33" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_SharePrice_34" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_RestrictedStockExpense_35" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_36" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_BonusShares" xlink:label="loc_immd_BonusShares_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_BonusShares_37" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_OptionToBuyShares" xlink:label="loc_immd_OptionToBuyShares_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_OptionToBuyShares_38" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_39" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NumerOfThresholds" xlink:label="loc_immd_NumerOfThresholds_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_NumerOfThresholds_40" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntercompanyAgreementsDescription" xlink:label="loc_us-gaap_IntercompanyAgreementsDescription_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_IntercompanyAgreementsDescription_41" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PremiumsPercentageAssumedToNet" xlink:label="loc_us-gaap_PremiumsPercentageAssumedToNet_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_PremiumsPercentageAssumedToNet_42" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_43" order="250" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_us-gaap_PresidentMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_immd_ImmudynePrLlcMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_immd_RelatedPartyTransactionsTextualAbstract_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_immd_RelatedPartyTransactionsTextualAbstract_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ReimbursementOfHomeOfficeExpenditures" xlink:label="loc_immd_ReimbursementOfHomeOfficeExpenditures_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_8" xlink:to="loc_immd_ReimbursementOfHomeOfficeExpenditures_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CompensationForLegalServices" xlink:label="loc_immd_CompensationForLegalServices_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_8" xlink:to="loc_immd_CompensationForLegalServices_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_8" xlink:to="loc_us-gaap_ProfessionalFees_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_AnnualIncentiveBonusAwardPercentage" xlink:label="loc_immd_AnnualIncentiveBonusAwardPercentage_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_8" xlink:to="loc_immd_AnnualIncentiveBonusAwardPercentage_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_8" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_13" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SubsequentEventsTextualAbstract" xlink:label="loc_immd_SubsequentEventsTextualAbstract_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_immd_SubsequentEventsTextualAbstract_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_5" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_5" xlink:to="loc_us-gaap_ContractualObligation_9" order="30" use="optional"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>immd-20170331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Friday, July 07, 2017 09:57:38 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_DocumentAndEntityInformationAbstract" xlink:label="loc_3I08H47I0615_immd_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_DocumentAndEntityInformationAbstract" xlink:to="lab_5K20J69K2837_immd_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_IHHH3GKKJK4895JJG478_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_dei_EntityRegistrantName" xlink:to="lab_KJJJ5IMMLM6017LLI690_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_3I08H47I0615_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_dei_EntityCentralIndexKey" xlink:to="lab_5K20J69K2837_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_IHHH3GKKJK4895JJG478_dei_TradingSymbol"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_dei_TradingSymbol" xlink:to="lab_KJJJ5IMMLM6017LLI690_dei_TradingSymbol"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_3I08H47I0615_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_dei_AmendmentFlag" xlink:to="lab_5K20J69K2837_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_IHHH3GKKJK4895JJG478_dei_CurrentFiscalYearEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_dei_CurrentFiscalYearEndDate" xlink:to="lab_KJJJ5IMMLM6017LLI690_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_3I08H47I0615_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_dei_DocumentType" xlink:to="lab_5K20J69K2837_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_IHHH3GKKJK4895JJG478_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_dei_DocumentPeriodEndDate" xlink:to="lab_KJJJ5IMMLM6017LLI690_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_3I08H47I0615_dei_DocumentFiscalYearFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_dei_DocumentFiscalYearFocus" xlink:to="lab_5K20J69K2837_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_IHHH3GKKJK4895JJG478_dei_DocumentFiscalPeriodFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_dei_DocumentFiscalPeriodFocus" xlink:to="lab_KJJJ5IMMLM6017LLI690_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_3I08H47I0615_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_dei_EntityFilerCategory" xlink:to="lab_5K20J69K2837_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_IHHH3GKKJK4895JJG478_dei_EntityCommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_KJJJ5IMMLM6017LLI690_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_3I08H47I0615_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_5K20J69K2837_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_AssetsAbstract" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_3I08H47I0615_us-gaap_AssetsCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_AssetsCurrentAbstract" xlink:to="lab_5K20J69K2837_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at beginning of the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at end of the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_3I08H47I0615_us-gaap_AccountsReceivableNetCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Trade accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_5K20J69K2837_us-gaap_AccountsReceivableNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_OtherReceivablesNetCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_OtherReceivablesNetCurrent" xml:lang="en-US">Other Receivables, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_OtherReceivablesNetCurrent" xml:lang="en-US">Other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_OtherReceivablesNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_3I08H47I0615_us-gaap_InventoryNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_InventoryNet" xml:lang="en-US">Inventory, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_InventoryNet" xml:lang="en-US">Inventory, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_5K20J69K2837_us-gaap_InventoryNet" xml:lang="en-US">Inventory, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_InventoryNet" xlink:to="lab_5K20J69K2837_us-gaap_InventoryNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_AssetsCurrent" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_3I08H47I0615_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_5K20J69K2837_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_5K20J69K2837_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_LiabilitiesCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_3I08H47I0615_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_5K20J69K2837_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DerivativeLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DerivativeLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_3I08H47I0615_us-gaap_ConvertibleNotesPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="lab_5K20J69K2837_us-gaap_ConvertibleNotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_NotesPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes payable, net of discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NotesPayableCurrent" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NotesPayableCurrent" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_NotesPayableCurrent" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_NotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_3I08H47I0615_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_5K20J69K2837_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_LiabilitiesCurrent" xlink:to="lab_5K20J69K2837_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Immudyne, Inc. Stockholders' Equity (Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_StockholdersEquityAbstract" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_3I08H47I0615_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.01 par value; 50,000,000 shares authorized, 40,543,373 and 35,570,157 shares issued, 40,205,573 and 35,245,157 outstanding as of March 31, 2017 and December 31, 2016, respectively</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.01 par value; 50,000,000 shares authorized, 30,609,973 shares issued and outstanding at June 30, 2015</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_5K20J69K2837_us-gaap_CommonStockValue" xml:lang="en-US">Common stock issued, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_CommonStockValue" xlink:to="lab_5K20J69K2837_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_AdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_AdditionalPaidInCapital" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_3I08H47I0615_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated (deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_5K20J69K2837_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_5K20J69K2837_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_5K20J69K2837_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_Equity" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_Equity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_Equity" xml:lang="en-US">Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_Equity" xml:lang="en-US">Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_Equity" xml:lang="en-US">Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_Equity" xml:lang="en-US">It represents total of common stock, additional paid in capital and accumulated deficit.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_Equity" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_Equity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_3I08H47I0615_us-gaap_TreasuryStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock, 325,000 shares, at cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_5K20J69K2837_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock, value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_5K20J69K2837_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock, 337,800 and 325,000 shares, at cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_TreasuryStockValue" xlink:to="lab_5K20J69K2837_us-gaap_TreasuryStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquity" xml:lang="en-US">Total Immudyne, Inc. Stockholders' (Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_StockholdersEquity" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_3I08H47I0615_us-gaap_MinorityInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_MinorityInterest" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_MinorityInterest" xml:lang="en-US">Non-controlling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_MinorityInterest" xlink:to="lab_5K20J69K2837_us-gaap_MinorityInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total Stockholders' (Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_3I08H47I0615_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_5K20J69K2837_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_5K20J69K2837_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_3I08H47I0615_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_5K20J69K2837_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_CommonStockSharesIssued" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_3I08H47I0615_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_5K20J69K2837_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_TreasuryStockCommonShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_TreasuryStockCommonShares" xml:lang="en-US">Treasury Stock, Common, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_TreasuryStockCommonShares" xml:lang="en-US">Treasury stock, common, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_TreasuryStockCommonShares" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_TreasuryStockCommonShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_3I08H47I0615_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_IncomeStatementAbstract" xlink:to="lab_5K20J69K2837_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_Revenues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_Revenues" xml:lang="en-US">Revenues, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_Revenues" xml:lang="en-US">Total sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_Revenues" xml:lang="en-US">Net Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_Revenues" xml:lang="en-US">Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_Revenues" xml:lang="en-US">Net sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_Revenues" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_Revenues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_3I08H47I0615_us-gaap_CostOfRevenue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of Revenue, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of Sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_CostOfRevenue" xlink:to="lab_5K20J69K2837_us-gaap_CostOfRevenue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_GrossProfit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_GrossProfit" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_GrossProfit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_3I08H47I0615_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_OperatingExpensesAbstract" xlink:to="lab_5K20J69K2837_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CompensationAndRelatedExpenses" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_CompensationAndRelatedExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_CompensationAndRelatedExpenses" xml:lang="en-US">Compensation and Related Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_CompensationAndRelatedExpenses" xml:lang="en-US">Compensation and related expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_CompensationAndRelatedExpenses" xml:lang="en-US">Represents the expense recognized during the period arising from equity-based compensation arrangements and related expenses (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_CompensationAndRelatedExpenses" xml:lang="en-US">Compensation and related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_CompensationAndRelatedExpenses" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_CompensationAndRelatedExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_3I08H47I0615_us-gaap_ProfessionalFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ProfessionalFees" xml:lang="en-US">Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ProfessionalFees" xml:lang="en-US">Professional fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ProfessionalFees" xml:lang="en-US">Consulting expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_5K20J69K2837_us-gaap_ProfessionalFees" xml:lang="en-US">Accountant charges per month</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_5K20J69K2837_us-gaap_ProfessionalFees" xml:lang="en-US">Professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ProfessionalFees" xlink:to="lab_5K20J69K2837_us-gaap_ProfessionalFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_MarketingExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_MarketingExpense" xml:lang="en-US">Marketing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_MarketingExpense" xml:lang="en-US">Marketing expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_MarketingExpense" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_MarketingExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_3I08H47I0615_us-gaap_GeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_5K20J69K2837_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_5K20J69K2837_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_OperatingExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_OperatingExpenses" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_3I08H47I0615_us-gaap_OperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss), Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_5K20J69K2837_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_5K20J69K2837_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating income (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_OperatingIncomeLoss" xlink:to="lab_5K20J69K2837_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_ChangeInFairValueOfDerivativeLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ChangeInFairValueOfDerivativeLiability" xml:lang="en-US">Change In Fair Value Of Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ChangeInFairValueOfDerivativeLiability" xml:lang="en-US">Change in fair value of derivative liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ChangeInFairValueOfDerivativeLiability" xml:lang="en-US">It represents change in fair value of derivative liability.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ChangeInFairValueOfDerivativeLiability" xml:lang="en-US">Change in fair value of derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_ChangeInFairValueOfDerivativeLiability" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_ChangeInFairValueOfDerivativeLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_3I08H47I0615_us-gaap_InterestExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_5K20J69K2837_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_5K20J69K2837_us-gaap_InterestExpense" xml:lang="en-US">Interest (expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_InterestExpense" xlink:to="lab_5K20J69K2837_us-gaap_InterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ProfitLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ProfitLoss" xml:lang="en-US">Net (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ProfitLoss" xml:lang="en-US">Net (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ProfitLoss" xml:lang="en-US">Net (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ProfitLoss" xml:lang="en-US">Net (loss) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ProfitLoss" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ProfitLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_3I08H47I0615_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net (loss) attributable to noncontrolling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_5K20J69K2837_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net (loss) attributable to noncontrolling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_5K20J69K2837_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (loss) attributable to Immudyne, Inc.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (loss) income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (loss) attributable to Immudyne, Inc.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_NetIncomeLoss" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_3I08H47I0615_us-gaap_EarningsPerShareBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted (loss) per share attributable to Immudyne, Inc.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_5K20J69K2837_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_EarningsPerShareAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Average number of common shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_EarningsPerShareAbstract" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_EarningsPerShareAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_3I08H47I0615_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_5K20J69K2837_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_3I08H47I0615_us-gaap_StatementOfStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_5K20J69K2837_us-gaap_StatementOfStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_StatementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_StatementTable" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_3I08H47I0615_us-gaap_StatementEquityComponentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_5K20J69K2837_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_EquityComponentDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_EquityComponentDomain" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_3I08H47I0615_us-gaap_CommonStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_CommonStockMember" xlink:to="lab_5K20J69K2837_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_AdditionalPaidInCapitalMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional paid-in-capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_AdditionalPaidInCapitalMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_3I08H47I0615_us-gaap_RetainedEarningsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated (Deficit) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_RetainedEarningsMember" xlink:to="lab_5K20J69K2837_us-gaap_RetainedEarningsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_TreasuryStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_TreasuryStockMember" xml:lang="en-US">Treasury Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_TreasuryStockMember" xml:lang="en-US">Treasury Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_TreasuryStockMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_TreasuryStockMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SummationMember" xlink:label="loc_3I08H47I0615_immd_SummationMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_SummationMember" xml:lang="en-US">Summation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_SummationMember" xml:lang="en-US">Sub Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_SummationMember" xml:lang="en-US">Sub total Member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_SummationMember" xlink:to="lab_5K20J69K2837_immd_SummationMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_NoncontrollingInterestMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_NoncontrollingInterestMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_NoncontrollingInterestMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_3I08H47I0615_us-gaap_StatementLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_StatementLineItems" xlink:to="lab_5K20J69K2837_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_SharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_SharesOutstanding" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_SharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Common stock issued for services as per agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Issuance of common stock for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Common stock issued for services as per agreement, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Issuance of common stock for services, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Sale of common stock and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of company stock, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Purchase of Company stock, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Company stock, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Sale of common stock and warrants, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Purchase of Company stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xml:lang="en-US">Conversion of NCI equity for shares, value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xml:lang="en-US">Conversion of non-controlling interest equity for shares and warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xml:lang="en-US">Conversion of NCI equity for shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xml:lang="en-US">Conversion of non-controlling interest equity for shares and warrants, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodValueOther"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Issuance of company stock for notes and other payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Issuance of company stock for notes and other payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Conversion of note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_StockIssuedDuringPeriodSharesOther"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Issuance of company stock for notes and other payables, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Conversion of note payable, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Issuance of common stock in relation to debt offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Issuance of common stock in relation to debt offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Issue of common stock, value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Issuance of common stock in relation to debt offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Issued of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Issuance of common stock in relation to debt offering, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">common stock shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_3I08H47I0615_us-gaap_TreasuryStockValueAcquiredCostMethod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_TreasuryStockValueAcquiredCostMethod" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_TreasuryStockValueAcquiredCostMethod" xml:lang="en-US">Purchase of treasury stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_5K20J69K2837_us-gaap_TreasuryStockValueAcquiredCostMethod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Issuance of stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Issuance of stock options for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_3I08H47I0615_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xml:lang="en-US">Investment in subsidiary by noncontrolling interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xml:lang="en-US">Investment in subsidiary by noncontrolling interest, net of distributions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_5K20J69K2837_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xml:lang="en-US">Adjustments To Additional Paid In Capital Share Based Compensation Reclassification Of Options Warrants And Other Contracts From Equity To Derivative Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xml:lang="en-US">Reclassification of options, warrants and other contracts from equity to derivative liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xml:lang="en-US">Reclassification of options, warrants and other contracts to derivative liabilities upon issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xml:lang="en-US">Adjustment to additional paid-in capital share based compensation reclassification of options, warrants and other contracts from equity to derivative liabilities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_3I08H47I0615_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_5K20J69K2837_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_3I08H47I0615_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net (loss) to net cash (used) provided by operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net (loss) to net cash (used) by operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_5K20J69K2837_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xml:lang="en-US">Change in fair value of derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_3I08H47I0615_us-gaap_ProvisionForDoubtfulAccounts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision for Doubtful Accounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Bad debt recovery</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_5K20J69K2837_us-gaap_ProvisionForDoubtfulAccounts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_AmortizationOfDebtDiscountPremium"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of debt discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_AmortizationOfDebtDiscountPremium"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_3I08H47I0615_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_5K20J69K2837_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on settlement of notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_5K20J69K2837_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensation" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_3I08H47I0615_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) In Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_5K20J69K2837_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) In Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Trade accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_3I08H47I0615_us-gaap_IncreaseDecreaseInOtherReceivables"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_IncreaseDecreaseInOtherReceivables" xml:lang="en-US">Increase (Decrease) in Other Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_IncreaseDecreaseInOtherReceivables" xml:lang="en-US">Other receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_5K20J69K2837_us-gaap_IncreaseDecreaseInOtherReceivables" xml:lang="en-US">Other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_5K20J69K2837_us-gaap_IncreaseDecreaseInOtherReceivables"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_IncreaseDecreaseInInventories"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_IncreaseDecreaseInInventories"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_3I08H47I0615_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) In Other Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_5K20J69K2837_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Negative cash flows from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash (used) by operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_3I08H47I0615_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_5K20J69K2837_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xml:lang="en-US">Proceeds from (Payments to) Noncontrolling Interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xml:lang="en-US">Investment in subsidiary by noncontrolling interest, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_3I08H47I0615_us-gaap_ProceedsFromNotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Borrowed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Borrowed from commercial lender</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_5K20J69K2837_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from notes payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_5K20J69K2837_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Borrowing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_5K20J69K2837_us-gaap_ProceedsFromNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_RepaymentsOfConvertibleDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Repayments of Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Repayment of convertible note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_RepaymentsOfConvertibleDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_3I08H47I0615_us-gaap_RepaymentsOfNotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayments of Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayment of note payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_5K20J69K2837_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_5K20J69K2837_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayment of notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_5K20J69K2837_us-gaap_RepaymentsOfNotesPayable"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_IssuanceOfCommonStockAndWarrants" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_IssuanceOfCommonStockAndWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_IssuanceOfCommonStockAndWarrants" xml:lang="en-US">Issuance Of Common Stock And Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_IssuanceOfCommonStockAndWarrants" xml:lang="en-US">Sale of common stock and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_IssuanceOfCommonStockAndWarrants" xml:lang="en-US">Issuance of common stock and warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_IssuanceOfCommonStockAndWarrants" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_IssuanceOfCommonStockAndWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_3I08H47I0615_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Purchase of treasury stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Issuance of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_5K20J69K2837_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_3I08H47I0615_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease), Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_5K20J69K2837_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_5K20J69K2837_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_SupplementalCashFlowInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_SupplementalCashFlowInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_3I08H47I0615_us-gaap_InterestPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_InterestPaid" xml:lang="en-US">Cash paid during the period for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_InterestPaid" xlink:to="lab_5K20J69K2837_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ConversionOfStockAmountIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConversionOfStockAmountIssued1" xml:lang="en-US">Conversion of Stock, Amount Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConversionOfStockAmountIssued1" xml:lang="en-US">Issuance of company stock for notes and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConversionOfStockAmountIssued1"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" xlink:label="loc_3I08H47I0615_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" xml:lang="en-US">Conversion Of Equity Invested In Subsidiary To Common Stock And Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" xml:lang="en-US">Conversion of equity invested in subsidiary to common stock and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" xml:lang="en-US">The conversion vale of equity invested in subsidiary to common stock and warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" xlink:to="lab_5K20J69K2837_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities" xml:lang="en-US">Reclassification Of Options Warrants And Other Contracts To Derivative Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities" xml:lang="en-US">Reclassification of options, warrants and other contracts to derivative liabilities upon issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities" xml:lang="en-US">Recorded upon issue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities" xml:lang="en-US">Reclassification of options, warrants and other contracts to derivative liabilities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_3I08H47I0615_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization and Going Concern [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_5K20J69K2837_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization and Going Concern</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization and Going Concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_3I08H47I0615_us-gaap_AccountingPoliciesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_5K20J69K2837_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_3I08H47I0615_us-gaap_DebtDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Notes Payable [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_DebtDisclosureAbstract" xlink:to="lab_5K20J69K2837_us-gaap_DebtDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Notes Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_3I08H47I0615_us-gaap_IncomeTaxDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Taxes [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Taxes [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_5K20J69K2837_us-gaap_IncomeTaxDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_IncomeTaxDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_IncomeTaxDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_3I08H47I0615_us-gaap_StockholdersEquityNoteAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_5K20J69K2837_us-gaap_StockholdersEquityNoteAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RoyaltiesAbstract" xlink:label="loc_3I08H47I0615_immd_RoyaltiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_RoyaltiesAbstract" xml:lang="en-US">Royalties [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_RoyaltiesAbstract" xlink:to="lab_5K20J69K2837_immd_RoyaltiesAbstract"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RoyaltiesDisclosureTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_RoyaltiesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_RoyaltiesDisclosureTextBlock" xml:lang="en-US">Royalties Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_RoyaltiesDisclosureTextBlock" xml:lang="en-US">Royalties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_RoyaltiesDisclosureTextBlock" xml:lang="en-US">The entire disclosure for royalties.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_RoyaltiesDisclosureTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_RoyaltiesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_3I08H47I0615_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_5K20J69K2837_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_3I08H47I0615_us-gaap_RelatedPartyTransactionsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_5K20J69K2837_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_3I08H47I0615_us-gaap_SubsequentEventsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_SubsequentEventsAbstract" xlink:to="lab_5K20J69K2837_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_SubsequentEventsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_3I08H47I0615_us-gaap_ConsolidationPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_5K20J69K2837_us-gaap_ConsolidationPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_VariableInterestEntitiesPolicyTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_VariableInterestEntitiesPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_VariableInterestEntitiesPolicyTextBlock" xml:lang="en-US">Variable Interest Entities [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_VariableInterestEntitiesPolicyTextBlock" xml:lang="en-US">Variable Interest Entities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_VariableInterestEntitiesPolicyTextBlock" xml:lang="en-US">It repressents variable interest entitues policy text block.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_VariableInterestEntitiesPolicyTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_VariableInterestEntitiesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_3I08H47I0615_us-gaap_UseOfEstimates"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_UseOfEstimates" xlink:to="lab_5K20J69K2837_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DerivativesPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivative Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DerivativesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SequencingPolicyPolicyTextBlock" xlink:label="loc_3I08H47I0615_immd_SequencingPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_SequencingPolicyPolicyTextBlock" xml:lang="en-US">Sequencing Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_SequencingPolicyPolicyTextBlock" xml:lang="en-US">Sequencing Policy</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_SequencingPolicyPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for sequencing.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_SequencingPolicyPolicyTextBlock" xlink:to="lab_5K20J69K2837_immd_SequencingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_InventoryPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_InventoryPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_3I08H47I0615_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_5K20J69K2837_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_3I08H47I0615_us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_5K20J69K2837_us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_IncomeTaxPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_3I08H47I0615_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_5K20J69K2837_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_EarningsPerSharePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings (Loss) Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_3I08H47I0615_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_5K20J69K2837_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_MinorityInterestPolicyTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_MinorityInterestPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_MinorityInterestPolicyTextBlock" xml:lang="en-US">Minority Interest [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_MinorityInterestPolicyTextBlock" xml:lang="en-US">Noncontrolling Interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_MinorityInterestPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for noncontrolling interest.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_MinorityInterestPolicyTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_MinorityInterestPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="loc_3I08H47I0615_us-gaap_ConsolidationVariableInterestEntityPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ConsolidationVariableInterestEntityPolicy" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ConsolidationVariableInterestEntityPolicy" xml:lang="en-US">Consolidation of Variable Interest Entities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ConsolidationVariableInterestEntityPolicy" xml:lang="en-US">Variable Interest Entities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_5K20J69K2837_us-gaap_ConsolidationVariableInterestEntityPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ConcentrationRiskCreditRisk"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConcentrationRiskCreditRisk"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_3I08H47I0615_us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule Of Inventory, Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Summary of inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_5K20J69K2837_us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xml:lang="en-US">Summary of reportable segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_3I08H47I0615_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule Of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Summary of deferred tax asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of deferred tax asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_5K20J69K2837_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_3I08H47I0615_us-gaap_AwardTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_AwardTypeAxis" xlink:to="lab_5K20J69K2837_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_3I08H47I0615_us-gaap_EmployeeStockOptionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_5K20J69K2837_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Service-Based Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_EmployeeStockOptionMember" xlink:to="lab_5K20J69K2837_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_WarrantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_WarrantMember" xml:lang="en-US">Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_WarrantMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_3I08H47I0615_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of outstanding service-based options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_3I08H47I0615_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xml:lang="en-US">Schedule of Assumptions Used [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xml:lang="en-US">Summary of significant assumptions used to determine fair values of options issued using Black-Scholes option-pricing model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_5K20J69K2837_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US">Summary of outstanding service-based options exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_3I08H47I0615_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_5K20J69K2837_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_3I08H47I0615_us-gaap_RelatedPartyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_RelatedPartyDomain" xlink:to="lab_5K20J69K2837_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_ImmudynePrLlcMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ImmudynePrLlcMember" xml:lang="en-US">Immudyne Pr Llc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ImmudynePrLlcMember" xml:lang="en-US">Immudyne PR LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ImmudynePrLlcMember" xml:lang="en-US">Immudyne PR [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ImmudynePrLlcMember" xml:lang="en-US">Immudyne PR LLC.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_ImmudynePrLlcMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_ImmudynePrLlcMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_InnateScientificLlcMember" xlink:label="loc_3I08H47I0615_immd_InnateScientificLlcMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_InnateScientificLlcMember" xml:lang="en-US">Innate Scientific, Llc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_InnateScientificLlcMember" xml:lang="en-US">Innate Skincare, LLC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_InnateScientificLlcMember" xlink:to="lab_5K20J69K2837_immd_InnateScientificLlcMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_RelatedPartyTransactionLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_RelatedPartyTransactionLineItems"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_OrganizationAndGoingConcernTextualAbstract" xlink:label="loc_3I08H47I0615_immd_OrganizationAndGoingConcernTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_OrganizationAndGoingConcernTextualAbstract" xml:lang="en-US">Organization And Going Concern Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_immd_OrganizationAndGoingConcernTextualAbstract" xml:lang="en-US">Organization and Going Concern (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_OrganizationAndGoingConcernTextualAbstract" xml:lang="en-US">organization and going concern textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_OrganizationAndGoingConcernTextualAbstract" xlink:to="lab_5K20J69K2837_immd_OrganizationAndGoingConcernTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage of ownership of equity interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage of ownership equity interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_3I08H47I0615_us-gaap_MinorityInterestOwnershipPercentageByParent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_MinorityInterestOwnershipPercentageByParent" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_MinorityInterestOwnershipPercentageByParent" xml:lang="en-US">Percentage of voting controlling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_5K20J69K2837_us-gaap_MinorityInterestOwnershipPercentageByParent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_MinorityInterestPeriodIncreaseDecrease" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_MinorityInterestPeriodIncreaseDecrease" xml:lang="en-US">Charge to noncontrolling interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_MinorityInterestPeriodIncreaseDecrease" xml:lang="en-US">Reduction in noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_3I08H47I0615_us-gaap_InventoryNetAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_InventoryNetAbstract" xml:lang="en-US">Inventory, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_InventoryNetAbstract" xml:lang="en-US">Summary of inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_InventoryNetAbstract" xlink:to="lab_5K20J69K2837_us-gaap_InventoryNetAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_InventoryRawMaterials"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_InventoryRawMaterials" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_InventoryRawMaterials" xml:lang="en-US">Raw materials</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_InventoryRawMaterials" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_InventoryRawMaterials"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_3I08H47I0615_us-gaap_InventoryFinishedGoods"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_InventoryFinishedGoods" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_InventoryFinishedGoods" xml:lang="en-US">Finished products</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_InventoryFinishedGoods" xlink:to="lab_5K20J69K2837_us-gaap_InventoryFinishedGoods"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_3I08H47I0615_us-gaap_ConsolidationItemsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ConsolidationItemsAxis" xml:lang="en-US">Consolidation Items [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ConsolidationItemsAxis" xlink:to="lab_5K20J69K2837_us-gaap_ConsolidationItemsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ConsolidationItemsDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConsolidationItemsDomain" xml:lang="en-US">Consolidation Items [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ConsolidationItemsDomain" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConsolidationItemsDomain"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NutraceuticalAndCosmeticMember" xlink:label="loc_3I08H47I0615_immd_NutraceuticalAndCosmeticMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_NutraceuticalAndCosmeticMember" xml:lang="en-US">Nutraceutical And Cosmetic [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_NutraceuticalAndCosmeticMember" xml:lang="en-US">Nutraceutical and cosmetic [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_immd_NutraceuticalAndCosmeticMember" xml:lang="en-US">Nutraceutical and Cosmetic Additives [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_NutraceuticalAndCosmeticMember" xml:lang="en-US">Nutraceutical and cosmetic member.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_5K20J69K2837_immd_NutraceuticalAndCosmeticMember" xml:lang="en-US">Nutraceutical and Cosmetic Additives [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_NutraceuticalAndCosmeticMember" xlink:to="lab_5K20J69K2837_immd_NutraceuticalAndCosmeticMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CosmeticGoodsMember" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_CosmeticGoodsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_CosmeticGoodsMember" xml:lang="en-US">Cosmetic Goods [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_CosmeticGoodsMember" xml:lang="en-US">Finished Cosmetic Products [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_CosmeticGoodsMember" xml:lang="en-US">Cosmetic goods member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_CosmeticGoodsMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_CosmeticGoodsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="loc_3I08H47I0615_us-gaap_IntersegmentEliminationMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_IntersegmentEliminationMember" xml:lang="en-US">Intersegment Eliminations [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_IntersegmentEliminationMember" xml:lang="en-US">Eliminations [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_IntersegmentEliminationMember" xlink:to="lab_5K20J69K2837_us-gaap_IntersegmentEliminationMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_EntityWideRevenueMajorCustomerLineItems" xml:lang="en-US">Revenue, Major Customer [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_EntityWideRevenueMajorCustomerLineItems" xml:lang="en-US">Summary of reportable segments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_3I08H47I0615_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_Assets" xml:lang="en-US">Assets, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_5K20J69K2837_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_Assets" xlink:to="lab_5K20J69K2837_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_OtherUnallocatedAmountsAbstract" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_OtherUnallocatedAmountsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_OtherUnallocatedAmountsAbstract" xml:lang="en-US">Other Unallocated Amounts [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_OtherUnallocatedAmountsAbstract" xml:lang="en-US">Other unallocated amounts:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_OtherUnallocatedAmountsAbstract" xml:lang="en-US">Other unallocated amounts.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_OtherUnallocatedAmountsAbstract" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_OtherUnallocatedAmountsAbstract"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CorporateExpenses" xlink:label="loc_3I08H47I0615_immd_CorporateExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_CorporateExpenses" xml:lang="en-US">Corporate Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_CorporateExpenses" xml:lang="en-US">Corporate expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_CorporateExpenses" xml:lang="en-US">Represents the amount of unallocated corporate expenses.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_5K20J69K2837_immd_CorporateExpenses" xml:lang="en-US">Corporate expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_CorporateExpenses" xlink:to="lab_5K20J69K2837_immd_CorporateExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_OtherNonoperatingIncomeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other income (expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_OtherNonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_3I08H47I0615_us-gaap_NonoperatingIncomeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Net (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_5K20J69K2837_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Consolidated income (loss) from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_5K20J69K2837_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTable" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_OptionIndexedToIssuersEquityTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_OptionIndexedToIssuersEquityTable" xml:lang="en-US">Option Indexed to Issuer's Equity [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_OptionIndexedToIssuersEquityTable" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_OptionIndexedToIssuersEquityTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_3I08H47I0615_us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_5K20J69K2837_us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_3I08H47I0615_us-gaap_ConcentrationRiskByBenchmarkAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_5K20J69K2837_us-gaap_ConcentrationRiskByBenchmarkAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ConcentrationRiskBenchmarkDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConcentrationRiskBenchmarkDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_3I08H47I0615_us-gaap_SalesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_SalesMember" xml:lang="en-US">Sales [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_SalesMember" xml:lang="en-US">Sales [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_SalesMember" xlink:to="lab_5K20J69K2837_us-gaap_SalesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_AccountsReceivableMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_AccountsReceivableMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_AccountsReceivableMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConcentrationRiskNumberOfCustomersAxis" xlink:label="loc_3I08H47I0615_immd_ConcentrationRiskNumberOfCustomersAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_ConcentrationRiskNumberOfCustomersAxis" xml:lang="en-US">Concentration Risk Number Of Customers [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_ConcentrationRiskNumberOfCustomersAxis" xlink:to="lab_5K20J69K2837_immd_ConcentrationRiskNumberOfCustomersAxis"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConcentrationRiskNumberOfCustomersDomain" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_ConcentrationRiskNumberOfCustomersDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ConcentrationRiskNumberOfCustomersDomain" xml:lang="en-US">Concentration Risk Number Of Customers [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_ConcentrationRiskNumberOfCustomersDomain" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_ConcentrationRiskNumberOfCustomersDomain"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_OneCustomerMember" xlink:label="loc_3I08H47I0615_immd_OneCustomerMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_OneCustomerMember" xml:lang="en-US">One Customer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_immd_OneCustomerMember" xml:lang="en-US">One customer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_OneCustomerMember" xlink:to="lab_5K20J69K2837_immd_OneCustomerMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SecondCustomerMember" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_SecondCustomerMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_SecondCustomerMember" xml:lang="en-US">Second Customer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_SecondCustomerMember" xml:lang="en-US">Second customer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_SecondCustomerMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_SecondCustomerMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis" xlink:label="loc_3I08H47I0615_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis" xml:lang="en-US">Industry of Counterparty, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis" xlink:to="lab_5K20J69K2837_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndustryOfCounterpartyDomain" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_IndustryOfCounterpartyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_IndustryOfCounterpartyDomain" xml:lang="en-US">Industry of Counterparty [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_IndustryOfCounterpartyDomain" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_IndustryOfCounterpartyDomain"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_OneCreditCardProcessorsMember" xlink:label="loc_3I08H47I0615_immd_OneCreditCardProcessorsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_OneCreditCardProcessorsMember" xml:lang="en-US">One Credit Card Processors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_OneCreditCardProcessorsMember" xml:lang="en-US">One credit card processor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_OneCreditCardProcessorsMember" xml:lang="en-US">One credit card processors member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_OneCreditCardProcessorsMember" xlink:to="lab_5K20J69K2837_immd_OneCreditCardProcessorsMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_TwoCreditCardProcessorsMember" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_TwoCreditCardProcessorsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_TwoCreditCardProcessorsMember" xml:lang="en-US">Two Credit Card Processors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_TwoCreditCardProcessorsMember" xml:lang="en-US">Two credit card processor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_TwoCreditCardProcessorsMember" xml:lang="en-US">Two credit card processors member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_TwoCreditCardProcessorsMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_TwoCreditCardProcessorsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_3I08H47I0615_us-gaap_OptionIndexedToIssuersEquityLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_OptionIndexedToIssuersEquityLineItems" xml:lang="en-US">Option Indexed to Issuer's Equity [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="lab_5K20J69K2837_us-gaap_OptionIndexedToIssuersEquityLineItems"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary Of Significant Accounting Policies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary of Significant Accounting Policies (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary of significant accounting policies textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_MinorityInterestRate" xlink:label="loc_3I08H47I0615_immd_MinorityInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_MinorityInterestRate" xml:lang="en-US">Minority Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_MinorityInterestRate" xml:lang="en-US">Non controlling interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_immd_MinorityInterestRate" xml:lang="en-US">Non-controlling interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_MinorityInterestRate" xml:lang="en-US">Non controlling stated interest rate.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_MinorityInterestRate" xlink:to="lab_5K20J69K2837_immd_MinorityInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLIFOReserve" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_InventoryLIFOReserve"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_InventoryLIFOReserve" xml:lang="en-US">Inventory, LIFO Reserve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_InventoryLIFOReserve" xml:lang="en-US">Inventory reserve</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_InventoryLIFOReserve" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_InventoryLIFOReserve"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xlink:label="loc_3I08H47I0615_us-gaap_SalesDiscountsReturnsAndAllowancesGoods"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xml:lang="en-US">Sales Discounts, Returns and Allowances, Goods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xml:lang="en-US">Customer discounts, returns and rebates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xlink:to="lab_5K20J69K2837_us-gaap_SalesDiscountsReturnsAndAllowancesGoods"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_3I08H47I0615_us-gaap_ConcentrationRiskPercentage1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration risk percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_5K20J69K2837_us-gaap_ConcentrationRiskPercentage1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_AccountsReceivableNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AccountsReceivableNet" xml:lang="en-US">Accounts Receivable, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AccountsReceivableNet" xml:lang="en-US">Accounts receivable reserve</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_AccountsReceivableNet" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_AccountsReceivableNet"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NonControllingInterestDescription" xlink:label="loc_3I08H47I0615_immd_NonControllingInterestDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_NonControllingInterestDescription" xml:lang="en-US">Non Controlling Interest Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_NonControllingInterestDescription" xml:lang="en-US">Description of non controlling interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_NonControllingInterestDescription" xml:lang="en-US">The description of non controlling interest.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_NonControllingInterestDescription" xlink:to="lab_5K20J69K2837_immd_NonControllingInterestDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesReturnsAndAllowancesGoods" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_SalesReturnsAndAllowancesGoods"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SalesReturnsAndAllowancesGoods" xml:lang="en-US">Sales Returns and Allowances, Goods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SalesReturnsAndAllowancesGoods" xml:lang="en-US">Sales returns and allowances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_SalesReturnsAndAllowancesGoods" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_SalesReturnsAndAllowancesGoods"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConclusionToConsolidate" xlink:label="loc_3I08H47I0615_us-gaap_VariableInterestEntityConclusionToConsolidate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_VariableInterestEntityConclusionToConsolidate" xml:lang="en-US">Variable Interest Entity, Conclusion to Consolidate, Change in Facts and Circumstances, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_VariableInterestEntityConclusionToConsolidate" xml:lang="en-US">consolidated VIE, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_VariableInterestEntityConclusionToConsolidate" xml:lang="en-US">Consolidated VIE, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_VariableInterestEntityConclusionToConsolidate" xlink:to="lab_5K20J69K2837_us-gaap_VariableInterestEntityConclusionToConsolidate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xml:lang="en-US">Variable Interest Entity, Consolidated, Carrying Amount, Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xml:lang="en-US">Variable Interest Entity, assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities" xlink:label="loc_3I08H47I0615_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities" xml:lang="en-US">Variable Interest Entity, Consolidated, Carrying Amount, Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities" xml:lang="en-US">Variable Interest Entity, liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities" xlink:to="lab_5K20J69K2837_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues" xml:lang="en-US">Variable Interest Entity, Measure of Activity, Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues" xml:lang="en-US">Variable Interest Entity, revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss" xlink:label="loc_3I08H47I0615_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss" xml:lang="en-US">Variable Interest Entity, Measure of Activity, Operating Income or Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss" xml:lang="en-US">Variable Interest Entity, operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss" xlink:to="lab_5K20J69K2837_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NoncontrollingInterestsDescription" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_NoncontrollingInterestsDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_NoncontrollingInterestsDescription" xml:lang="en-US">Noncontrolling Interests Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_NoncontrollingInterestsDescription" xml:lang="en-US">Noncontrolling interests, description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_NoncontrollingInterestsDescription" xml:lang="en-US">Description of noncontrolling interests.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_NoncontrollingInterestsDescription" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_NoncontrollingInterestsDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="loc_3I08H47I0615_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xml:lang="en-US">Income Tax Examination, Likelihood of Unfavorable Settlement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xml:lang="en-US">Income tax, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="lab_5K20J69K2837_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtInstrumentTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtInstrumentTable" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtInstrumentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis" xlink:label="loc_3I08H47I0615_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis" xml:lang="en-US">Class of Financing Receivable, Type of Borrower [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis" xlink:to="lab_5K20J69K2837_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" xml:lang="en-US">Class of Financing Receivable, Type of Borrower [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommercialLenderMember" xlink:label="loc_3I08H47I0615_immd_CommercialLenderMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_CommercialLenderMember" xml:lang="en-US">Commercial Lender [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_CommercialLenderMember" xml:lang="en-US">Commercial Lender [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_CommercialLenderMember" xlink:to="lab_5K20J69K2837_immd_CommercialLenderMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_TitleOfIndividualAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_TitleOfIndividualAxis" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_3I08H47I0615_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_5K20J69K2837_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficerMember" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_OfficerMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_OfficerMember" xml:lang="en-US">Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_OfficerMember" xml:lang="en-US">Officer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_OfficerMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_OfficerMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_3I08H47I0615_us-gaap_CashAndCashEquivalentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_5K20J69K2837_us-gaap_CashAndCashEquivalentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_3I08H47I0615_us-gaap_CommercialPaperMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial Paper [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_CommercialPaperMember" xml:lang="en-US">Promissory note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_CommercialPaperMember" xlink:to="lab_5K20J69K2837_us-gaap_CommercialPaperMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommercialPaperOneMember" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_CommercialPaperOneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_CommercialPaperOneMember" xml:lang="en-US">Commercial Paper One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_CommercialPaperOneMember" xml:lang="en-US">Promissory note one [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_CommercialPaperOneMember" xml:lang="en-US">Commercial paper one .</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_CommercialPaperOneMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_CommercialPaperOneMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommercialPaperTwoMember" xlink:label="loc_3I08H47I0615_immd_CommercialPaperTwoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_CommercialPaperTwoMember" xml:lang="en-US">Commercial Paper Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_CommercialPaperTwoMember" xml:lang="en-US">Promissory note two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_CommercialPaperTwoMember" xml:lang="en-US">Commercial paper two.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_CommercialPaperTwoMember" xlink:to="lab_5K20J69K2837_immd_CommercialPaperTwoMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_SubsequentEventTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_3I08H47I0615_us-gaap_SubsequentEventTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_5K20J69K2837_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_SubsequentEventMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Events [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_SubsequentEventMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_3I08H47I0615_us-gaap_ShortTermDebtTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_5K20J69K2837_us-gaap_ShortTermDebtTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ShortTermDebtTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShortTermDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NotesPayableMember" xlink:label="loc_3I08H47I0615_immd_NotesPayableMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_NotesPayableMember" xml:lang="en-US">Notes Payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_NotesPayableMember" xlink:to="lab_5K20J69K2837_immd_NotesPayableMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtInstrumentLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtInstrumentLineItems" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtInstrumentLineItems"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NotesPayableTextualAbstract" xlink:label="loc_3I08H47I0615_immd_NotesPayableTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_NotesPayableTextualAbstract" xml:lang="en-US">Notes Payable Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_NotesPayableTextualAbstract" xml:lang="en-US">Notes Payable (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_immd_NotesPayableTextualAbstract" xml:lang="en-US">Notes Payable (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_NotesPayableTextualAbstract" xml:lang="en-US">Notes payable textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_NotesPayableTextualAbstract" xlink:to="lab_5K20J69K2837_immd_NotesPayableTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest rate on notes payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest rate on notes payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest rate on notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_3I08H47I0615_us-gaap_DebtInstrumentMaturityDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Maturity date on notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_5K20J69K2837_us-gaap_DebtInstrumentMaturityDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Interest rate period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_3I08H47I0615_us-gaap_DebtInstrumentFaceAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Outstanding principal balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Repaid of principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_5K20J69K2837_us-gaap_DebtInstrumentFaceAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Common stock for maximum offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_3I08H47I0615_us-gaap_ConvertibleDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible promissory note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ConvertibleDebt" xlink:to="lab_5K20J69K2837_us-gaap_ConvertibleDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Conversion price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="loc_3I08H47I0615_invest_InvestmentOptionsExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_invest_InvestmentOptionsExercisePrice" xml:lang="en-US">Investment Options, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_invest_InvestmentOptionsExercisePrice" xml:lang="en-US">Exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_invest_InvestmentOptionsExercisePrice" xlink:to="lab_5K20J69K2837_invest_InvestmentOptionsExercisePrice"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_TermOfWarrant" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_TermOfWarrant"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_TermOfWarrant" xml:lang="en-US">Term Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_TermOfWarrant" xml:lang="en-US">Term of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_TermOfWarrant" xml:lang="en-US">Term of warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_TermOfWarrant" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_TermOfWarrant"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_3I08H47I0615_us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Original debt, discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_5K20J69K2837_us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtConversionOriginalDebtAmount1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Debt Conversion, Original Debt, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Original debt, principle amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtConversionOriginalDebtAmount1"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommonStockSharesIssuedRelatedPromissoryNote" xlink:label="loc_3I08H47I0615_immd_CommonStockSharesIssuedRelatedPromissoryNote"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_CommonStockSharesIssuedRelatedPromissoryNote" xml:lang="en-US">Common Stock Shares Issued Related Promissory Note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_CommonStockSharesIssuedRelatedPromissoryNote" xml:lang="en-US">Common stock shares issued related promissory note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_CommonStockSharesIssuedRelatedPromissoryNote" xml:lang="en-US">Common stock shares issued related promissory note.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_CommonStockSharesIssuedRelatedPromissoryNote" xlink:to="lab_5K20J69K2837_immd_CommonStockSharesIssuedRelatedPromissoryNote"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_InterestExpenseDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest expense on notes payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest expense on notes payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest expense on notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_InterestExpenseDebt" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_InterestExpenseDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_3I08H47I0615_us-gaap_NotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_NotesPayable" xml:lang="en-US">Note repaid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_NotesPayable" xml:lang="en-US">Borrowing amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroLabel" xlink:label="lab_5K20J69K2837_us-gaap_NotesPayable" xml:lang="en-US">Note payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_5K20J69K2837_us-gaap_NotesPayable" xml:lang="en-US">Borrowing amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_5K20J69K2837_us-gaap_NotesPayable" xml:lang="en-US">Borrowing amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_NotesPayable" xlink:to="lab_5K20J69K2837_us-gaap_NotesPayable"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_FlatFee" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_FlatFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_FlatFee" xml:lang="en-US">Flat Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_FlatFee" xml:lang="en-US">Flat fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_FlatFee" xml:lang="en-US">It represents flat fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_FlatFee" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_FlatFee"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_3I08H47I0615_us-gaap_DebtInstrumentTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt Instrument, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Working capital line</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_DebtInstrumentTerm" xlink:to="lab_5K20J69K2837_us-gaap_DebtInstrumentTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtConversionConvertedInstrumentAmount1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Converted remaining principle balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DebtConversionConvertedInstrumentAmount1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_3I08H47I0615_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Converted remaining principle balance, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Converted shares of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_5K20J69K2837_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConversionOfFairMarketValueSharesAndWarrantsIssued" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_ConversionOfFairMarketValueSharesAndWarrantsIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ConversionOfFairMarketValueSharesAndWarrantsIssued" xml:lang="en-US">Conversion Of Fair Market Value Shares And Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ConversionOfFairMarketValueSharesAndWarrantsIssued" xml:lang="en-US">Conversion of fair market value shares and warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ConversionOfFairMarketValueSharesAndWarrantsIssued" xml:lang="en-US">Conversion of fair market value shares and warrants issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_ConversionOfFairMarketValueSharesAndWarrantsIssued" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_ConversionOfFairMarketValueSharesAndWarrantsIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementInterest" xlink:label="loc_3I08H47I0615_us-gaap_LitigationSettlementInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_LitigationSettlementInterest" xml:lang="en-US">Litigation Settlement Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_LitigationSettlementInterest" xml:lang="en-US">Loss on settlement of notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_LitigationSettlementInterest" xlink:to="lab_5K20J69K2837_us-gaap_LitigationSettlementInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestReceivable" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_InterestReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_InterestReceivable" xml:lang="en-US">Interest Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_InterestReceivable" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_InterestReceivable" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_InterestReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_3I08H47I0615_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components of deferred tax liabilities and assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_5K20J69K2837_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_3I08H47I0615_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xml:lang="en-US">Accounts receivable reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_5K20J69K2837_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DeferredTaxAssetsInventory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredTaxAssetsInventory" xml:lang="en-US">Deferred Tax Assets, Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredTaxAssetsInventory" xml:lang="en-US">Inventory Reserve Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredTaxAssetsInventory" xml:lang="en-US">Inventory reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredTaxAssetsInventory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_3I08H47I0615_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_5K20J69K2837_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DeferredTaxAssetsGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Net deferred tax assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Net deferred tax asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredTaxAssetsGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_3I08H47I0615_us-gaap_DeferredTaxAssetsValuationAllowance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_5K20J69K2837_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_5K20J69K2837_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_5K20J69K2837_us-gaap_DeferredTaxAssetsValuationAllowance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_IncomeTaxesTextualAbstract" xlink:label="loc_3I08H47I0615_immd_IncomeTaxesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_IncomeTaxesTextualAbstract" xml:lang="en-US">Income Taxes Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_IncomeTaxesTextualAbstract" xml:lang="en-US">Income Taxes (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_IncomeTaxesTextualAbstract" xlink:to="lab_5K20J69K2837_immd_IncomeTaxesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_OperatingLossCarryforwards"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_OperatingLossCarryforwards" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_OperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_3I08H47I0615_us-gaap_OperatingLossCarryforwardsExpirationDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US">Operating loss carryforwards, expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="lab_5K20J69K2837_us-gaap_OperatingLossCarryforwardsExpirationDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Percentage of tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_3I08H47I0615_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Warrants outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options/Warrants, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options/Warrants, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of options, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Options, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options granted, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of stock options issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_3I08H47I0615_us-gaap_RangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_RangeAxis" xlink:to="lab_5K20J69K2837_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_RangeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_RangeMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_3I08H47I0615_us-gaap_MaximumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_MaximumMember" xlink:to="lab_5K20J69K2837_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_MinimumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_MinimumMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_3I08H47I0615_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Summary of significant assumptions used to determine the fair values of options using black-scholes option-pricing model</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Summary of fair value of options and warrants granted using black-scholes option-pricing model with weighted-average assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate at grant date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_3I08H47I0615_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected stock price volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend payout</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_3I08H47I0615_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected option life-years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (in years)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/exampleGuidance" xlink:label="lab_5K20J69K2837_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected option term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_5K20J69K2837_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Weighted average grant date fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" xlink:label="loc_3I08H47I0615_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fairvalue Assumptions Forfeiture Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" xml:lang="en-US">Forfeiture rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" xml:lang="en-US">Share based compensation arrangement by share Based Payment Award fair value assumptions forfeiture rate.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" xlink:to="lab_5K20J69K2837_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_3I08H47I0615_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US">Exercise Price Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_5K20J69K2837_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ExercisePriceRangeOneMember" xlink:label="loc_3I08H47I0615_immd_ExercisePriceRangeOneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_ExercisePriceRangeOneMember" xml:lang="en-US">Exercise Price Range One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_ExercisePriceRangeOneMember" xml:lang="en-US">$0.10 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_ExercisePriceRangeOneMember" xml:lang="en-US">Exercise price range one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_ExercisePriceRangeOneMember" xlink:to="lab_5K20J69K2837_immd_ExercisePriceRangeOneMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ExercisePriceRangeTwoMember" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_ExercisePriceRangeTwoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ExercisePriceRangeTwoMember" xml:lang="en-US">Exercise Price Range Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ExercisePriceRangeTwoMember" xml:lang="en-US">$0.20 - $0.25 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ExercisePriceRangeTwoMember" xml:lang="en-US">Exercise price range two member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_ExercisePriceRangeTwoMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_ExercisePriceRangeTwoMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ExercisePriceRangeThreeMember" xlink:label="loc_3I08H47I0615_immd_ExercisePriceRangeThreeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_ExercisePriceRangeThreeMember" xml:lang="en-US">Exercise Price Range Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_ExercisePriceRangeThreeMember" xml:lang="en-US">0.40 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_ExercisePriceRangeThreeMember" xml:lang="en-US">Exercise price range three member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_ExercisePriceRangeThreeMember" xlink:to="lab_5K20J69K2837_immd_ExercisePriceRangeThreeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xlink:label="loc_3I08H47I0615_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Beginning of Period [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xml:lang="en-US">Summary of outstanding service-based options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xlink:to="lab_5K20J69K2837_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of warrants outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance,</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance,</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_3I08H47I0615_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_5K20J69K2837_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price stock option issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price stock option issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" xlink:label="loc_3I08H47I0615_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Beinning Year Of Expiration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" xml:lang="en-US">Year of Expiration, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" xml:lang="en-US">Share based compensation arrangement by share based payment during period year of expiration.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" xlink:to="lab_5K20J69K2837_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Year Of Expiration, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" xml:lang="en-US">Year of Expiration, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" xml:lang="en-US">Share based compensation arrangement by share based payment during period Issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" xlink:label="loc_3I08H47I0615_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Ending Year Of Expiration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" xml:lang="en-US">Year of Expiration, Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" xml:lang="en-US">Share based compensation arrangement by share based payment during period year of expiration.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" xlink:to="lab_5K20J69K2837_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConsultantMember" xlink:label="loc_3I08H47I0615_immd_ConsultantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_ConsultantMember" xml:lang="en-US">Consultant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_ConsultantMember" xml:lang="en-US">Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_immd_ConsultantMember" xml:lang="en-US">Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_ConsultantMember" xml:lang="en-US">Consultant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_ConsultantMember" xlink:to="lab_5K20J69K2837_immd_ConsultantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_IHHH3GKKJK4895JJG478_dei_LegalEntityAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_dei_LegalEntityAxis" xlink:to="lab_KJJJ5IMMLM6017LLI690_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_3I08H47I0615_dei_EntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_dei_EntityDomain" xlink:to="lab_5K20J69K2837_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_PerformanceBasedStockOptionsMember" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_PerformanceBasedStockOptionsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_PerformanceBasedStockOptionsMember" xml:lang="en-US">Performance Based Stock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_PerformanceBasedStockOptionsMember" xml:lang="en-US">Performance Based Stock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_PerformanceBasedStockOptionsMember" xml:lang="en-US">Performance based stock options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_PerformanceBasedStockOptionsMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_PerformanceBasedStockOptionsMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_WarrantOneMember" xlink:label="loc_3I08H47I0615_immd_WarrantOneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_WarrantOneMember" xml:lang="en-US">Warrant One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_WarrantOneMember" xml:lang="en-US">Warrant One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_WarrantOneMember" xlink:to="lab_5K20J69K2837_immd_WarrantOneMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DirectorMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DirectorMember" xml:lang="en-US">Director [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DirectorMember" xml:lang="en-US">Director [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DirectorMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DirectorMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_3I08H47I0615_us-gaap_VestingAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_VestingAxis" xlink:to="lab_5K20J69K2837_us-gaap_VestingAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_VestingDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_VestingDomain" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_VestingDomain"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_VestedMember" xlink:label="loc_3I08H47I0615_immd_VestedMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_VestedMember" xml:lang="en-US">Vested [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_VestedMember" xml:lang="en-US">Vested [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_VestedMember" xlink:to="lab_5K20J69K2837_immd_VestedMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_UnvestedMember" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_UnvestedMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_UnvestedMember" xml:lang="en-US">Unvested [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_UnvestedMember" xml:lang="en-US">Unvested [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_UnvestedMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_UnvestedMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_3I08H47I0615_us-gaap_SubsidiarySaleOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_5K20J69K2837_us-gaap_SubsidiarySaleOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_3I08H47I0615_us-gaap_IPOMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_IPOMember" xml:lang="en-US">Sale of common stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_IPOMember" xml:lang="en-US">Sale of common stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_IPOMember" xlink:to="lab_5K20J69K2837_us-gaap_IPOMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConsultingServicesMember" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_ConsultingServicesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ConsultingServicesMember" xml:lang="en-US">Consulting Services [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_ConsultingServicesMember" xml:lang="en-US">Consulting services [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_ConsultingServicesMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_ConsultingServicesMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_IssuanceOfCommonStockMember" xlink:label="loc_3I08H47I0615_immd_IssuanceOfCommonStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_IssuanceOfCommonStockMember" xml:lang="en-US">Issuance Of Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_IssuanceOfCommonStockMember" xml:lang="en-US">Issuance of Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_IssuanceOfCommonStockMember" xlink:to="lab_5K20J69K2837_immd_IssuanceOfCommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_StockholdersEquityTextualAbstract" xlink:label="loc_3I08H47I0615_immd_StockholdersEquityTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_StockholdersEquityTextualAbstract" xml:lang="en-US">Stockholders Equity Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_immd_StockholdersEquityTextualAbstract" xml:lang="en-US">Stockholders' Equity (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_StockholdersEquityTextualAbstract" xlink:to="lab_5K20J69K2837_immd_StockholdersEquityTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_CommonStockOtherSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_CommonStockOtherSharesOutstanding" xml:lang="en-US">Common Stock, Other Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_CommonStockOtherSharesOutstanding" xml:lang="en-US">Outstanding shares purchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_CommonStockOtherSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_PurchaseOfCommonStockDescriptionOfTransaction" xlink:label="loc_3I08H47I0615_immd_PurchaseOfCommonStockDescriptionOfTransaction"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_PurchaseOfCommonStockDescriptionOfTransaction" xml:lang="en-US">Purchase Of Common Stock Description Of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_immd_PurchaseOfCommonStockDescriptionOfTransaction" xml:lang="en-US">Purchase of common stock description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_PurchaseOfCommonStockDescriptionOfTransaction" xml:lang="en-US">It represents about purchase price of common stock description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_PurchaseOfCommonStockDescriptionOfTransaction" xlink:to="lab_5K20J69K2837_immd_PurchaseOfCommonStockDescriptionOfTransaction"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ConversionOfStockAmountConverted1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConversionOfStockAmountConverted1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_3I08H47I0615_us-gaap_AllocatedShareBasedCompensationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Recognized expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_5K20J69K2837_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Offering to sell shares of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_3I08H47I0615_us-gaap_SaleOfStockPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of stock, price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_5K20J69K2837_us-gaap_SaleOfStockPricePerShare"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_WarrantsToPurchaseOfCommonStock" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_WarrantsToPurchaseOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_WarrantsToPurchaseOfCommonStock" xml:lang="en-US">Warrants To Purchase Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_WarrantsToPurchaseOfCommonStock" xml:lang="en-US">Warrants to purchase of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_WarrantsToPurchaseOfCommonStock" xml:lang="en-US">Number of warrants topurchase of common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_WarrantsToPurchaseOfCommonStock" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_WarrantsToPurchaseOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_3I08H47I0615_us-gaap_CommonStockSharesSubscribedButUnissued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US">Common Stock, Shares Subscribed but Unissued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US">Subscriptions shares received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="lab_5K20J69K2837_us-gaap_CommonStockSharesSubscribedButUnissued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Issued of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_3I08H47I0615_us-gaap_CommonStockSharesSubscriptions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_CommonStockSharesSubscriptions" xml:lang="en-US">Common Stock, Value, Subscriptions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_CommonStockSharesSubscriptions" xml:lang="en-US">Proceeds from subscription of value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_CommonStockSharesSubscriptions" xlink:to="lab_5K20J69K2837_us-gaap_CommonStockSharesSubscriptions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ConversionOfStockSharesIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Common stock issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of common stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ConversionOfStockSharesIssued1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_3I08H47I0615_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Minority interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_5K20J69K2837_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xml:lang="en-US">Stock Granted, Value, Share-based Compensation, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xml:lang="en-US">Options granted, value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xml:lang="en-US">Number of options granted, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_3I08H47I0615_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Options fully vested and expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_5K20J69K2837_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NumberOfConsultant" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_NumberOfConsultant"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_NumberOfConsultant" xml:lang="en-US">Number Of Consultant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_NumberOfConsultant" xml:lang="en-US">Number of consultant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_NumberOfConsultant" xml:lang="en-US">Number of consultant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_NumberOfConsultant" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_NumberOfConsultant"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_3I08H47I0615_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Stock expiration period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Options expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_5K20J69K2837_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Intrinsic value of options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_3I08H47I0615_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Stock options, Expiration date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Stock options, expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="lab_5K20J69K2837_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_AnnualSalesRevenueTarget" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_AnnualSalesRevenueTarget"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_AnnualSalesRevenueTarget" xml:lang="en-US">Annual Sales Revenue Target</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_AnnualSalesRevenueTarget" xml:lang="en-US">Annual sales revenue target</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_AnnualSalesRevenueTarget" xml:lang="en-US">Stock options exercisable upon the Company achieving annual sales revenue.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_AnnualSalesRevenueTarget" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_AnnualSalesRevenueTarget"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Company cancelled service-based options, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Company cancelled service-based options, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xml:lang="en-US">Company stock cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xml:lang="en-US">Company cancelled service-based options, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_FairValueOfPerformanceBasedStockOptions" xlink:label="loc_3I08H47I0615_immd_FairValueOfPerformanceBasedStockOptions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_FairValueOfPerformanceBasedStockOptions" xml:lang="en-US">Fair Value Of Performance Based Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_FairValueOfPerformanceBasedStockOptions" xml:lang="en-US">Fair value stock options, stock warrants embedded conversion features</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_immd_FairValueOfPerformanceBasedStockOptions" xml:lang="en-US">Fair value of performance-based stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_FairValueOfPerformanceBasedStockOptions" xml:lang="en-US">Fair value of performance-based stock options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_FairValueOfPerformanceBasedStockOptions" xlink:to="lab_5K20J69K2837_immd_FairValueOfPerformanceBasedStockOptions"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_AggregateOfFairValue" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_AggregateOfFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_AggregateOfFairValue" xml:lang="en-US">Aggregate Of Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_AggregateOfFairValue" xml:lang="en-US">Aggregate fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_AggregateOfFairValue" xml:lang="en-US">Aggregate of fair value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_AggregateOfFairValue" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_AggregateOfFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_3I08H47I0615_us-gaap_DeferredCompensationEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_DeferredCompensationEquity" xml:lang="en-US">Deferred Compensation Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_DeferredCompensationEquity" xml:lang="en-US">Unearned share based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_DeferredCompensationEquity" xlink:to="lab_5K20J69K2837_us-gaap_DeferredCompensationEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_3I08H47I0615_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrants exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Weighted average exercise price of warrants outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_5K20J69K2837_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Warrants fully vested and expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_UnamortizedOfServiceAgreements" xlink:label="loc_3I08H47I0615_immd_UnamortizedOfServiceAgreements"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_UnamortizedOfServiceAgreements" xml:lang="en-US">Unamortized Of Service Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_UnamortizedOfServiceAgreements" xml:lang="en-US">Unamortized of service agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_UnamortizedOfServiceAgreements" xml:lang="en-US">Unamortized of service agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_UnamortizedOfServiceAgreements" xlink:to="lab_5K20J69K2837_immd_UnamortizedOfServiceAgreements"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_PresidentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_PresidentMember" xml:lang="en-US">President [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_PresidentMember" xml:lang="en-US">President [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_PresidentMember" xml:lang="en-US">Mr. McLaughlin [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_PresidentMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_PresidentMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RoyaltiesTextualAbstract" xlink:label="loc_3I08H47I0615_immd_RoyaltiesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_RoyaltiesTextualAbstract" xml:lang="en-US">Royalties Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_RoyaltiesTextualAbstract" xml:lang="en-US">Royalties (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_RoyaltiesTextualAbstract" xlink:to="lab_5K20J69K2837_immd_RoyaltiesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_PercentageOfRoyaltyBasedUponSales" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_PercentageOfRoyaltyBasedUponSales"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_PercentageOfRoyaltyBasedUponSales" xml:lang="en-US">Percentage Of Royalty Based Upon Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_PercentageOfRoyaltyBasedUponSales" xml:lang="en-US">Percentage of royalty based upon sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_PercentageOfRoyaltyBasedUponSales" xml:lang="en-US">The percentage of royalty based upon sales.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_PercentageOfRoyaltyBasedUponSales" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_PercentageOfRoyaltyBasedUponSales"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RoyaltyBasedUponSalesAmount" xlink:label="loc_3I08H47I0615_immd_RoyaltyBasedUponSalesAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_RoyaltyBasedUponSalesAmount" xml:lang="en-US">Royalty Based Upon Sales Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_immd_RoyaltyBasedUponSalesAmount" xml:lang="en-US">Royalty based upon sales amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_RoyaltyBasedUponSalesAmount" xml:lang="en-US">The amount of royalty based upon sales.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_RoyaltyBasedUponSalesAmount" xlink:to="lab_5K20J69K2837_immd_RoyaltyBasedUponSalesAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_RoyaltyExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_RoyaltyExpense" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_RoyaltyExpense"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_InterestInRoyalty" xlink:label="loc_3I08H47I0615_immd_InterestInRoyalty"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_InterestInRoyalty" xml:lang="en-US">Interest In Royalty</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_immd_InterestInRoyalty" xml:lang="en-US">Interest in royalties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_InterestInRoyalty" xml:lang="en-US">The percentage of interest in royalty.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_InterestInRoyalty" xlink:to="lab_5K20J69K2837_immd_InterestInRoyalty"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xml:lang="en-US">Accrued Royalties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xml:lang="en-US">Royalties payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_3I08H47I0615_us-gaap_SharesIssuedPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Stock price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_5K20J69K2837_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Stock price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_5K20J69K2837_us-gaap_SharesIssuedPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommitmentsAndContingenciesTable" xlink:label="loc_3I08H47I0615_immd_CommitmentsAndContingenciesTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_CommitmentsAndContingenciesTable" xml:lang="en-US">This table lists commitments and contingencies.The line items identify information about the commitments and contingencies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_CommitmentsAndContingenciesTable" xlink:to="lab_5K20J69K2837_immd_CommitmentsAndContingenciesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_RestrictedStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock and Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_RestrictedStockMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_RestrictedStockMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RestrictedStockOneMember" xlink:label="loc_3I08H47I0615_immd_RestrictedStockOneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_RestrictedStockOneMember" xml:lang="en-US">Restricted Stock One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_RestrictedStockOneMember" xml:lang="en-US">Restricted Stock One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_RestrictedStockOneMember" xml:lang="en-US">Restricted stock one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_RestrictedStockOneMember" xlink:to="lab_5K20J69K2837_immd_RestrictedStockOneMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RestrictedStockTwoMember" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_RestrictedStockTwoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_RestrictedStockTwoMember" xml:lang="en-US">Restricted Stock Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_RestrictedStockTwoMember" xml:lang="en-US">Restricted Stock Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_RestrictedStockTwoMember" xml:lang="en-US">Restricted stock two.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_RestrictedStockTwoMember" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_RestrictedStockTwoMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RestrictedStockThreeMember" xlink:label="loc_3I08H47I0615_immd_RestrictedStockThreeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_RestrictedStockThreeMember" xml:lang="en-US">Restricted Stock Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_RestrictedStockThreeMember" xml:lang="en-US">Restricted Stock Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_RestrictedStockThreeMember" xml:lang="en-US">Restricted stock three.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_RestrictedStockThreeMember" xlink:to="lab_5K20J69K2837_immd_RestrictedStockThreeMember"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommitmentsAndContingenciesLineItems" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_CommitmentsAndContingenciesLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_CommitmentsAndContingenciesLineItems" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_CommitmentsAndContingenciesLineItems"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_3I08H47I0615_immd_CommitmentsAndContingenciesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments And Contingencies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_CommitmentsAndContingenciesTextualAbstract" xlink:to="lab_5K20J69K2837_immd_CommitmentsAndContingenciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_LeaseExpirationDate1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Operating lease expired date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_LeaseExpirationDate1" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_LeaseExpirationDate1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_3I08H47I0615_us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_OperatingLeasesRentExpenseMinimumRentals" xml:lang="en-US">Operating Leases, Rent Expense, Minimum Rentals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_OperatingLeasesRentExpenseMinimumRentals" xml:lang="en-US">Monthly base lease rental payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="lab_5K20J69K2837_us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_LeaseAndRentalExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Operating Leases, Rent Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Operating leases, rent expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_LeaseAndRentalExpense" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_LeaseAndRentalExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_3I08H47I0615_us-gaap_OperatingLeasesRentExpenseNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Office space subleased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_5K20J69K2837_us-gaap_OperatingLeasesRentExpenseNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_SalariesWagesAndOfficersCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SalariesWagesAndOfficersCompensation" xml:lang="en-US">Salaries, Wages and Officers' Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SalariesWagesAndOfficersCompensation" xml:lang="en-US">Annual compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_SalariesWagesAndOfficersCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_3I08H47I0615_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US">Stock options, Exercise Price Range, Lower Range Limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US">Stock option exercise prices lower range limit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_5K20J69K2837_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US">Stock options, Exercise Price Range, Upper Range Limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US">Stock option exercise prices upper range limit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" xlink:label="loc_3I08H47I0615_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" xml:lang="en-US">Stock Issued During Period Performance Based Options To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" xml:lang="en-US">Stock issued during period performance based options to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" xml:lang="en-US">Represents the performance based options issued by the company to purchase common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" xlink:to="lab_5K20J69K2837_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_SalesRevenueNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SalesRevenueNet" xml:lang="en-US">Revenue, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SalesRevenueNet" xml:lang="en-US">Annual revenue base</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_SalesRevenueNet" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_SalesRevenueNet"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SalesRevenueIncreased" xlink:label="loc_3I08H47I0615_immd_SalesRevenueIncreased"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_SalesRevenueIncreased" xml:lang="en-US">Sales Revenue Increased</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_SalesRevenueIncreased" xml:lang="en-US">Annual revenue exceeding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_SalesRevenueIncreased" xml:lang="en-US">Sales revenue increased.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_SalesRevenueIncreased" xlink:to="lab_5K20J69K2837_immd_SalesRevenueIncreased"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_BonusPercentageOfCompensationForPretaxIncome" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_BonusPercentageOfCompensationForPretaxIncome"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_BonusPercentageOfCompensationForPretaxIncome" xml:lang="en-US">Bonus Percentage Of Compensation For Pretax Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_BonusPercentageOfCompensationForPretaxIncome" xml:lang="en-US">Percentage of bonus compensation for pretax income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_BonusPercentageOfCompensationForPretaxIncome" xml:lang="en-US">Percentage of bonus agreement compensation for pretax income during the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_BonusPercentageOfCompensationForPretaxIncome" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_BonusPercentageOfCompensationForPretaxIncome"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_PertaxIncomePercentage" xlink:label="loc_3I08H47I0615_immd_PertaxIncomePercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_PertaxIncomePercentage" xml:lang="en-US">Pertax Income Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_PertaxIncomePercentage" xml:lang="en-US">Pretax income percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_PertaxIncomePercentage" xml:lang="en-US">Pertax income percentage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_PertaxIncomePercentage" xlink:to="lab_5K20J69K2837_immd_PertaxIncomePercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Restricted shares issued to consultants, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Restricted shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Restricted shares value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_DebtLongTermAndShortTermCombinedAmountShares" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_DebtLongTermAndShortTermCombinedAmountShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_DebtLongTermAndShortTermCombinedAmountShares" xml:lang="en-US">Debt Long Term And Short Term Combined Amount Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_DebtLongTermAndShortTermCombinedAmountShares" xml:lang="en-US">Combined capped</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_DebtLongTermAndShortTermCombinedAmountShares" xml:lang="en-US">Debt long term and short term combined amount shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_DebtLongTermAndShortTermCombinedAmountShares" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_DebtLongTermAndShortTermCombinedAmountShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_3I08H47I0615_us-gaap_SharePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_SharePrice" xml:lang="en-US">Share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_SharePrice" xlink:to="lab_5K20J69K2837_us-gaap_SharePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_RestrictedStockExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_RestrictedStockExpense" xml:lang="en-US">Restricted Stock or Unit Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_RestrictedStockExpense" xml:lang="en-US">Restricted stock expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_RestrictedStockExpense" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_RestrictedStockExpense"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_BonusShares" xlink:label="loc_3I08H47I0615_immd_BonusShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_BonusShares" xml:lang="en-US">Bonus Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K20J69K2837_immd_BonusShares" xml:lang="en-US">Additional bonus shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_BonusShares" xml:lang="en-US">It represents bonus of an additional shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_BonusShares" xlink:to="lab_5K20J69K2837_immd_BonusShares"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_OptionToBuyShares" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_OptionToBuyShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_OptionToBuyShares" xml:lang="en-US">Option To Buy Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_OptionToBuyShares" xml:lang="en-US">Option to buy shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_OptionToBuyShares" xml:lang="en-US">Contracts conveying rights, but not obligations, to buy or sell a specific quantity of a security at a specified price during a specified period or at a specified date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_OptionToBuyShares" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_OptionToBuyShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Purchase common stock option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_5K20J69K2837_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NumerOfThresholds" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_NumerOfThresholds"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_NumerOfThresholds" xml:lang="en-US">Numer Of Thresholds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_NumerOfThresholds" xml:lang="en-US">Number of thresholds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_NumerOfThresholds" xml:lang="en-US">Numer of thresholds.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_NumerOfThresholds" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_NumerOfThresholds"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntercompanyAgreementsDescription" xlink:label="loc_3I08H47I0615_us-gaap_IntercompanyAgreementsDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_IntercompanyAgreementsDescription" xml:lang="en-US">Intercompany Agreements, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_IntercompanyAgreementsDescription" xml:lang="en-US">Agreements of performance fees, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_IntercompanyAgreementsDescription" xlink:to="lab_5K20J69K2837_us-gaap_IntercompanyAgreementsDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PremiumsPercentageAssumedToNet" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_PremiumsPercentageAssumedToNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_PremiumsPercentageAssumedToNet" xml:lang="en-US">Premiums, Percentage Assumed to Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_PremiumsPercentageAssumedToNet" xml:lang="en-US">Percentage of net income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_PremiumsPercentageAssumedToNet" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_PremiumsPercentageAssumedToNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_3I08H47I0615_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_5K20J69K2837_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_RelatedPartyTransactionsTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_RelatedPartyTransactionsTextualAbstract" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_RelatedPartyTransactionsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ReimbursementOfHomeOfficeExpenditures" xlink:label="loc_3I08H47I0615_immd_ReimbursementOfHomeOfficeExpenditures"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_ReimbursementOfHomeOfficeExpenditures" xml:lang="en-US">Reimbursement Of Home Office Expenditures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_ReimbursementOfHomeOfficeExpenditures" xml:lang="en-US">Reimbursement of home office expenditures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_ReimbursementOfHomeOfficeExpenditures" xml:lang="en-US">Reimbursement of home office expenditures.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_ReimbursementOfHomeOfficeExpenditures" xlink:to="lab_5K20J69K2837_immd_ReimbursementOfHomeOfficeExpenditures"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CompensationForLegalServices" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_CompensationForLegalServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_CompensationForLegalServices" xml:lang="en-US">Compensation For Legal Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_CompensationForLegalServices" xml:lang="en-US">Compensation for legal and business advisory services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_CompensationForLegalServices" xml:lang="en-US">Compensation for legal services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_CompensationForLegalServices" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_CompensationForLegalServices"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_AnnualIncentiveBonusAwardPercentage" xlink:label="loc_3I08H47I0615_immd_AnnualIncentiveBonusAwardPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_immd_AnnualIncentiveBonusAwardPercentage" xml:lang="en-US">Annual Incentive Bonus Award Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_immd_AnnualIncentiveBonusAwardPercentage" xml:lang="en-US">Annual incentive bonus award percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K20J69K2837_immd_AnnualIncentiveBonusAwardPercentage" xml:lang="en-US">Percentage of annual incentive bonus award.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_immd_AnnualIncentiveBonusAwardPercentage" xlink:to="lab_5K20J69K2837_immd_AnnualIncentiveBonusAwardPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_IHHH3GKKJK4895JJG478_us-gaap_SubsequentEventTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_us-gaap_SubsequentEventTable" xlink:to="lab_KJJJ5IMMLM6017LLI690_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_3I08H47I0615_us-gaap_SubsequentEventLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_SubsequentEventLineItems" xlink:to="lab_5K20J69K2837_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SubsequentEventsTextualAbstract" xlink:label="loc_IHHH3GKKJK4895JJG478_immd_SubsequentEventsTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KJJJ5IMMLM6017LLI690_immd_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IHHH3GKKJK4895JJG478_immd_SubsequentEventsTextualAbstract" xlink:to="lab_KJJJ5IMMLM6017LLI690_immd_SubsequentEventsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_3I08H47I0615_us-gaap_ContractualObligation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K20J69K2837_us-gaap_ContractualObligation" xml:lang="en-US">Contractual Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K20J69K2837_us-gaap_ContractualObligation" xml:lang="en-US">Satisfaction of obligation to pay amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I08H47I0615_us-gaap_ContractualObligation" xlink:to="lab_5K20J69K2837_us-gaap_ContractualObligation"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>immd-20170331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Friday, July 07, 2017 09:57:38 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#DocumentAndEntityInformation" roleURI="http://www.immudyne.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#Consolidatedbalancesheets" roleURI="http://www.immudyne.com/role/Consolidatedbalancesheets"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.immudyne.com/role/ConsolidatedBalanceSheetsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.immudyne.com/role/ConsolidatedStatementsOfOperationsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#ConsolidatedStatementOfStockholdersEquityDeficitUnaudited" roleURI="http://www.immudyne.com/role/ConsolidatedStatementOfStockholdersEquityDeficitUnaudited"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#OrganizationAndGoingConcern" roleURI="http://www.immudyne.com/role/OrganizationAndGoingConcern"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#NotesPayable" roleURI="http://www.immudyne.com/role/NotesPayable"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#IncomeTaxes" roleURI="http://www.immudyne.com/role/IncomeTaxes"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#StockholdersEquity" roleURI="http://www.immudyne.com/role/StockholdersEquity"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#Royalties" roleURI="http://www.immudyne.com/role/Royalties"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#CommitmentsAndContingencies" roleURI="http://www.immudyne.com/role/CommitmentsAndContingencies"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#RelatedPartyTransactions" roleURI="http://www.immudyne.com/role/RelatedPartyTransactions"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#SubsequentEvents" roleURI="http://www.immudyne.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#IncomeTaxesTables" roleURI="http://www.immudyne.com/role/IncomeTaxesTables"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#StockholdersEquityTables" roleURI="http://www.immudyne.com/role/StockholdersEquityTables"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#OrganizationAndGoingConcernDetails" roleURI="http://www.immudyne.com/role/OrganizationAndGoingConcernDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#Summaryofsignificantaccountingpoliciesdetailstextual" roleURI="http://www.immudyne.com/role/Summaryofsignificantaccountingpoliciesdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#NotesPayableDetails" roleURI="http://www.immudyne.com/role/NotesPayableDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#IncomeTaxesDetails" roleURI="http://www.immudyne.com/role/IncomeTaxesDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.immudyne.com/role/IncomeTaxesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#StockholdersEquityDetails" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#StockholdersEquityDetails1" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails1"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#StockholdersEquityDetails2" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails2"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#StockholdersEquityDetails4" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails4"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#StockholdersEquityDetails5" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails5"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.immudyne.com/role/StockholdersEquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#RoyaltiesDetails" roleURI="http://www.immudyne.com/role/RoyaltiesDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.immudyne.com/role/CommitmentsAndContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.immudyne.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20170331.xsd#SubsequentEventsDetails" roleURI="http://www.immudyne.com/role/SubsequentEventsDetails"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_DocumentAndEntityInformationAbstract" xlink:label="loc_immd_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_TradingSymbol_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_10" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_11" order="100" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Consolidatedbalancesheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_InventoryNet_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_NotesPayableCurrent_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_LiabilitiesCurrent_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15" xlink:to="loc_us-gaap_CommonStockValue_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15" xlink:to="loc_us-gaap_AdditionalPaidInCapital_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_Equity" xlink:label="loc_immd_Equity_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15" xlink:to="loc_immd_Equity_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15" xlink:to="loc_us-gaap_TreasuryStockValue_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15" xlink:to="loc_us-gaap_StockholdersEquity_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_MinorityInterest_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_TreasuryStockCommonShares_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_CostOfRevenue_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GrossProfit_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CompensationAndRelatedExpenses" xlink:label="loc_immd_CompensationAndRelatedExpenses_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_immd_CompensationAndRelatedExpenses_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_ProfessionalFees_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_MarketingExpense_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_OperatingExpenses_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_immd_ChangeInFairValueOfDerivativeLiability_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_immd_ChangeInFairValueOfDerivativeLiability_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_InterestExpense_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_ProfitLoss_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_16" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareAbstract_17" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_18" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_19" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementOfStockholdersEquityDeficitUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_TreasuryStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SummationMember" xlink:label="loc_immd_SummationMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_immd_SummationMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_SharesOutstanding_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_19" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_20" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_21" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_22" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_23" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_24" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_25" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xlink:label="loc_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities_26" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_ProfitLoss_27" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_28" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_SharesOutstanding_29" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_ProfitLoss_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ShareBasedCompensation_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_IssuanceOfCommonStockAndWarrants" xlink:label="loc_immd_IssuanceOfCommonStockAndWarrants_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_immd_IssuanceOfCommonStockAndWarrants_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_28" xlink:to="loc_us-gaap_InterestPaid_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_28" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_30" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" xlink:label="loc_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_28" xlink:to="loc_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants_31" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities" xlink:label="loc_immd_ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_28" xlink:to="loc_immd_ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities_32" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/OrganizationAndGoingConcern">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/NotesPayable">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Royalties">
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RoyaltiesAbstract" xlink:label="loc_immd_RoyaltiesAbstract_0"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RoyaltiesDisclosureTextBlock" xlink:label="loc_immd_RoyaltiesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesAbstract_0" xlink:to="loc_immd_RoyaltiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_VariableInterestEntitiesPolicyTextBlock" xlink:label="loc_immd_VariableInterestEntitiesPolicyTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_immd_VariableInterestEntitiesPolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SequencingPolicyPolicyTextBlock" xlink:label="loc_immd_SequencingPolicyPolicyTextBlock_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_immd_SequencingPolicyPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_MinorityInterestPolicyTextBlock" xlink:label="loc_immd_MinorityInterestPolicyTextBlock_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_immd_MinorityInterestPolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/OrganizationAndGoingConcernDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_immd_ImmudynePrLlcMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_InnateScientificLlcMember" xlink:label="loc_immd_InnateScientificLlcMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_immd_InnateScientificLlcMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6" xlink:to="loc_us-gaap_EquityComponentDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_OrganizationAndGoingConcernTextualAbstract" xlink:label="loc_immd_OrganizationAndGoingConcernTextualAbstract_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9" xlink:to="loc_immd_OrganizationAndGoingConcernTextualAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_10" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_10" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_10" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_10" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_InventoryNetAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1" xlink:to="loc_us-gaap_InventoryRawMaterials_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1" xlink:to="loc_us-gaap_InventoryFinishedGoods_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1" xlink:to="loc_us-gaap_InventoryNet_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_ConsolidationItemsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsAxis_2" xlink:to="loc_us-gaap_ConsolidationItemsDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NutraceuticalAndCosmeticMember" xlink:label="loc_immd_NutraceuticalAndCosmeticMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_3" xlink:to="loc_immd_NutraceuticalAndCosmeticMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CosmeticGoodsMember" xlink:label="loc_immd_CosmeticGoodsMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_3" xlink:to="loc_immd_CosmeticGoodsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="loc_us-gaap_IntersegmentEliminationMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_3" xlink:to="loc_us-gaap_IntersegmentEliminationMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7" xlink:to="loc_us-gaap_Assets_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7" xlink:to="loc_us-gaap_Revenues_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7" xlink:to="loc_us-gaap_ProfitLoss_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_OtherUnallocatedAmountsAbstract" xlink:label="loc_immd_OtherUnallocatedAmountsAbstract_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7" xlink:to="loc_immd_OtherUnallocatedAmountsAbstract_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CorporateExpenses" xlink:label="loc_immd_CorporateExpenses_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_OtherUnallocatedAmountsAbstract_11" xlink:to="loc_immd_CorporateExpenses_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_OtherUnallocatedAmountsAbstract_11" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_OtherUnallocatedAmountsAbstract_11" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Summaryofsignificantaccountingpoliciesdetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTable" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9" xlink:to="loc_us-gaap_SalesMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9" xlink:to="loc_us-gaap_AccountsReceivableMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConcentrationRiskNumberOfCustomersAxis" xlink:label="loc_immd_ConcentrationRiskNumberOfCustomersAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_immd_ConcentrationRiskNumberOfCustomersAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConcentrationRiskNumberOfCustomersDomain" xlink:label="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_ConcentrationRiskNumberOfCustomersAxis_12" xlink:to="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_OneCustomerMember" xlink:label="loc_immd_OneCustomerMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13" xlink:to="loc_immd_OneCustomerMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SecondCustomerMember" xlink:label="loc_immd_SecondCustomerMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13" xlink:to="loc_immd_SecondCustomerMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_ConsolidationItemsAxis_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsAxis_16" xlink:to="loc_us-gaap_ConsolidationItemsDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NutraceuticalAndCosmeticMember" xlink:label="loc_immd_NutraceuticalAndCosmeticMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_17" xlink:to="loc_immd_NutraceuticalAndCosmeticMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CosmeticGoodsMember" xlink:label="loc_immd_CosmeticGoodsMember_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_17" xlink:to="loc_immd_CosmeticGoodsMember_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndustryOfCounterpartyDomain" xlink:label="loc_us-gaap_IndustryOfCounterpartyDomain_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_20" xlink:to="loc_us-gaap_IndustryOfCounterpartyDomain_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_OneCreditCardProcessorsMember" xlink:label="loc_immd_OneCreditCardProcessorsMember_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndustryOfCounterpartyDomain_21" xlink:to="loc_immd_OneCreditCardProcessorsMember_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_TwoCreditCardProcessorsMember" xlink:label="loc_immd_TwoCreditCardProcessorsMember_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndustryOfCounterpartyDomain_21" xlink:to="loc_immd_TwoCreditCardProcessorsMember_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_24" xlink:to="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_MinorityInterestRate" xlink:label="loc_immd_MinorityInterestRate_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_immd_MinorityInterestRate_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLIFOReserve" xlink:label="loc_us-gaap_InventoryLIFOReserve_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_InventoryLIFOReserve_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_29" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_30" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_Revenues_31" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_AccountsReceivableNet_32" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NonControllingInterestDescription" xlink:label="loc_immd_NonControllingInterestDescription_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_immd_NonControllingInterestDescription_33" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesReturnsAndAllowancesGoods" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesGoods_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesGoods_34" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConclusionToConsolidate" xlink:label="loc_us-gaap_VariableInterestEntityConclusionToConsolidate_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_VariableInterestEntityConclusionToConsolidate_35" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xlink:label="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_36" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities" xlink:label="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_37" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues" xlink:label="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues_38" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss" xlink:label="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss_39" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NoncontrollingInterestsDescription" xlink:label="loc_immd_NoncontrollingInterestsDescription_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_immd_NoncontrollingInterestsDescription_40" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="loc_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_41" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/NotesPayableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis" xlink:label="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" xlink:label="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_2" xlink:to="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommercialLenderMember" xlink:label="loc_immd_CommercialLenderMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3" xlink:to="loc_immd_CommercialLenderMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficerMember" xlink:label="loc_us-gaap_OfficerMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_us-gaap_OfficerMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9" xlink:to="loc_us-gaap_CommercialPaperMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommercialPaperOneMember" xlink:label="loc_immd_CommercialPaperOneMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9" xlink:to="loc_immd_CommercialPaperOneMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommercialPaperTwoMember" xlink:label="loc_immd_CommercialPaperTwoMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9" xlink:to="loc_immd_CommercialPaperTwoMember_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_13" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_14" xlink:to="loc_us-gaap_SubsequentEventMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_16" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NotesPayableMember" xlink:label="loc_immd_NotesPayableMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_17" xlink:to="loc_immd_NotesPayableMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_19" xlink:to="loc_us-gaap_EquityComponentDomain_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_20" xlink:to="loc_us-gaap_CommonStockMember_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_20" xlink:to="loc_us-gaap_WarrantMember_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NotesPayableTextualAbstract" xlink:label="loc_immd_NotesPayableTextualAbstract_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23" xlink:to="loc_immd_NotesPayableTextualAbstract_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_InterestExpense_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_30" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_31" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_32" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_33" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_34" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_ConvertibleDebt_35" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_36" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="loc_invest_InvestmentOptionsExercisePrice_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_invest_InvestmentOptionsExercisePrice_37" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_TermOfWarrant" xlink:label="loc_immd_TermOfWarrant_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_immd_TermOfWarrant_38" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_39" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_40" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommonStockSharesIssuedRelatedPromissoryNote" xlink:label="loc_immd_CommonStockSharesIssuedRelatedPromissoryNote_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_immd_CommonStockSharesIssuedRelatedPromissoryNote_41" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_InterestExpenseDebt_42" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_NotesPayable_43" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_FlatFee" xlink:label="loc_immd_FlatFee_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_immd_FlatFee_44" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_DebtInstrumentTerm_45" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_46" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_47" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConversionOfFairMarketValueSharesAndWarrantsIssued" xlink:label="loc_immd_ConversionOfFairMarketValueSharesAndWarrantsIssued_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_immd_ConversionOfFairMarketValueSharesAndWarrantsIssued_48" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementInterest" xlink:label="loc_us-gaap_LitigationSettlementInterest_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_LitigationSettlementInterest_49" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_24" xlink:to="loc_us-gaap_InterestReceivable_50" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/IncomeTaxesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_IncomeTaxesTextualAbstract" xlink:label="loc_immd_IncomeTaxesTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_immd_IncomeTaxesTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_IncomeTaxesTextualAbstract_1" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_IncomeTaxesTextualAbstract_1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_IncomeTaxesTextualAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ExercisePriceRangeOneMember" xlink:label="loc_immd_ExercisePriceRangeOneMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_immd_ExercisePriceRangeOneMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ExercisePriceRangeTwoMember" xlink:label="loc_immd_ExercisePriceRangeTwoMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_immd_ExercisePriceRangeTwoMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ExercisePriceRangeThreeMember" xlink:label="loc_immd_ExercisePriceRangeThreeMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_immd_ExercisePriceRangeThreeMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_RangeAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_7" xlink:to="loc_us-gaap_RangeMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MinimumMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MaximumMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12" xlink:to="loc_us-gaap_EmployeeStockOptionMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/zeroLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails5">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConsultantMember" xlink:label="loc_immd_ConsultantMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_immd_ConsultantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_immd_ImmudynePrLlcMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MinimumMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13" xlink:to="loc_us-gaap_EmployeeStockOptionMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_PerformanceBasedStockOptionsMember" xlink:label="loc_immd_PerformanceBasedStockOptionsMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13" xlink:to="loc_immd_PerformanceBasedStockOptionsMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13" xlink:to="loc_us-gaap_WarrantMember_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_WarrantOneMember" xlink:label="loc_immd_WarrantOneMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13" xlink:to="loc_immd_WarrantOneMember_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_18" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_19" xlink:to="loc_us-gaap_DirectorMember_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_VestingAxis_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_21" xlink:to="loc_us-gaap_VestingDomain_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_VestedMember" xlink:label="loc_immd_VestedMember_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_22" xlink:to="loc_immd_VestedMember_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_UnvestedMember" xlink:label="loc_immd_UnvestedMember_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_22" xlink:to="loc_immd_UnvestedMember_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_25" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26" xlink:to="loc_us-gaap_IPOMember_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConsultingServicesMember" xlink:label="loc_immd_ConsultingServicesMember_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26" xlink:to="loc_immd_ConsultingServicesMember_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_IssuanceOfCommonStockMember" xlink:label="loc_immd_IssuanceOfCommonStockMember_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26" xlink:to="loc_immd_IssuanceOfCommonStockMember_29" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_30" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_StockholdersEquityTextualAbstract" xlink:label="loc_immd_StockholdersEquityTextualAbstract_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_30" xlink:to="loc_immd_StockholdersEquityTextualAbstract_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_34" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_PurchaseOfCommonStockDescriptionOfTransaction" xlink:label="loc_immd_PurchaseOfCommonStockDescriptionOfTransaction_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_immd_PurchaseOfCommonStockDescriptionOfTransaction_35" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_TreasuryStockValue_36" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_TreasuryStockCommonShares_37" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_CommonStockSharesIssued_38" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_39" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_NotesPayable_40" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/zeroLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_41" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_42" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_43" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_WarrantsToPurchaseOfCommonStock" xlink:label="loc_immd_WarrantsToPurchaseOfCommonStock_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_immd_WarrantsToPurchaseOfCommonStock_44" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_45" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_46" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_47" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_48" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_49" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_50" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_51"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_ProfitLoss_51" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_52"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_52" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_53"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_53" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_54"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_54" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_55"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_55" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NumberOfConsultant" xlink:label="loc_immd_NumberOfConsultant_56"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_immd_NumberOfConsultant_56" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_57"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_57" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_58"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_ShareBasedCompensation_58" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_59"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_59" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_60"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_60" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_AnnualSalesRevenueTarget" xlink:label="loc_immd_AnnualSalesRevenueTarget_61"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_immd_AnnualSalesRevenueTarget_61" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_62"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_62" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_63"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_63" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_FairValueOfPerformanceBasedStockOptions" xlink:label="loc_immd_FairValueOfPerformanceBasedStockOptions_64"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_immd_FairValueOfPerformanceBasedStockOptions_64" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_AggregateOfFairValue" xlink:label="loc_immd_AggregateOfFairValue_65"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_immd_AggregateOfFairValue_65" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_us-gaap_DeferredCompensationEquity_66"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_DeferredCompensationEquity_66" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_67"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_67" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_68"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_68" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_69"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_69" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_UnamortizedOfServiceAgreements" xlink:label="loc_immd_UnamortizedOfServiceAgreements_70"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_31" xlink:to="loc_immd_UnamortizedOfServiceAgreements_70" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/RoyaltiesDetails">
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RoyaltiesAbstract" xlink:label="loc_immd_RoyaltiesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_us-gaap_PresidentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RoyaltiesTextualAbstract" xlink:label="loc_immd_RoyaltiesTextualAbstract_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_immd_RoyaltiesTextualAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_PercentageOfRoyaltyBasedUponSales" xlink:label="loc_immd_PercentageOfRoyaltyBasedUponSales_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_immd_PercentageOfRoyaltyBasedUponSales_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RoyaltyBasedUponSalesAmount" xlink:label="loc_immd_RoyaltyBasedUponSalesAmount_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_immd_RoyaltyBasedUponSalesAmount_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_us-gaap_RoyaltyExpense_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_InterestInRoyalty" xlink:label="loc_immd_InterestInRoyalty_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_immd_InterestInRoyalty_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommitmentsAndContingenciesTable" xlink:label="loc_immd_CommitmentsAndContingenciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_immd_CommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_RestrictedStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RestrictedStockOneMember" xlink:label="loc_immd_RestrictedStockOneMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_RestrictedStockOneMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RestrictedStockTwoMember" xlink:label="loc_immd_RestrictedStockTwoMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_RestrictedStockTwoMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RestrictedStockThreeMember" xlink:label="loc_immd_RestrictedStockThreeMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_RestrictedStockThreeMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" xlink:to="loc_us-gaap_RelatedPartyDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ConsultantMember" xlink:label="loc_immd_ConsultantMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9" xlink:to="loc_immd_ConsultantMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_dei_LegalEntityAxis_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_11" xlink:to="loc_dei_EntityDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_12" xlink:to="loc_immd_ImmudynePrLlcMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_14" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" xlink:to="loc_us-gaap_PresidentMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommitmentsAndContingenciesLineItems" xlink:label="loc_immd_CommitmentsAndContingenciesLineItems_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_immd_CommitmentsAndContingenciesLineItems_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_immd_CommitmentsAndContingenciesTextualAbstract_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesLineItems_17" xlink:to="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_LeaseExpirationDate1_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_LeaseAndRentalExpense_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_SalariesWagesAndOfficersCompensation_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" xlink:label="loc_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_SalesRevenueNet_27" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SalesRevenueIncreased" xlink:label="loc_immd_SalesRevenueIncreased_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_SalesRevenueIncreased_28" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_BonusPercentageOfCompensationForPretaxIncome" xlink:label="loc_immd_BonusPercentageOfCompensationForPretaxIncome_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_BonusPercentageOfCompensationForPretaxIncome_29" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_PertaxIncomePercentage" xlink:label="loc_immd_PertaxIncomePercentage_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_PertaxIncomePercentage_30" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_31" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_32" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_33" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_DebtLongTermAndShortTermCombinedAmountShares" xlink:label="loc_immd_DebtLongTermAndShortTermCombinedAmountShares_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_DebtLongTermAndShortTermCombinedAmountShares_34" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_SharePrice_35" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_RestrictedStockExpense_36" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_37" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_BonusShares" xlink:label="loc_immd_BonusShares_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_BonusShares_38" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_OptionToBuyShares" xlink:label="loc_immd_OptionToBuyShares_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_OptionToBuyShares_39" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_40" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_NumerOfThresholds" xlink:label="loc_immd_NumerOfThresholds_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_NumerOfThresholds_41" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntercompanyAgreementsDescription" xlink:label="loc_us-gaap_IntercompanyAgreementsDescription_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_IntercompanyAgreementsDescription_42" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PremiumsPercentageAssumedToNet" xlink:label="loc_us-gaap_PremiumsPercentageAssumedToNet_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_PremiumsPercentageAssumedToNet_43" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_44" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_us-gaap_PresidentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_immd_ImmudynePrLlcMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_immd_RelatedPartyTransactionsTextualAbstract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8" xlink:to="loc_immd_RelatedPartyTransactionsTextualAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_ReimbursementOfHomeOfficeExpenditures" xlink:label="loc_immd_ReimbursementOfHomeOfficeExpenditures_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_9" xlink:to="loc_immd_ReimbursementOfHomeOfficeExpenditures_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_CompensationForLegalServices" xlink:label="loc_immd_CompensationForLegalServices_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_9" xlink:to="loc_immd_CompensationForLegalServices_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_9" xlink:to="loc_us-gaap_ProfessionalFees_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_AnnualIncentiveBonusAwardPercentage" xlink:label="loc_immd_AnnualIncentiveBonusAwardPercentage_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_9" xlink:to="loc_immd_AnnualIncentiveBonusAwardPercentage_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_9" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="immd-20170331.xsd#immd_SubsequentEventsTextualAbstract" xlink:label="loc_immd_SubsequentEventsTextualAbstract_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5" xlink:to="loc_immd_SubsequentEventsTextualAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_6" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_6" xlink:to="loc_us-gaap_ContractualObligation_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763069840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jul. 05, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immudyne, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000948320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,543,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763384848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 381,056<span></span>
</td>
<td class="nump">$ 182,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, net</a></td>
<td class="nump">555,708<span></span>
</td>
<td class="nump">444,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">136,938<span></span>
</td>
<td class="nump">160,270<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">1,073,702<span></span>
</td>
<td class="nump">789,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">562,220<span></span>
</td>
<td class="nump">752,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="nump">1,809,890<span></span>
</td>
<td class="nump">192,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, net of discount</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">106,365<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">2,397,110<span></span>
</td>
<td class="nump">1,151,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Immudyne, Inc. Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 50,000,000 shares authorized, 40,543,373 and 35,570,157 shares issued, 40,205,573 and 35,245,157 outstanding as of March 31, 2017 and December 31, 2016, respectively</a></td>
<td class="nump">405,433<span></span>
</td>
<td class="nump">355,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">9,363,160<span></span>
</td>
<td class="nump">9,070,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated (deficit)</a></td>
<td class="num">(10,738,687)<span></span>
</td>
<td class="num">(9,693,882)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_Equity', window );">Equity</a></td>
<td class="num">(970,094)<span></span>
</td>
<td class="num">(268,117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, 337,800 and 325,000 shares, at cost</a></td>
<td class="num">(90,204)<span></span>
</td>
<td class="num">(87,053)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Immudyne, Inc. Stockholders' (Deficit)</a></td>
<td class="num">(1,060,298)<span></span>
</td>
<td class="num">(355,170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="num">(263,110)<span></span>
</td>
<td class="num">(6,555)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Stockholders' (Deficit)</a></td>
<td class="num">(1,323,408)<span></span>
</td>
<td class="num">(361,725)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' (Deficit)</a></td>
<td class="nump">$ 1,073,702<span></span>
</td>
<td class="nump">$ 789,824<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents total of common stock, additional paid in capital and accumulated deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749441088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">40,543,373<span></span>
</td>
<td class="nump">35,570,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">40,205,573<span></span>
</td>
<td class="nump">35,245,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, shares</a></td>
<td class="nump">337,800<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763312848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">$ 424,462<span></span>
</td>
<td class="nump">$ 1,641,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of Sales</a></td>
<td class="nump">203,356<span></span>
</td>
<td class="nump">1,337,942<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">221,106<span></span>
</td>
<td class="nump">303,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CompensationAndRelatedExpenses', window );">Compensation and related expenses</a></td>
<td class="nump">358,488<span></span>
</td>
<td class="nump">240,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">99,632<span></span>
</td>
<td class="nump">69,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">Marketing expenses</a></td>
<td class="nump">10,800<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">127,172<span></span>
</td>
<td class="nump">98,412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">596,092<span></span>
</td>
<td class="nump">408,182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (Loss)</a></td>
<td class="num">(374,986)<span></span>
</td>
<td class="num">(105,096)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ChangeInFairValueOfDerivativeLiability', window );">Change in fair value of derivative liability</a></td>
<td class="num">(48,192)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest (expense)</a></td>
<td class="num">(649,357)<span></span>
</td>
<td class="num">(3,063)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (Loss)</a></td>
<td class="num">(1,072,535)<span></span>
</td>
<td class="num">(108,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) attributable to noncontrolling interests</a></td>
<td class="num">(27,730)<span></span>
</td>
<td class="num">(46,110)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) attributable to Immudyne, Inc.</a></td>
<td class="num">$ (1,044,805)<span></span>
</td>
<td class="num">$ (62,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (loss) per share attributable to Immudyne, Inc.</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">37,581,987<span></span>
</td>
<td class="nump">32,010,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">37,581,987<span></span>
</td>
<td class="nump">32,010,375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ChangeInFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents change in fair value of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ChangeInFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_CompensationAndRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements and related expenses (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_CompensationAndRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6756111792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - 3 months ended Mar. 31, 2017 - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated (Deficit)</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Sub Total</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2016</a></td>
<td class="num">$ (361,725)<span></span>
</td>
<td class="nump">$ 355,701<span></span>
</td>
<td class="nump">$ 9,070,064<span></span>
</td>
<td class="num">$ (9,693,882)<span></span>
</td>
<td class="num">$ (87,053)<span></span>
</td>
<td class="num">$ (355,170)<span></span>
</td>
<td class="num">$ (6,555)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,570,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">76,667<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">76,667<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">76,667<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock and warrants</a></td>
<td class="nump">647,944<span></span>
</td>
<td class="nump">$ 28,171<span></span>
</td>
<td class="nump">619,773<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">647,944<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock and warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,817,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of non-controlling interest equity for shares and warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11,835<span></span>
</td>
<td class="nump">260,368<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">272,203<span></span>
</td>
<td class="num">(272,203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of non-controlling interest equity for shares and warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,183,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Conversion of note payable</a></td>
<td class="nump">745,414<span></span>
</td>
<td class="nump">$ 7,552<span></span>
</td>
<td class="nump">737,862<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">745,414<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Conversion of note payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in relation to debt offering</a></td>
<td class="nump">56,522<span></span>
</td>
<td class="nump">$ 2,174<span></span>
</td>
<td class="nump">54,348<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">56,522<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock in relation to debt offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock</a></td>
<td class="num">(3,151)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,151)<span></span>
</td>
<td class="num">(3,151)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Issuance of stock options for services</a></td>
<td class="nump">113,522<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">113,522<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">113,522<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Investment in subsidiary by noncontrolling interest, net of distributions</a></td>
<td class="nump">43,378<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">43,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities', window );">Reclassification of options, warrants and other contracts to derivative liabilities upon issuance</a></td>
<td class="num">(1,569,444)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,569,444)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,569,444)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss)</a></td>
<td class="num">(1,072,535)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,044,805)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,044,805)<span></span>
</td>
<td class="num">(27,730)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2017</a></td>
<td class="num">$ (1,323,408)<span></span>
</td>
<td class="nump">$ 405,433<span></span>
</td>
<td class="nump">$ 9,363,160<span></span>
</td>
<td class="num">$ (10,738,687)<span></span>
</td>
<td class="num">$ (90,204)<span></span>
</td>
<td class="num">$ (1,060,298)<span></span>
</td>
<td class="num">$ (263,110)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,543,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid-in capital share based compensation reclassification of options, warrants and other contracts from equity to derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=immd_SummationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=immd_SummationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763654128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) attributable to Immudyne, Inc.</a></td>
<td class="num">$ (1,044,805)<span></span>
</td>
<td class="num">$ (62,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) attributable to noncontrolling interests</a></td>
<td class="num">(27,730)<span></span>
</td>
<td class="num">(46,110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss)</a></td>
<td class="num">(1,072,535)<span></span>
</td>
<td class="num">(108,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) to net cash (used) by operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of derivative liability</a></td>
<td class="nump">48,192<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt recovery</a></td>
<td class="num">(38,027)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">81,558<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on settlement of notes payable</a></td>
<td class="nump">553,222<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="nump">190,188<span></span>
</td>
<td class="nump">38,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade accounts receivable</a></td>
<td class="num">(72,938)<span></span>
</td>
<td class="num">(144,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">23,332<span></span>
</td>
<td class="num">(77,443)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(188,498)<span></span>
</td>
<td class="nump">169,482<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used) by operating activities</a></td>
<td class="num">(473,256)<span></span>
</td>
<td class="num">(122,155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Investment in subsidiary by noncontrolling interest, net</a></td>
<td class="nump">43,378<span></span>
</td>
<td class="nump">92,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="nump">235,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible note payable</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="num">(151,420)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_IssuanceOfCommonStockAndWarrants', window );">Sale of common stock and warrants</a></td>
<td class="nump">647,944<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Purchase of treasury stock</a></td>
<td class="num">(3,151)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">671,751<span></span>
</td>
<td class="nump">92,793<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash</a></td>
<td class="nump">198,495<span></span>
</td>
<td class="num">(29,362)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of the period</a></td>
<td class="nump">182,561<span></span>
</td>
<td class="nump">232,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of the period</a></td>
<td class="nump">381,056<span></span>
</td>
<td class="nump">203,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the period for interest</a></td>
<td class="nump">3,612<span></span>
</td>
<td class="nump">3,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Issuance of company stock for notes and other payables</a></td>
<td class="nump">192,192<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants', window );">Conversion of equity invested in subsidiary to common stock and warrants</a></td>
<td class="nump">272,203<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities', window );">Reclassification of options, warrants and other contracts to derivative liabilities upon issuance</a></td>
<td class="nump">$ 1,569,444<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The conversion vale of equity invested in subsidiary to common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_IssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_IssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of options, warrants and other contracts to derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ReclassificationOfOptionsWarrantsAndOtherContractsToDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753941824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Going Concern<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Going Concern</a></td>
<td class="text"><div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>1.</b></font></td><td style="text-align: justify; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Organization and Going Concern</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Immudyne, Inc. (the &#8220;Company&#8221;) is a Delaware corporation established to develop, manufacture and sell natural immune support products containing the Company&#8217;s proprietary yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast that have been shown through testing and analysis to support the immune system. The Company&#8217;s products include once a day oral intake tablets and topical creams and gels for skin application. The Company concentrates its sales and marketing efforts on healthcare professionals, distributors for its all-natural raw material ingredient products and direct-to-consumer sales.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In 2015, the Company formed a joint venture domiciled in Puerto Rico, Innate Skincare, LLC (&#8220;Innate&#8221;). Under the terms of the joint venture agreement, the Company held a 33.3% equity interest, and a 51% controlling voting interest, in Innate. On January 20, 2016, Innate amended its limited liability company operating agreement and changed its legal name to Immudyne PR LLC (&#8220;Immudyne PR&#8221;). On April 1, 2016, Immudyne PR further amended its operating agreement and restated the Company&#8217;s ownership and voting interest in Immudyne PR increasing its ownership to 78.1667% resulting in a charge to noncontrolling interest and additional paid-in-capital of $91,612. Immudyne PR was formed to launch a complete skin care regime formulated using strategic ingredients provided by the Company. In the second quarter of 2017, Immudyne PR expanded their product line and launched their in-licensed patented hair loss shampoo and conditioner.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company has funded operations in the past through the sales of its products, issuance of common stock and through loans and advances from officers and directors. The Company&#8217;s continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers and directors or the issuance of additional shares of common stock.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. At March 31, 2017, the Company has an accumulated deficit approximating $10.7 million and has incurred negative cash flows from operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Based on the Company's cash balance at March 31, 2017, and projected cash needs for 2017, management estimates that it will need to increase sales revenue and/or raise additional capital to cover operating and capital requirements for the remainder of the 2017 year. Management will need to raise the additional needed funds through increased sales volume, issuing additional shares of common stock or other equity securities, or obtaining debt financing. Although management has been successful to date in raising necessary funding, there can be no assurance that sales revenue will substantially increase or that any required future financing can be successfully completed on a timely
 basis, or on terms
 acceptable to the Company.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754068160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div>
<table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 36pt; text-align: justify; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>2.</b></font></td>
<td style="text-align: justify; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Summary of Significant Accounting Policies</b></font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>&#160;</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Principles of Consolidation</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (&#8220;ASC 810&#8221;).</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Immudyne PR and variable interest entities (VIE&#8217;s) in which the Company has been determined to be the primary beneficiary. The non- controlling interest in Immudyne PR represents the 21.8333% equity interest held by other members of the joint venture. All significant consolidated transactions and balances have been eliminated in consolidation.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Variable Interest Entities</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company follows ASC 810-10-15 guidance with respect to accounting for variable interest entities (each, a &#8220;VIE&#8221;). These entities do not have sufficient equity at risk to finance their activities without additional subordinated financial support from other parties or whose equity investors lack any of the characteristics of a controlling financial interest. A variable interest is an investment or other interest that will absorb portions of a VIE&#8217;s expected losses or receive portions of its expected residual returns and are contractual, ownership, or pecuniary in nature and that change with changes in the fair value of the entity&#8217;s net assets. A reporting entity is the primary beneficiary of a VIE and must consolidate it when that party has a variable interest, or combination of variable interests, that provides it with a controlling financial interest. A party is deemed to have a controlling financial interest if it meets both of the power and losses/benefits criteria. The power criterion is the ability to direct the activities of the VIE that most significantly impact its economic performance. The losses/benefits criterion is the obligation to absorb losses from, or right to receive benefits from, the VIE that could potentially be significant to the VIE. The VIE model requires an ongoing reconsideration of whether a reporting entity is the primary beneficiary of a VIE due to changes in facts and circumstances.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">As of March 31, 2017 and December 31, 2016, the Company consolidated nine VIEs.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Immudyne PR as the primary beneficiary of Ace Account Management LLC, Innerwell Skincare LLC, MCD Merchants LLC, One Equity Research
 LLC, Inate Gems LLC, Retriever Health Products LLC, Spurs 5, LLC, Salus LLC and Huntley LLC which are qualified as VIEs. The assets and liabilities and revenues and expenses of these VIEs included in the financial statements of Immudyne PR and further included in the consolidated financial statements. As of March 31, 2017, the VIEs had assets of $19,421, liabilities of $5,748, revenues of $981, and operating expenses of $953. As of December 31, 2016, the VIEs had assets of $10,306, liabilities of $5,748. The assets and liabilities include balances due from and due to the subsidiaries of Immudyne PR. Any inter-company receivables and payables are eliminated upon consolidation of the VIE with Immudyne PR and Immudyne, Inc. No assets were pledged or given as collateral against any borrowings.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company utilizes third party entities to provide and increase credit card processing capacity and optimize corresponding rates and fees. A majority of these entities provide this service as independent contractors in exchange for a one percent (1%) fee of the net revenues processed and collected by such contractors from sales initiated by the Company. The VIEs consolidated in the Company&#8217;s financial statements are primarily contracted to provide credit card processing through one or more merchant banks. Upon receipt of funds by each VIE, the collection of receipts less any returns, chargeback and other fees charged by such merchant bank is transferred to Immudyne PR.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i><br /></i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Use of Estimates</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>&#160;</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the determination of reserves for accounts receivable, returns and allowances, the accounting for derivatives, the valuation of inventory and stockholders&#8217; equity based transactions. Actual results could differ from those estimates.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Derivative Liabilities</i></b>&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Under ASC 815-40-05, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in a Company&#8217;s Own Stock, in the event the Company does not have a sufficient number of authorized and unissued shares of common stock to satisfy obligations for stock options, warrants and other instruments potentially convertible into common stock, the fair value of these instruments should be reported as a liability. Pursuant to the outstanding option, warrant and convertible debt agreements, there is currently no effective registration statement covering the shares of common stock underlying these agreements, which are currently subject to a cashless exercise whereby the holders, at their option, may surrender their options and warrants to the company in exchange for shares of common stock. The number of shares of common stock into which an option or a warrant would be exchangeable in such a cashless exercise depends on both the exercise price of the options or warrant and the market price of the common stock, each at or near the time of exercise. Because both of these factors are variable, it is possible that the Company could have insufficient authorized shares to satisfy a cashless exercise. In this scenario, if the Company were unable to obtain shareholder approval to increase the number of authorized shares, the Company could be obligated to settle such a cashless exercise with cash rather than by issuing shares of common stock. Further, ASC 815-40-05 requires that the Company record the potential settlement obligation at each reporting date using the current estimated fair value of these contracts, with any changes in fair value being recorded through our statement of operations. The Company will continue to report the potential settlement obligation as a liability until such time as these contracts are
 exercised or expire or we are otherwise able to modify the warrant agreement to remove the provisions which require this treatment. The Company also plans to amend its Articles of Incorporation in the third quarter of 2017 to increase the number of shares of its authorized common stock after the approval by its shareholders.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Sequencing Policy</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Under ASC 815-40-35, the Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company&#8217;s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of authorized but unissued shares, and all future instruments being classified as a derivative liability, with the exception of instruments related to share-based compensation issued to employees or directors.&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Inventory&#160;</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">At March 31, 2017 and December 31, 2016, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic products. Inventory is maintained in the Company&#8217;s leased Kentucky warehouse and third party warehouses in Pennsylvania and Louisiana.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Inventory is valued at the lower of cost or market with cost determined on a first-in, first-out (&#8220;FIFO&#8221;) basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to market value, if lower. At March 31, 2017 and December 31, 2016, the Company recorded an inventory reserve in the amount of $20,000. Inventory consists of the following:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">March&#160;31,<br />2017</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">December&#160;31,<br />2016</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 36pt; background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman',
 times, serif; text-align: left; font-stretch: normal;">Raw materials</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 100px; text-align: right; font-stretch: normal;">29,577</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 100px; text-align: right; font-stretch: normal;">38,460</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Finished products</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">107,361</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">121,810</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">136,938</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">160,270</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Revenue Recognition</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company&#8217;s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer, and for sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped, but in limited cases if title does not pass until the product reaches the customer&#8217;s delivery site, then recognition of revenue is deferred until that time. Delivery is considered to have occurred when title and risk of loss have transferred to the customer. Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates approximated $38,000 and $517,000 in the three months ended March 31, 2017 and 2016, respectively. There are no formal sales incentives offered to any of the Company&#8217;s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Revenue for the three months ended March 31, 2017 consisted of nutraceutical and cosmetic additives ($256,563) and finished cosmetic products ($167,899). Revenue for the three months ended March 31, 2016 consists of nutraceutical and cosmetic additives ($265,910) and finished cosmetic products ($1,375,118).</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Accounts receivable</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Accounts receivable are carried at original invoice amount less an estimate made for holdbacks and doubtful receivables based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#8217;s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers&#8217; accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. At March 31, 2017 and December 31, 2016 the accounts receivable reserve was approximately $37,800 for both periods. As of March 31, 2017 and December 31, 2016, the reserve for sales returns and allowances was approximately $12,500 and $50,500, respectively.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;<b><i>&#160;</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Segments</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The guidance for disclosures about segments of an enterprise requires that a public business enterprise report financial and descriptive information about its operating segments. Generally, financial information is required to be reported on the basis used internally for evaluating segment performance and resource allocation. The Company manages its operations in two reportable segments for purposes of assessing performance and making operating decisions. Revenue is generated predominately in the United States, and all significant assets are held in the United States, or United States territories.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company allocates resources and evaluates the performance of segments based on income or loss from operations, excluding interest, corporate expenses and other income (expenses).</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">A summary of the company&#8217;s reportable segments is as follows:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">Total assets:</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times,
 serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">March&#160;31,<br />2017</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">December&#160;31,<br />2016</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 36pt; background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Nutraceutical and Cosmetic Additives</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 100px; text-align: right; font-stretch: normal;">1,350,785</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 100px; text-align: right; font-stretch: normal;">556,234</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Finished Cosmetic Products</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">385,345</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">422,288</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">Eliminations</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(662,428</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(188,698</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">Total</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">1,073,702</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">789,824</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1250.4px;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Three Months ended</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">March&#160;31, 2017</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">March&#160;31, 2016</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Net sales by segment:</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 36pt; background-color: white;">&#160;</td>
<td style="text-align: left;">Nutraceutical and Cosmetic Additives</td>
<td style="width: 12px;">&#160;</td>
<td style="width: 12px; text-align: left;">$</td>
<td style="width: 100px; text-align: right;">256,563</td>
<td style="width: 12px; text-align: left;">&#160;</td>
<td style="width: 12px;">&#160;</td>
<td style="width: 12px; text-align: left;">$</td>
<td style="width: 100px; text-align: right;">285,160</td>
<td style="width: 12px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left;">Finished Cosmetic Products</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">167,899</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,375,118</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 1.5pt;">Eliminations</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(19,250</td>
<td style="text-align: left; padding-bottom: 1.5pt;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 4pt; font-weight: bold;">Total</td>
<td style="padding-bottom: 4pt; font-weight: bold;">&#160;</td>
<td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">424,462</td>
<td style="text-align: left; padding-bottom: 4pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 4pt; font-weight: bold;">&#160;</td>
<td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,641,028</td>
<td style="text-align: left; padding-bottom: 4pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left; font-weight: bold; text-decoration: underline;">Net (loss) income by segment:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left;">Nutraceutical and Cosmetic Additives</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">26,807</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">84,777</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left;">Finished Cosmetic Products</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(127,007</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(69,165</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align:
 left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left; font-weight: bold; text-decoration: underline;">Other unallocated amounts:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left;">Corporate expenses</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(274,786</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(120,708</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left; padding-bottom: 1.5pt;">Other income (expense)</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(697,549</td>
<td style="text-align: left; padding-bottom: 1.5pt;">)</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(3,063</td>
<td style="text-align: left; padding-bottom: 1.5pt;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left; padding-bottom: 4pt; font-weight: bold;">Net (loss)</td>
<td style="padding-bottom: 4pt; font-weight: bold;">&#160;</td>
<td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(1,072,535</td>
<td style="text-align: left; padding-bottom: 4pt; font-weight: bold;">)</td>
<td style="padding-bottom: 4pt; font-weight: bold;">&#160;</td>
<td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(108,159</td>
<td style="text-align: left; padding-bottom: 4pt; font-weight: bold;">)</td>
</tr>
</table>
<br class="apple-interchange-newline" />
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Income Taxes</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company files Corporate Federal and State tax returns, while Immudyne PR, which was formed as a limited liability corporation, files a separate tax return with any tax liabilities or benefits passing through to its members.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company records current and deferred taxes in accordance with Accounting Standards Codification (ASC) 740, &#8220;Accounting for Income Taxes.&#8221; This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company&#8217;s tax returns for all years since December 31, 2013, remain open to taxing authorities.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Stock-Based Compensation</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company follows the provisions of ASC 718, &#8220;Share-Based Payment&#8221;. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company&#8217;s shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i><br /></i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Earnings (Loss) Per Share</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Common stock equivalents comprising shares underlying 18,295,335 options and warrants for the three months ended March 31, 2017 have not been included in the loss per share calculation as the effects are anti-dilutive. Common stock equivalents comprising shares underlying 12,525,273 options and warrants for the three months ended March 31, 2016 have not been included in the loss per share calculations as the effects are anti-dilutive.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Recent Accounting Pronouncements</i></b>&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017 but early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance.</p>
<p style="font: 10pt/normal 'times new roman', times,
 serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (&#8220;ASU 2016-15&#8221;). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of adoption of ASU 2016-15.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement on its consolidated financial statements. At this time, the adoption of this pronouncement is not expected to have a material impact on the Company&#8217;s consolidated financial statements or related disclosures.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In May 2014, the Financial Accounting Standards Board ("FASB") issued accounting guidance, "Revenue from Contracts with Customers." The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal year 2018. The Company does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Noncontrolling Interests</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px
 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest&#8217;s share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Consolidation of Variable Interest Entities</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In accordance with ASC 810-10-25-37 and as amended by ASU 2009-17, the Company determines whether any legal entity in which the Company becomes involved is a VIE and subject to consolidation. The Company conducts an assessment on an ongoing basis for each VIE including (1) the power to direct activities of the VIE that most significantly impact the VIE&#8217;s economic performance, and (2) the obligation to absorb losses or right to receive benefits from the VIE that could potentially be significant to the VIE. As a result, the Company determined that nine (9) entities were VIEs and subject to consolidation.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Concentration of Credit Risk</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">One customer in the nutraceutical and cosmetic additives division accounted for 59% and 16% of consolidated sales for the three months ended March 31, 2017 and 2016, respectively. This customer also accounted for 45% and 54% of accounts receivable at March 31, 2017 and December 31, 2016, respectively.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In the finished cosmetic products division, two credit card processors accounted for 42% and 35% of accounts receivable at March 31, 2017. In the finished cosmetic products division, two credit card processors accounted for 35% and 32% of accounts receivable at December 31, 2016.</p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6922774816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><div>
<table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 36pt; text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>3.</b></font></td>
<td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Notes Payable</b></font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>&#160;</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In November 2015, the Company borrowed $100,000 from a commercial lender. The loan incurred interest at 11% and with a maturity date of November 1, 2016. In October 2016, the Company repaid the entire principal balance. Interest expense related to this loan for the period ended March 31, 2016 amounted to $3,063.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In the third quarter of 2016 the Company commenced an offering pursuant to which it offered 11% subordinated promissory notes in fifty thousand ($50,000) dollar increments combined with 62,500 shares of the Company&#8217;s Common Stock for a maximum offering amount of $200,000 (the &#8220;Offering&#8221;). In August and September 2016, the Company sold promissory notes totaling $150,000 to three unrelated individuals. Two of the promissory notes totaling $100,000 were payable in February 2017 and one promissory note for $50,000 was payable in March 2017. In October 2016, the Company sold promissory notes totaling $50,000 to two unrelated individuals. These promissory notes are payable in October 2017. In connection with these promissory notes sold, pursuant to the Offering, the Company issued 250,000 shares of common stock valued at $58,750 which was recorded as a debt discount and will be amortized over the term of these notes. Amortization of the debt discounts for the period ended March 31, 2017 was $25,035. During 2016, the Company repaid $68,600 of the principal balance. During 2017, the Company repaid $81,420 of the principal balance and converted the remaining balance of $49,980 into 196,000 shares of common stock and 98,000 warrants. The fair market value of the shares and warrants issued upon conversion was determined to be $179,384, of which $129,404 was included in interest expense as loss on settlement of notes payable. Interest expense related to these notes for the three months ended March 31, 2017 amounted to $131,117.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In December 2016, the Company borrowed $100,000 from an officer and issued a convertible promissory note with a maturity date of February 28, 2017. The loan incurs no interest. This note is convertible if not repaid by the maturity date at a conversion price of $0.23 per Unit. Each Unit shall consist of one share of the Company&#8217;s common stock and one three-year common-stock warrant to purchase one-half of one share of the Company&#8217;s common stock with an exercise price of $0.40 per share. In March 2017, the Company repaid the entire outstanding balance of this note.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January 2017, the Company borrowed $200,000 and issued a promissory note with a 5% original issue discount for a total principal amount of $210,000. The loan incurs 11% interest per annum and matures in various tranches from February 2017 through April 2017. In addition, the Company issued 217,391 shares of common stock related to this note. In February 2017, the Company repaid $70,000 of the principal balance of this note. In March 2017, the Company converted the remaining $140,000 of the principal balance of this note and accrued interest of $2,212 in exchange for 559,179 shares of common stock and 304,348 warrants. The fair market value of the shares and warrants issued upon conversion was determined to be $566,030, of which $423,818 was included in interest expense as loss on settlement of notes payable.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal;
 word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In February 2017, the Company borrowed $25,000 from an American Express working capital line with 60 days maturity. The interest for this loan is a flat fee of $250. As of March 31, 2017, there were no available borrowings under the working capital line.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Interest expense related to loans from officers, directors and other related individuals amounted to $1,713 and $312 for the three months ended March 31, 2017 and 2016, respectively.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Total interest expense on notes payable, inclusive of amortization of debt discount of $91,556 and $-0-, amounted to $649,357 and $3,063 for the three months ended March 31, 2017 and 2016, respectively.</p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911653312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><table style="width: 888.57px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>4.</b></font></td><td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Income Taxes</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company is not expected to have taxable income in 2017 and incurred a loss for the year ended December 31, 2016 and accordingly, no provision for federal income tax has been made in the accompanying financial statements. At March 31, 2017, the Company had available net operating loss carryforwards of approximately $4,294,800, expiring during various years through 2037.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">A summary of the deferred tax asset using an approximate 34% tax rate is as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 888.57px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="width: 36pt; background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-size: 10pt;">Net operating loss</font></td><td style="width: 8.57px; background-color: #cceeff;">&#160;</td><td style="width: 8.57px; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td><td style="width: 70.85px; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">1,699,000</font></td><td style="width: 8.57px; background-color: #cceeff;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td><font style="font-size: 10pt;">Accounts receivable reserves</font></td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font-size: 10pt;">17,000</font></td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-size: 10pt;">Inventory reserves</font></td><td style="background-color: #cceeff;">&#160;</td><td style="background-color: #cceeff;">&#160;</td><td style="text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">7,000</font></td><td style="background-color: #cceeff;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td style="padding-bottom: 1.5pt;"><font style="font-size: 10pt;">Stock compensation</font></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-size: 10pt;">229,000</font></td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-size: 10pt;">Net deferred tax asset</font></td><td style="background-color: #cceeff;">&#160;</td><td style="background-color: #cceeff;">&#160;</td><td style="text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">1,952,000</font></td><td style="background-color: #cceeff;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td style="padding-bottom: 1.5pt;"><font style="font-size: 10pt;">Valuation allowance</font></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-size: 10pt;">(1,952,000</font></td><td style="padding-bottom: 1.5pt;"><font style="font-size: 10pt;">)</font></td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt; padding-left: 10pt; background-color: #cceeff;"><font style="font-size: 10pt;">Total</font></td><td style="padding-bottom: 4pt; background-color: #cceeff;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; background-color: #cceeff;"><font style="font-size: 10pt;">-</font></td><td style="padding-bottom: 4pt; background-color: #cceeff;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The net operating loss carryforwards could be
 subject to limitation in any given year in the event of a change in
 ownership as defined by IRC Section 382.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The difference between the statutory and the effective tax rate is primarily due to a change in valuation allowance on deferred taxes, as the Company has fully reserved the deferred tax asset resulting from available net operating loss carryforwards.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753916448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div>
<table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 36pt; text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>5.</b></font></td>
<td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Stockholders&#8217; Equity</b></font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Common Stock</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On April 1, 2016, the Company entered into two agreements with two consultants to provide services over a nine-month period in exchange for 2,300,000 shares of common stock. The Company calculated a fair value of $690,000 based on the market price of the shares on the date of the agreements. During the third quarter of 2016, the Company and the consultants renegotiated the agreements by extending the service requirement to December 31, 2017. For the period ended March 31, 2017, the Company has recognized expense of $76,667 in connection with these agreements. As of March 31, 2017 and December 31, 2016, the unamortized portion of these service agreements are $230,000 and $306,667, respectively.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During 2016, the Company purchased 325,000 shares of outstanding Company common stock through an exchange for a price per share of $0.23 to $0.29. During 2017, the Company purchased an additional 12,800 shares of outstanding Company common stock for a price per share of $0.24 to $0.26. As of the March 31, 2017, a total of 337,800 shares are being held by the Company valued at cost is $90,204 and are included in treasury stock in the consolidated balance sheet.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January 2017, the Company issued 1,183,490 shares of common stock pursuant to a conversion of Immudyne PR equity contributions of $272,203 into equity of Immudyne, Inc. by the noncontrolling interest.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January 2017, the Company issued 217,391 shares of common stock in relation to the remaining outstanding principal balance on the $210,000 note payable.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In the first quarter of 2017, the Company commenced an offering to sell up to 4,000,000 shares of common stock at a price of $0.23 per share and warrants to purchase up to 2,000,000 shares of common stock excisable any time prior to the secondary anniversary of the issuance. The warrants are paired with the stock on the basis of one warrant for every two shares of stock purchased. During the first quarter of 2017, the Company received subscriptions in the amount of 2,817,156 shares and issued 1,408,578 warrants and proceeds in the amount of $647,944.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In March 2017, the Company issued 755,179 shares of common stock for the conversion of the outstanding balance of three notes payable totaling $499,802 (see Note 3).</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Noncontrolling Interest</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On April 1, 2016, the Company increased its ownership in Immudyne PR to 78.1667% decreasing the minority interest from 66.7% to 21.8333% resulting in a charge to noncontrolling interest and additional paid-in-capital of $91,612.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the three months ended March 31, 2017 and 2016, the net loss of Immudyne PR attributed to the noncontrolling interest amounted to $27,730 and $46,110, respectively.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Service-Based Stock Options</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In May 2016, the Company issued 175,000 service-based options valued at $40,829 to two consultants at exercise prices of $0.20 per share. The options are fully vested and expire in 10 years.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style:
 initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In July 2016, the Company issued 50,000 service-based options valued at $12,397 to a consultant with an exercise price of $0.20 per share. The options are fully vested and expire in 10 years.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In November 2016, the Company issued 50,000 service-based options valued at $9,980 to a consultant with an exercise price of $0.50 per share. The options are fully vested and expire in 2 years.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In February 2017, the Company issued 500,000 service-based options valued at $113,522 to a director with an exercise price of $0.20 per share. The options are fully vested and expire in 10 years.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Accordingly, stock based compensation for the periods ended March 31, 2017 and 2016 included $113,522 and $-0-, respectively, related to such service-based stock options.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">A summary of the outstanding service-based options are as follows:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Number of</font><br /><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Options</font></td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 36pt; background-color: white;">&#160;</td>
<td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Balance at December 31, 2016</font></td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 156px; text-align: right;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">10,700,273</font></td>
<td style="width: 15px;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Issued</font></td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">500,000</font></td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Balance at March 31, 2017</font></td>
<td style="padding-bottom:
 4pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">11,200,273</font></td>
<td style="padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">All outstanding options are exercisable and have a cashless exercise provision, and certain options provide for accelerated vesting provisions and modifications, as defined, if the Company is sold or acquired. The intrinsic value of service based options outstanding and exercisable at March 31, 2017 and December 31, 2016 amounted to $3,261,859 and $704,794, respectively.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The significant assumptions used to determine the fair values of options issued, using the Black-Scholes option-pricing model are as follows:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="width: 48px; background-color: white;">&#160;</td>
<td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><u>Significant assumptions:</u></font></td>
<td style="width: 15px;">&#160;</td>
<td nowrap="nowrap" style="width: 141px;">&#160;</td>
<td style="width: 15px;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Risk-free interest rate at grant date</font></td>
<td style="background-color: #cceeff;">&#160;</td>
<td nowrap="nowrap" style="text-align: center; background-color: #cceeff;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">1.49</font><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">%</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Expected stock price volatility</font></td>
<td>&#160;</td>
<td nowrap="nowrap" style="text-align: center;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">216.7</font><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">%</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Expected dividend payout</font></td>
<td style="background-color: #cceeff;">&#160;</td>
<td nowrap="nowrap" style="text-align: center; background-color: #cceeff;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#8212;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Expected option life-years</font></td>
<td>&#160;</td>
<td nowrap="nowrap" style="text-align: center;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">3</font>&#160;<font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">years</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Weighted average grant date fair value</font></td>
<td style="background-color: #cceeff;">&#160;</td>
<td nowrap="nowrap" style="text-align: center; background-color: #cceeff;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">$0.24</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Forfeiture rate</font></td>
<td>&#160;</td>
<td nowrap="nowrap" style="text-align: center;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">0</font><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">%</font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt;
 text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following is a summary of outstanding service-based options at March 31, 2017:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Exercise Price</font></td>
<td>&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Number of</font><br /><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Options</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Weighted Average Remaining Contractual Life</font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="width: 48px; background-color: white;">&#160;</td>
<td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$0.10</font></td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
<td style="width: 141px; text-align: right; background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,380,273</font></td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
<td style="width: 15px; text-align: center; background-color: #cceeff;">&#160;</td>
<td style="width: 141px; text-align: center; background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1 year</font></td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$0.20 - $0.25</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">8,620,000</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">5 years</font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$0.40</font></td>
<td style="background-color: #cceeff;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,200,000</font></td>
<td style="background-color: #cceeff;">&#160;</td>
<td style="background-color: #cceeff;">&#160;</td>
<td style="text-align: center; background-color: #cceeff;">&#160;</td>
<td style="text-align: center; background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">5 years</font></td>
<td style="background-color: #cceeff;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td style="padding-left: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Total</font></td>
<td>&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">11,200,273</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">&#160;</td>
<td>&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Performance-Based Stock Options</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal;
 orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i><u>Vested</u></i></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company granted performance-based options to purchase 2,925,000 shares of common stock at exercise prices of $0.40. The options expire at various dates between 2021 and 2026 and are exercisable upon the Company achieving annual sales revenue of $5,000,000. &#160;During the year ended December 31, 2016, the Company cancelled 287,500 of these service-based options issued to two consultants, valued at $12,457.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value of the vested performance-based options aggregated $120,867 and was expensed over the implicit service period commencing once management believed the performance criteria was met. During 2016, the Company met the performance criteria and accordingly, recorded stock based compensation expense of $38,867 for the three months ended March 31, 2016.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i><u>Unvested</u></i></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>&#160;</i></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company granted performance-based options to purchase 1,150,000 shares of common stock at exercise prices of $0.40 and $0.80. The options expire at various dates between 2021 and 2027 and are exercisable upon the Company achieving annual sales revenue of $5,000,000 and $10,000,000. &#160;During the year ended December 31, 2016, the Company cancelled 287,500 of these service-based options issued to two consultants, valued at $5,542.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The performance criteria for options exercisable upon the Company achieving annual sales revenue of $5,000,000 and $10,000,000 with an aggregate fair value of $85,608. As of March 31, 2017, no amounts have been expensed and the unearned compensation for all the performance based options is $85,608.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Warrants</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following is a summary of outstanding and exercisable warrants:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal;
 word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Number of Shares</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">
<p style="margin-top: 0px; margin-bottom: 0px;">Weighted Average</p>
<p style="margin-top: 0px; margin-bottom: 0px;">Exercise Price</p>
</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Year&#160;of&#160;<br />Expiration</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 36pt; background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Balance at December 31, 2016</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">1,954,981</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">0.19</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 235px; text-align: center; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">2017 - 2019</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Issued</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">2,402,671</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">0.40</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;">2019</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;
 font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Balance at March 31, 2017</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">4,357,562</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">0.31</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">2017 - 2019</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In September 2016, the Company issued 100,000 warrants with an exercise price of $0.50 per share, in relation to a sale of common stock. These warrants are fully vested and expire in two years.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In September 2016, the Company issued 100,000 warrants with exercise prices between $0.20 and $0.50 per share, for consulting services. These warrants are fully vested and expire in three years.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In December 2016, the Company issued 37,500 warrants with an exercise price of $0.50 per share, in relation to a sale of common stock. These warrants are fully vested and expire in two years.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In December 2016, the Company issued 217,391 warrants with an exercise price of $0.40 per share, in relation to an issuance of common stock. These warrants are fully vested and expire in two years.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2;
 font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January 2017, the Company issued 591,745 warrants with an exercise price of $0.40 per share, in relation to an issuance of common stock for the conversion of an equity contribution into Immudyne PR by the noncontrolling interest. These warrants are fully vested and expire in two years.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In March 2017, the Company issued 403,348 warrants with an exercise price of $0.40 per share, in relation to an issuance of common stock for the conversion of debt. These warrants are fully vested and expire in two years.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In the first quarter of 2017, the Company issued 1,407,578 warrants with an exercise price of $0.40 per share, in relation to a sale of common stock. These warrants are fully vested and expire in two years.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value of warrants granted during the period ended March 31, 2017, was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="width: 36pt; background-color: white;">&#160;</td>
<td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Expected volatility</font></td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
<td style="width: 219px; text-align: center; background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">181% - 211%</font></td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Risk free interest rate</font></td>
<td>&#160;</td>
<td style="text-align: center;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.03% - 2.22</font>%</td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Expected dividend yield</font></td>
<td style="background-color: #cceeff;">&#160;</td>
<td style="text-align: center; background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</font></td>
<td style="background-color: #cceeff;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Expected term (in years)</font></td>
<td>&#160;</td>
<td style="text-align: center;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.4 - 8.5</font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Weighted average grant date fair value</font></td>
<td style="background-color: #cceeff;">&#160;</td>
<td style="text-align: center; background-color: #cceeff;">$<font style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.37 - 0.50</font></td>
<td style="background-color: #cceeff;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt
 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of March 31, 2017 and December 31, 2016, certain of the Company&#8217;s stock options, stock warrants and convertible debt instruments were accounted for as derivative liabilities due to insufficient authorized shares of common stock to settle outstanding contracts. At March 31, 2017 and December 31, 2016, the Company estimated the fair value of these stock options, stock warrants and embedded conversion features using the Black-Scholes option pricing model (&#8220;Black-Scholes&#8221;) to be $1,809,890 and $192,254, based on Level 2 valuation inputs.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Stock Based Compensation</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The total stock based compensation expense related Service-Based Stock Options, Performance-Based Stock Options and Warrants and common stock issued for service amounted to $190,189 and $38,867 for the three months ended March 31, 2017 and 2016, respectively. Such amounts are included in compensation and related expenses in the accompanying statement of operations.</p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754068160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RoyaltiesAbstract', window );"><strong>Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RoyaltiesDisclosureTextBlock', window );">Royalties</a></td>
<td class="text"><div><table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>6.</b></font></td><td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Royalties</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company was subject to a royalty agreement based upon sales of certain skin care products. The agreement required the Company to pay a royalty based upon 8% of such sales, up to $227,175. During the year ended December 31, 2015 the Company&#8217;s sales reached the maximum amount under which the Company was required to pay a royalty under this agreement, accordingly no royalty expense was incurred for the three month periods ended March 31, 2017 and 2016, respectively. During December 2015, the Company&#8217;s President who had a 60% interest in the royalties, converted royalties payable under the agreement in the amount of $84,868 to 499,225 shares of Company stock at $0.17 cents per share.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Included in accounts payable and accrued expenses at March 31, 2017 and December 31, 2016 was $56,579 in regards to this agreement.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_RoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_RoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_RoyaltiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_RoyaltiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753999728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div><table style="width: 888.57px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>7.</b></font></td><td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Commitments and Contingencies</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Leases</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company leases a plant in Kentucky under an operating lease which expired on May 31, 2016. Management is currently discussing renewal lease options for the Kentucky plant and is operating on a month-to-month lease arrangement until a final agreement has been accepted. Monthly base rental payments are approximately $9,000. The Company&#8217;s principal executive offices are in office space provided to us by the Company&#8217;s President, Mr. McLaughlin, at the rate of $2,000 per month, which includes rents, utilities and other office related expenditures. This arrangement commenced as of January 1, 2016. In addition, Immudyne PR utilizes office space in Puerto Rico which is subleased from Justin Schreiber (President of Immudyne PR) and incurs expense of approximately $4,000 a month for this office space. Rent expense for the three month periods ended March 31, 2017 and 2016, was $36,061 and $16,616, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Employment and Consulting Agreements</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company has entered into various agreements with officers, directors, employees and consultants that expire in one to five years. The agreements provide for annual compensation of up to $145,000 and the issuance of stock options, at exercise prices of $0.40 and $0.80, to purchase 4,400,000 shares of common stock issuable upon the Company&#8217;s revenue exceeding $5,000,000 and $10,000,000, as defined. In addition, the agreements provide for bonus compensation to these individuals aggregating up to 15% (with no individual having more than 5%) of the Company&#8217;s pretax income.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Restricted Stock and Options</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company has entered into two agreements on April 1, 2016 with two consultants of Immudyne PR for business development, marketing and sales related services (the &#8220;Consultant Agreements&#8221;). The consultants are treated as employees for accounting purposes. Upon signing, each consultant was issued 1,000,000 restricted shares of Immudyne, Inc. common stock. In addition, each consultant shall receive an additional 150,000 restricted shares of Immudyne, Inc. common stock for each $500,000 distributed by Immudyne PR to the Company. For each consultant, the amount of shares to be issued by the Company to the consultants shall be capped at 1,500,000 restricted shares when Immudyne PR has transferred $5,000,000 to the Company, for a combined capped total of 3,000,000 restricted shares. For the three months ended March 31, 2017 and 2016, -0- restricted shares of common stock have been issued related to these agreements. During 2016, 2,300,000 restricted shares of common stock were issued related to these agreements. The Company valued the shares at their grant date for a value of $0.30 per share for a total of $690,000 to be expensed over the estimated service period ending December 31, 2017.</p><p style="font: 10pt/normal 'times new roman',
 times, serif; margin:
 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In addition, the Consulting Agreements provided that each consultant shall receive a bonus of an additional 750,000 restricted shares of Immudyne, Inc. common stock, plus an option to buy 1,000,000 shares of Immudyne, Inc. common stock at $0.20/share (including a cashless exercise feature) when Immudyne PR has transferred to the Company at each of the following three (3) thresholds: $1,250,000, $2,000,000 and $3,000,000 for a total of 2,250,000 of restricted shares of Immudyne, Inc. common stock and options to purchase up to 3,000,000 shares of Immudyne, Inc. common stock at $0.20/share. As of March 31, 2017, no bonus shares have been issued and no options have been granted under this agreement.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Sole and Exclusive License, Royalty, and Advisory Agreement</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On September 1, 2016 Immudyne PR entered into a sole and exclusive license, royalty and advisory agreement with Pilaris Laboratories, LLC (&#8220;Pilaris&#8221;) relating to Pilaris&#8217; PilarisMax shampoo formulation and conditioner. The term of the agreement will be the life of the US Patent held by Pilaris. As consideration for granting Immudyne PR this license, Pilaris will receive on quarterly basis, 10% of the net income collected by the licensed products based on the following formula: Net Income = total income &#8211; cost of goods sold &#8211; advertising and operating expenses directly related to the marketing of the licensed products. In addition, Immudyne PR share pay Pilaris a performance fee of $50,000 on the 180-day anniversary of the agreement and an additional $50,000 performance fee on the 365-day anniversary of the agreement. As of March 31, 2017, the Company has accrued $58,333 expense related to this agreement.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Legal Matters</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In the normal course of business operations, the Company may become involved in various legal matters. At March 31, 2017, the Company&#8217;s management does not believe that there are any potential legal matters that could have an adverse effect on the Company&#8217;s financial position.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754031152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div><table style="width: 888.57px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>8.</b></font></td><td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Related Party Transactions</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">During 2016, legal and business advisory services were provided to the Company by one of its directors. For the three months ended March 31, 2016 this director was compensated $6,000. No services were provided during the three months ended March 31, 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">During the three months ended March 31, 2017 and 2016, the Company&#8217;s President received $8,000 and $8,000, respectively for reimbursement of home office expenditures, including rent, utilities and other related expenses for two offices.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Immudyne, Inc. employs the wife of the President of the Company as an accountant and incurs $3,000 per month, plus an annual incentive bonus award equal to 0.5% of the Company&#8217;s pre-tax earnings.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Immudyne PR utilizes BV Global Fulfillment, owned by the father of Immudyne PR&#8217;s President, and incurred $10,396 for the three months ended March 31, 2017 for these services. During the three months ended March 31, 2016, Immudyne PR did not utilize BV Global Fulfillment.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Taggart International Trust (&#8220;Taggart&#8221;), a shareholder, provides credit card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">JLS Ventures LLC, owned by a shareholder, provides credit card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">JSDC, Inc., owned by a shareholder, provides credit card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Immudyne PR utilizes office space in Puerto Rico which
 is subleased from the
 President of Immudyne PR and incurs expense of approximately $4,000 a month for this office space.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6642696352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>9.</b></font></td><td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Subsequent Events</b>&#160;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has evaluated subsequent events through the date these financial statements were issued.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On April 24, 2017, the Company, issued 217,390 shares of common stock pursuant to a stock subscription agreement and the Company issued 108,696 warrants with an exercise price of $0.40 per share for the stated consideration and satisfaction of obligation to pay $50,000 on the 180-day anniversary of the execution of the Sole and Exclusive License, Royalty, and Advisory Agreement dated September 1, 2016 with Pilaris Laboratories, LLC.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749521840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Principles of Consolidation</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (&#8220;ASC 810&#8221;).</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Immudyne PR and variable interest entities (VIE&#8217;s) in which the Company has been determined to be the primary beneficiary. The non- controlling interest in Immudyne PR represents the 21.8333% equity interest held by other members of the joint venture. All significant consolidated transactions and balances have been eliminated in consolidation.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_VariableInterestEntitiesPolicyTextBlock', window );">Variable Interest Entities</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Variable Interest Entities</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company follows ASC 810-10-15 guidance with respect to accounting for variable interest entities (each, a &#8220;VIE&#8221;). These entities do not have sufficient equity at risk to finance their activities without additional subordinated financial support from other parties or whose equity investors lack any of the characteristics of a controlling financial interest. A variable interest is an investment or other interest that will absorb portions of a VIE&#8217;s expected losses or receive portions of its expected residual returns and are contractual, ownership, or pecuniary in nature and that change with changes in the fair value of the entity&#8217;s net assets. A reporting entity is the primary beneficiary of a VIE and must consolidate it when that party has a variable interest, or combination of variable interests, that provides it with a controlling financial interest. A party is deemed to have a controlling financial interest if it meets both of the power and losses/benefits criteria. The power criterion is the ability to direct the activities of the VIE that most significantly impact its economic performance. The losses/benefits criterion is the obligation to absorb losses from, or right to receive benefits from, the VIE that could potentially be significant to the VIE. The VIE model requires an ongoing reconsideration of whether a reporting entity is the primary beneficiary of a VIE due to changes in facts and circumstances.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">As of March 31, 2017 and December 31, 2016, the Company consolidated nine VIEs.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Immudyne PR as the primary beneficiary of Ace Account Management LLC, Innerwell Skincare LLC, MCD Merchants LLC, One Equity Research LLC, Inate Gems LLC, Retriever Health Products LLC, Spurs 5, LLC, Salus LLC and Huntley LLC which are qualified as VIEs. The assets and liabilities and revenues and expenses of these VIEs included in the financial statements of Immudyne PR and further included in the consolidated financial statements. As of March 31, 2017, the VIEs had assets of $19,421, liabilities of $5,748, revenues of $981, and operating expenses of $953. As of December 31, 2016, the VIEs had assets of $10,306, liabilities of $5,748. The assets and liabilities include balances due from and due to the subsidiaries of Immudyne PR. Any inter-company receivables and payables are eliminated upon consolidation of the VIE with Immudyne PR and Immudyne, Inc. No assets were pledged or given as collateral against any borrowings.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company utilizes third party entities to provide and increase credit card processing capacity and optimize corresponding rates and fees. A majority of these entities provide this service as independent contractors in exchange for a one percent (1%) fee of the net revenues processed and collected by such contractors from sales initiated by the Company. The VIEs consolidated in the Company&#8217;s financial statements are primarily contracted to provide credit card processing through one or more merchant banks. Upon receipt of funds by each VIE, the collection of receipts less any returns, chargeback and other fees charged by such merchant bank is transferred to Immudyne PR.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Use of Estimates</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>&#160;</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the determination of reserves for accounts receivable, returns and allowances, the accounting for derivatives, the valuation of inventory and stockholders&#8217; equity based transactions. Actual results could differ from those estimates.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Derivative Liabilities</i></b>&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Under ASC 815-40-05, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in a Company&#8217;s Own Stock, in the event the Company does not have a sufficient number of authorized and unissued shares of common stock to satisfy obligations for stock options, warrants and other instruments potentially convertible into common stock, the fair value of these instruments should be reported as a liability. Pursuant to the outstanding option, warrant and convertible debt agreements, there is currently no effective registration statement covering the shares of common stock underlying these agreements, which are currently subject to a cashless exercise whereby the holders, at their option, may surrender their options and warrants to the company in exchange for shares of common stock. The number of shares of common stock into which an option or a warrant would be exchangeable in such a cashless exercise depends on both the exercise price of the options or warrant and the market price of the common stock, each at or near the time of exercise. Because both of these factors are variable, it is possible that the Company could have insufficient authorized shares to satisfy a cashless exercise. In this scenario, if the Company were unable to obtain shareholder approval to increase the number of authorized shares, the Company could be obligated to settle such a cashless exercise with cash rather than by issuing shares of common stock. Further, ASC 815-40-05 requires that the Company record the potential settlement obligation at each reporting date using the current estimated fair value of these contracts, with any changes in fair value being recorded through our statement of operations. The Company will continue to report the potential settlement obligation as a liability until such time as these contracts are exercised or expire or we are otherwise able to modify the warrant agreement to remove the provisions which require this treatment. The Company also plans to amend its Articles of Incorporation in the third quarter of 2017 to increase the number of shares of its authorized common stock after the approval by its shareholders.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SequencingPolicyPolicyTextBlock', window );">Sequencing Policy</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Sequencing Policy</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Under ASC 815-40-35, the Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company&#8217;s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of authorized but unissued shares, and all future instruments being classified as a derivative liability, with the exception of instruments related to share-based compensation issued to employees or directors.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Inventory&#160;</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">At March 31, 2017 and December 31, 2016, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic products. Inventory is maintained in the Company&#8217;s leased Kentucky warehouse and third party warehouses in Pennsylvania and Louisiana.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Inventory is valued at the lower of cost or market with cost determined on a first-in, first-out (&#8220;FIFO&#8221;) basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to market value, if lower. At March 31, 2017 and December 31, 2016, the Company recorded an inventory reserve in the amount of $20,000. Inventory consists of the following:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">March&#160;31,<br />2017</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">December&#160;31,<br />2016</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 36pt; background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Raw materials</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 113.63px; text-align: right; font-stretch: normal;">29,577</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 113.63px; text-align: right; font-stretch: normal;">38,460</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Finished products</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">107,361</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">121,810</td><td style="font: 10pt/normal 'times new roman',
 times,
 serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">136,938</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">160,270</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Revenue Recognition</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company&#8217;s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer, and for sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped, but in limited cases if title does not pass until the product reaches the customer&#8217;s delivery site, then recognition of revenue is deferred until that time. Delivery is considered to have occurred when title and risk of loss have transferred to the customer. Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates approximated $38,000 and $517,000 in the three months ended March 31, 2017 and 2016, respectively. There are no formal sales incentives offered to any of the Company&#8217;s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Revenue for the three months ended March 31, 2017 consisted of nutraceutical and cosmetic additives ($256,563) and finished cosmetic products ($167,899). Revenue for the three months ended March 31, 2016 consists of nutraceutical and cosmetic additives ($265,910) and finished cosmetic products ($1,375,118).</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Accounts receivable</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Accounts receivable are carried at original invoice amount less an estimate made for holdbacks and doubtful receivables based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#8217;s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers&#8217; accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. At March 31, 2017 and December 31, 2016 the accounts receivable reserve was approximately $37,800 for both periods. As of March 31, 2017 and December 31, 2016, the reserve for sales returns and allowances was approximately $12,500 and $50,500, respectively.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Segments</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The guidance for disclosures about segments of an enterprise requires that a public business enterprise report financial and descriptive information about its operating segments. Generally, financial information is required to be reported on the basis used internally for evaluating segment performance and resource allocation. The Company manages its operations in two reportable segments for purposes of assessing performance and making operating decisions. Revenue is generated predominately in the United States, and all significant assets are held in the United States, or United States territories.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company allocates resources and evaluates the performance of segments based on income or loss from operations, excluding interest, corporate expenses and other income (expenses).</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">A summary of the company&#8217;s reportable segments is as follows:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">Total assets:</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">March&#160;31,<br />2017</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">December&#160;31,<br />2016</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 36pt; background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Nutraceutical and Cosmetic Additives</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;">1,350,785</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;">556,234</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch:
 normal;">Finished Cosmetic Products</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">385,345</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">422,288</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">Eliminations</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(662,428</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(188,698</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">Total</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">1,073,702</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">789,824</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Three Months ended</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">March&#160;31, 2017</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">March&#160;31, 2016</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Net sales by segment:</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 36pt; background-color: white;">&#160;</td>
<td style="text-align: left;">Nutraceutical and Cosmetic Additives</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 125px;
 text-align: right;">256,563</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 125px; text-align: right;">285,160</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left;">Finished Cosmetic Products</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">167,899</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,375,118</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 1.5pt;">Eliminations</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(19,250</td>
<td style="text-align: left; padding-bottom: 1.5pt;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 4pt; font-weight: bold;">Total</td>
<td style="padding-bottom: 4pt; font-weight: bold;">&#160;</td>
<td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">424,462</td>
<td style="text-align: left; padding-bottom: 4pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 4pt; font-weight: bold;">&#160;</td>
<td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,641,028</td>
<td style="text-align: left; padding-bottom: 4pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left; font-weight: bold; text-decoration: underline;">Net (loss) income by segment:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left;">Nutraceutical and Cosmetic Additives</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">26,807</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">84,777</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left;">Finished Cosmetic Products</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(127,007</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(69,165</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left; font-weight: bold; text-decoration: underline;">Other unallocated amounts:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left;">Corporate expenses</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(274,786</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(120,708</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left; padding-bottom: 1.5pt;">Other income (expense)</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(697,549</td>
<td style="text-align: left; padding-bottom: 1.5pt;">)</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(3,063</td>
<td style="text-align: left; padding-bottom: 1.5pt;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td
 style="text-align: left; padding-bottom: 4pt; font-weight: bold;">Net (loss)</td>
<td style="padding-bottom: 4pt; font-weight: bold;">&#160;</td>
<td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(1,072,535</td>
<td style="text-align: left; padding-bottom: 4pt; font-weight: bold;">)</td>
<td style="padding-bottom: 4pt; font-weight: bold;">&#160;</td>
<td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(108,159</td>
<td style="text-align: left; padding-bottom: 4pt; font-weight: bold;">)</td>
</tr>
</table>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Income Taxes</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company files Corporate Federal and State tax returns, while Immudyne PR, which was formed as a limited liability corporation, files a separate tax return with any tax liabilities or benefits passing through to its members.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company records current and deferred taxes in accordance with Accounting Standards Codification (ASC) 740, &#8220;Accounting for Income Taxes.&#8221; This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company&#8217;s tax returns for all years since December 31, 2013, remain open to taxing authorities.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Stock-Based Compensation</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company follows the provisions of ASC 718, &#8220;Share-Based Payment&#8221;. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company&#8217;s shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Earnings (Loss) Per Share</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Common stock equivalents comprising shares underlying 18,295,335 options and warrants for the three months ended March 31, 2017 have not been included in the loss per share calculation as the effects are anti-dilutive. Common stock equivalents comprising shares underlying 12,525,273 options and warrants for the three months ended March 31, 2016 have not been included in the loss per share calculations as the effects are anti-dilutive.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Recent Accounting Pronouncements</i></b>&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017 but early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (&#8220;ASU 2016-15&#8221;). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of adoption of ASU 2016-15.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement on its consolidated financial statements. At this time, the adoption of this pronouncement is not expected to have a material impact on the Company&#8217;s consolidated financial statements or related disclosures.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In May 2014, the Financial Accounting Standards Board ("FASB") issued accounting guidance, "Revenue from Contracts with Customers." The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal year 2018. The Company does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt
 0px 0pt
 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_MinorityInterestPolicyTextBlock', window );">Noncontrolling Interests</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Noncontrolling Interests</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest&#8217;s share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Consolidation of Variable Interest Entities</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Consolidation of Variable Interest Entities</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In accordance with ASC 810-10-25-37 and as amended by ASU 2009-17, the Company determines whether any legal entity in which the Company becomes involved is a VIE and subject to consolidation. The Company conducts an assessment on an ongoing basis for each VIE including (1) the power to direct activities of the VIE that most significantly impact the VIE&#8217;s economic performance, and (2) the obligation to absorb losses or right to receive benefits from the VIE that could potentially be significant to the VIE. As a result, the Company determined that nine (9) entities were VIEs and subject to consolidation.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">One customer in the nutraceutical and cosmetic additives division accounted for 59% and 16% of consolidated sales for the three months ended March 31, 2017 and 2016, respectively. This customer also accounted for 45% and 54% of accounts receivable at March 31, 2017 and December 31, 2016, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In the finished cosmetic products division, two credit card processors accounted for 42% and 35% of accounts receivable at March 31, 2017. In the finished cosmetic products division, two credit card processors accounted for 35% and 32% of accounts receivable at December 31, 2016.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_MinorityInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_MinorityInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_SequencingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for sequencing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_SequencingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_VariableInterestEntitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It repressents variable interest entitues policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_VariableInterestEntitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=SL6759159-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5728-111685<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=SL6759068-111685<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41620-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579240-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41675-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41638-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65890831&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5212-111524<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5093-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6915784368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of inventory</a></td>
<td class="text"><div><table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">March&#160;31,<br />2017</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">December&#160;31,<br />2016</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 36pt; background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Raw materials</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 113.63px; text-align: right; font-stretch: normal;">29,577</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 113.63px; text-align: right; font-stretch: normal;">38,460</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Finished products</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">107,361</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">121,810</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">136,938</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">160,270</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Summary of reportable segments</a></td>
<td class="text"><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">Total assets:</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2">March&#160;31,<br />2017</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2">December&#160;31,<br />2016</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 36pt; background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">Nutraceutical and Cosmetic Additives</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-size-adjust: none; font-stretch: normal;">1,350,785</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-size-adjust: none; font-stretch: normal;">556,234</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">Finished Cosmetic Products</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">385,345</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">422,288</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">Eliminations</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">(662,428</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">(188,698</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">Total</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal
 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">1,073,702</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">789,824</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Three Months ended</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">March&#160;31, 2017</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">March&#160;31, 2016</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Net sales by segment:</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 36pt; background-color: white;">&#160;</td>
<td style="text-align: left;">Nutraceutical and Cosmetic Additives</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 125px; text-align: right;">256,563</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 125px; text-align: right;">285,160</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left;">Finished Cosmetic Products</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">167,899</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,375,118</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 1.5pt;">Eliminations</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(19,250</td>
<td style="text-align: left; padding-bottom: 1.5pt;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 4pt; font-weight: bold;">Total</td>
<td style="padding-bottom: 4pt; font-weight: bold;">&#160;</td>
<td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">424,462</td>
<td style="text-align: left; padding-bottom: 4pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 4pt; font-weight: bold;">&#160;</td>
<td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,641,028</td>
<td style="text-align: left; padding-bottom: 4pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align:
 left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left; font-weight: bold; text-decoration: underline;">Net (loss) income by segment:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left;">Nutraceutical and Cosmetic Additives</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">26,807</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">84,777</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left;">Finished Cosmetic Products</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(127,007</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(69,165</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left; font-weight: bold; text-decoration: underline;">Other unallocated amounts:</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left;">Corporate expenses</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(274,786</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(120,708</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left; padding-bottom: 1.5pt;">Other income (expense)</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(697,549</td>
<td style="text-align: left; padding-bottom: 1.5pt;">)</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(3,063</td>
<td style="text-align: left; padding-bottom: 1.5pt;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left; padding-bottom: 4pt; font-weight: bold;">Net (loss)</td>
<td style="padding-bottom: 4pt; font-weight: bold;">&#160;</td>
<td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(1,072,535</td>
<td style="text-align: left; padding-bottom: 4pt; font-weight: bold;">)</td>
<td style="padding-bottom: 4pt; font-weight: bold;">&#160;</td>
<td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(108,159</td>
<td style="text-align: left; padding-bottom: 4pt; font-weight: bold;">)</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6643639280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of deferred tax asset</a></td>
<td class="text"><table style="width: 888px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="width: 36pt; background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-size: 10pt;">Net operating loss</font></td><td style="width: 8px; background-color: #cceeff;">&#160;</td><td style="width: 8px; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td><td style="width: 70px; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">1,699,000</font></td><td style="width: 8px; background-color: #cceeff;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td><font style="font-size: 10pt;">Accounts receivable reserves</font></td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font-size: 10pt;">17,000</font></td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-size: 10pt;">Inventory reserves</font></td><td style="background-color: #cceeff;">&#160;</td><td style="background-color: #cceeff;">&#160;</td><td style="text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">7,000</font></td><td style="background-color: #cceeff;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td style="padding-bottom: 1.5pt;"><font style="font-size: 10pt;">Stock compensation</font></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-size: 10pt;">229,000</font></td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-size: 10pt;">Net deferred tax asset</font></td><td style="background-color: #cceeff;">&#160;</td><td style="background-color: #cceeff;">&#160;</td><td style="text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">1,952,000</font></td><td style="background-color: #cceeff;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td style="padding-bottom: 1.5pt;"><font style="font-size: 10pt;">Valuation allowance</font></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-size: 10pt;">(1,952,000</font></td><td style="padding-bottom: 1.5pt;"><font style="font-size: 10pt;">)</font></td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt; padding-left: 10pt; background-color: #cceeff;"><font style="font-size: 10pt;">Total</font></td><td style="padding-bottom: 4pt; background-color: #cceeff;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; background-color: #cceeff;"><font style="font-size: 10pt;">-</font></td><td style="padding-bottom: 4pt; background-color: #cceeff;"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763165680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of outstanding service-based options</a></td>
<td class="text"><div><table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Number of Shares</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"><p style="margin-top: 0px; margin-bottom: 0px;">Weighted Average</p><p style="margin-top: 0px; margin-bottom: 0px;">Exercise Price</p></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Year&#160;of&#160;<br />Expiration</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 36pt; background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Balance at December 31, 2016</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 112px; text-align: right; font-stretch: normal;">1,954,981</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 112px; text-align: right; font-stretch: normal;">0.19</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 187.2px; text-align: center; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">2017 - 2019</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Issued</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">2,402,671</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">0.40</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;">2019</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size:
 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Balance at March 31, 2017</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">4,357,562</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">0.31</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">2017 - 2019</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Summary of significant assumptions used to determine fair values of options issued using Black-Scholes option-pricing model</a></td>
<td class="text"><div><table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="width: 36pt; background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Expected volatility</font></td><td style="width: 12px; background-color: #cceeff;">&#160;</td><td style="width: 174.4px; text-align: center; background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">181% - 211%</font></td><td style="width: 12px; background-color: #cceeff;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Risk free interest rate</font></td><td>&#160;</td><td style="text-align: center;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.03% - 2.22</font>%</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Expected dividend yield</font></td><td style="background-color: #cceeff;">&#160;</td><td style="text-align: center; background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</font></td><td style="background-color: #cceeff;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Expected term (in years)</font></td><td>&#160;</td><td style="text-align: center;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.4 - 8.5</font></td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Weighted average grant date fair value</font></td><td style="background-color: #cceeff;">&#160;</td><td style="text-align: center; background-color: #cceeff;">$<font style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.37 - 0.50</font></td><td style="background-color: #cceeff;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Service-Based Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of outstanding service-based options</a></td>
<td class="text"><div><table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Number of</font><br /><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Options</font></td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 36pt; background-color: white;">&#160;</td><td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Balance at December 31, 2016</font></td><td style="width: 12px;">&#160;</td><td style="width: 12px;">&#160;</td><td style="width: 124.8px; text-align: right;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">10,700,273</font></td><td style="width: 12px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Issued</font></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">500,000</font></td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Balance at March 31, 2017</font></td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">11,200,273</font></td><td style="padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Summary of significant assumptions used to determine fair values of options issued using Black-Scholes option-pricing model</a></td>
<td class="text"><div><table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="width: 48px; background-color: white;">&#160;</td><td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><u>Significant assumptions:</u></font></td><td style="width: 12px;">&#160;</td><td nowrap="nowrap" style="width: 112px;">&#160;</td><td style="width: 12px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Risk-free interest rate at grant date</font></td><td style="background-color: #cceeff;">&#160;</td><td nowrap="nowrap" style="text-align: center; background-color: #cceeff;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">1.49</font><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">%</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Expected stock price volatility</font></td><td>&#160;</td><td nowrap="nowrap" style="text-align: center;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">216.7</font><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">%</font></td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Expected dividend payout</font></td><td style="background-color: #cceeff;">&#160;</td><td nowrap="nowrap" style="text-align: center; background-color: #cceeff;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#8212;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Expected option life-years</font></td><td>&#160;</td><td nowrap="nowrap" style="text-align: center;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">3</font>&#160;<font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">years</font></td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Weighted average grant date fair value</font></td><td style="background-color: #cceeff;">&#160;</td><td nowrap="nowrap" style="text-align: center; background-color: #cceeff;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">$0.24</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Forfeiture rate</font></td><td>&#160;</td><td nowrap="nowrap" style="text-align: center;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">0</font><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">%</font></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of outstanding service-based options exercise price</a></td>
<td class="text"><div><table style="width: 888px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Exercise Price</font></td><td>&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Number of</font><br /><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Options</font></td><td>&#160;</td><td>&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Weighted Average Remaining Contractual Life</font></td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="width: 48px; background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$0.10</font></td><td style="width: 8px; background-color: #cceeff;">&#160;</td><td style="width: 8px; background-color: #cceeff;">&#160;</td><td style="width: 79px; text-align: right; background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,380,273</font></td><td style="width: 8px; background-color: #cceeff;">&#160;</td><td style="width: 8px; background-color: #cceeff;">&#160;</td><td style="width: 8px; text-align: center; background-color: #cceeff;">&#160;</td><td style="width: 79px; text-align: center; background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1 year</font></td><td style="width: 8px; background-color: #cceeff;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$0.20 - $0.25</font></td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">8,620,000</font></td><td>&#160;</td><td>&#160;</td><td style="text-align: center;">&#160;</td><td style="text-align: center;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">5 years</font></td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$0.40</font></td><td style="background-color: #cceeff;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,200,000</font></td><td style="background-color: #cceeff;">&#160;</td><td style="background-color: #cceeff;">&#160;</td><td style="text-align: center; background-color: #cceeff;">&#160;</td><td style="text-align: center; background-color: #cceeff;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">5 years</font></td><td style="background-color: #cceeff;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td style="padding-left: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Total</font></td><td>&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">11,200,273</font></td><td>&#160;</td><td>&#160;</td><td style="text-align: center;">&#160;</td><td style="text-align: center;">&#160;</td><td></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation and net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751820736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Going Concern (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 01, 2016</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_OrganizationAndGoingConcernTextualAbstract', window );"><strong>Organization and Going Concern (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,738,687)<span></span>
</td>
<td class="num">$ (9,693,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional paid-in-capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_OrganizationAndGoingConcernTextualAbstract', window );"><strong>Organization and Going Concern (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Reduction in noncontrolling interest</a></td>
<td class="nump">$ 91,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ImmudynePrLlcMember', window );">Immudyne PR LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_OrganizationAndGoingConcernTextualAbstract', window );"><strong>Organization and Going Concern (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership equity interest</a></td>
<td class="nump">78.1667%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_InnateScientificLlcMember', window );">Innate Skincare, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_OrganizationAndGoingConcernTextualAbstract', window );"><strong>Organization and Going Concern (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of voting controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_OrganizationAndGoingConcernTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>organization and going concern textual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_OrganizationAndGoingConcernTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ImmudynePrLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ImmudynePrLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_InnateScientificLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_InnateScientificLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923547920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Summary of inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 29,577<span></span>
</td>
<td class="nump">$ 38,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">107,361<span></span>
</td>
<td class="nump">121,810<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 136,938<span></span>
</td>
<td class="nump">$ 160,270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763367968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Summary of reportable segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 1,073,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 789,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">424,462<span></span>
</td>
<td class="nump">$ 1,641,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(1,072,535)<span></span>
</td>
<td class="num">(108,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_OtherUnallocatedAmountsAbstract', window );"><strong>Other unallocated amounts:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CorporateExpenses', window );">Corporate expenses</a></td>
<td class="num">(274,786)<span></span>
</td>
<td class="num">(120,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(697,549)<span></span>
</td>
<td class="num">(3,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Net (loss)</a></td>
<td class="num">(1,072,535)<span></span>
</td>
<td class="num">(108,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=immd_NutraceuticalAndCosmeticMember', window );">Nutraceutical and Cosmetic Additives [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Summary of reportable segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,350,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">256,563<span></span>
</td>
<td class="nump">265,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="nump">26,807<span></span>
</td>
<td class="nump">84,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=immd_CosmeticGoodsMember', window );">Finished Cosmetic Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Summary of reportable segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">385,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">422,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">167,899<span></span>
</td>
<td class="nump">1,375,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(127,007)<span></span>
</td>
<td class="num">(69,165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Eliminations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Summary of reportable segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="num">(662,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (188,698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (19,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_CorporateExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of unallocated corporate expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_CorporateExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_OtherUnallocatedAmountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other unallocated amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_OtherUnallocatedAmountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=immd_NutraceuticalAndCosmeticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=immd_NutraceuticalAndCosmeticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=immd_CosmeticGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=immd_CosmeticGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764492944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_MinorityInterestRate', window );">Non-controlling interest rate</a></td>
<td class="nump">21.8333%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLIFOReserve', window );">Inventory reserve</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoods', window );">Customer discounts, returns and rebates</a></td>
<td class="nump">38,000<span></span>
</td>
<td class="nump">$ 517,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">424,462<span></span>
</td>
<td class="nump">1,641,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable reserve</a></td>
<td class="nump">37,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NonControllingInterestDescription', window );">Description of non controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesReturnsAndAllowancesGoods', window );">Sales returns and allowances</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityConclusionToConsolidate', window );">Consolidated VIE, description</a></td>
<td class="text">Company consolidated nine VIEs.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Company consolidated nine VIEs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets', window );">Variable Interest Entity, assets</a></td>
<td class="nump">$ 19,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities', window );">Variable Interest Entity, liabilities</a></td>
<td class="nump">5,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues', window );">Variable Interest Entity, revenues</a></td>
<td class="nump">981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss', window );">Variable Interest Entity, operating expenses</a></td>
<td class="nump">$ 953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NoncontrollingInterestsDescription', window );">Noncontrolling interests, description</a></td>
<td class="text">The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest's share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Income tax, description</a></td>
<td class="text">More than 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=immd_NutraceuticalAndCosmeticMember', window );">Nutraceutical and Cosmetic Additives [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 256,563<span></span>
</td>
<td class="nump">265,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=immd_CosmeticGoodsMember', window );">Finished Cosmetic Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 167,899<span></span>
</td>
<td class="nump">$ 1,375,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember', window );">Sales [Member] | One customer [Member] | Nutraceutical and Cosmetic Additives [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">59.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | One credit card processor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Two credit card processor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | One customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">18,295,335<span></span>
</td>
<td class="nump">12,525,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_MinorityInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non controlling stated interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_MinorityInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_NonControllingInterestDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of non controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_NonControllingInterestDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_NoncontrollingInterestsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_NoncontrollingInterestsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies textual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_SummaryOfSignificantAccountingPoliciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 15<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877542&amp;loc=d3e27249-109313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 50<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68069731&amp;loc=d3e63676-111659<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 15<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68051624&amp;loc=d3e47468-111626<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesDiscountsReturnsAndAllowancesGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesReturnsAndAllowancesGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions) and price reductions (allowance, price protection agreements) given by the entity. Returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesReturnsAndAllowancesGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income (loss) from operations derived by the reporting entity during the period from the Variable Interest Entity (VIE).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph d<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5747-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income between the reporting entity and the Variable Interest Entity (VIE).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph d<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5747-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityConclusionToConsolidate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the primary factors that caused the change in conclusion to consolidate a Variable Interest Entity (VIE) in the most recent financial statements (for example, the VIE was previously consolidated and is not currently consolidated) and the effect of the change on the reporting entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityConclusionToConsolidate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the consolidated Variable Interest Entity's assets included in the reporting entity's statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the consolidated Variable Interest Entity's liabilities included in the reporting entity's statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=immd_NutraceuticalAndCosmeticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=immd_NutraceuticalAndCosmeticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=immd_CosmeticGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=immd_CosmeticGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ConcentrationRiskNumberOfCustomersAxis=immd_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ConcentrationRiskNumberOfCustomersAxis=immd_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis=immd_OneCreditCardProcessorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis=immd_OneCreditCardProcessorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis=immd_TwoCreditCardProcessorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis=immd_TwoCreditCardProcessorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767136880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Aug. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Borrowed from commercial lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov.  01,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">649,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">common stock shares issued</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in relation to debt offering</a></td>
<td class="nump">$ 58,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Repaid of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,420<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Common stock for maximum offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommonStockSharesIssuedRelatedPromissoryNote', window );">Common stock shares issued related promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,802<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,802<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_FlatFee', window );">Flat fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Working capital line</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted remaining principle balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ConversionOfFairMarketValueSharesAndWarrantsIssued', window );">Conversion of fair market value shares and warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementInterest', window );">Loss on settlement of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 423,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in relation to debt offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted remaining principle balance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted remaining principle balance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=immd_NotesPayableMember', window );">Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Promissory note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Original debt, discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Original debt, principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Borrowing amount</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=immd_CommercialPaperOneMember', window );">Promissory note one [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=immd_CommercialPaperTwoMember', window );">Promissory note two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_OfficerMember', window );">Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 28,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis=immd_CommercialLenderMember', window );">Commercial Lender [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Borrowed from commercial lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_CommonStockSharesIssuedRelatedPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issued related promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_CommonStockSharesIssuedRelatedPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ConversionOfFairMarketValueSharesAndWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of fair market value shares and warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ConversionOfFairMarketValueSharesAndWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_FlatFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents flat fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_FlatFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_NotesPayableTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes payable textual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_NotesPayableTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of the option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Footnote 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest expense (income) directly attributable to an award in settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=immd_NotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=immd_NotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=immd_CommercialPaperOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=immd_CommercialPaperOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=immd_CommercialPaperTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=immd_CommercialPaperTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis=immd_CommercialLenderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis=immd_CommercialLenderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6610292528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of deferred tax liabilities and assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 1,699,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Accounts receivable reserves</a></td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory reserves</a></td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">229,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Net deferred tax asset</a></td>
<td class="nump">1,952,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(1,952,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6756204848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 4,294,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Percentage of tax rate</a></td>
<td class="nump">34.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_IncomeTaxesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_IncomeTaxesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763111456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - Service-Based Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options/Warrants, Beginning Balance</a></td>
<td class="nump">10,700,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Issued</a></td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options/Warrants, Ending balance</a></td>
<td class="nump">11,200,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923871344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 1) - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Summary of significant assumptions used to determine the fair values of options using black-scholes option-pricing model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate at grant date</a></td>
<td class="nump">1.49%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">216.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend payout</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life-years</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 0.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share Based Payment Award fair value assumptions forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763845232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Summary of outstanding service-based options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options</a></td>
<td class="nump">11,200,273<span></span>
</td>
<td class="nump">10,700,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeOneMember', window );">$0.10 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Summary of outstanding service-based options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options</a></td>
<td class="nump">1,380,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeTwoMember', window );">$0.20 - $0.25 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Summary of outstanding service-based options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options</a></td>
<td class="nump">8,620,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeTwoMember', window );">$0.20 - $0.25 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Summary of outstanding service-based options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeTwoMember', window );">$0.20 - $0.25 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Summary of outstanding service-based options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeThreeMember', window );">0.40 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Summary of outstanding service-based options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6907056560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 3) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options/Warrants, Beginning Balance | shares</a></td>
<td class="nump">1,954,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Issued | shares</a></td>
<td class="nump">2,402,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options/Warrants, Ending balance | shares</a></td>
<td class="nump">4,357,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance, | $ / shares</a></td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Issued | $ / shares</a></td>
<td class="nump">0.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance, | $ / shares</a></td>
<td class="nump">$ 0.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration', window );">Year of Expiration, Beginning Balance</a></td>
<td class="text">2017-2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued', window );">Year of Expiration, Issued</a></td>
<td class="text">2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration', window );">Year of Expiration, Ending Balance</a></td>
<td class="text">2017-2019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment during period year of expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment during period year of expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment during period Issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752610480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 4) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Summary of fair value of options and warrants granted using black-scholes option-pricing model with weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Summary of fair value of options and warrants granted using black-scholes option-pricing model with weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">211.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.22%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Summary of fair value of options and warrants granted using black-scholes option-pricing model with weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">181.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.03%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773247312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2016 </div>
<div>USD ($) </div>
<div>Consultants </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2016 </div>
<div>USD ($) </div>
<div>Consultants </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>Consultants </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services as per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Outstanding shares purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_PurchaseOfCommonStockDescriptionOfTransaction', window );">Purchase of common stock description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Common stock for a price per share of $0.24 to $0.26.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div>Common stock through an exchange for a price per share of $0.23 to $0.29.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,543,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,570,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 499,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Offering to sell shares of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_WarrantsToPurchaseOfCommonStock', window );">Warrants to purchase of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Subscriptions shares received | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,817,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Proceeds from subscription of value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 647,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,072,535)<span></span>
</td>
<td class="num">$ (108,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,188<span></span>
</td>
<td class="nump">38,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,261,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 704,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock options, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_FairValueOfPerformanceBasedStockOptions', window );">Fair value stock options, stock warrants embedded conversion features</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,809,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_UnamortizedOfServiceAgreements', window );">Unamortized of service agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,522<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Number of options granted, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price stock option issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options fully vested and expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=immd_PerformanceBasedStockOptionsMember', window );">Performance Based Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,189<span></span>
</td>
<td class="nump">38,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_AggregateOfFairValue', window );">Aggregate fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationEquity', window );">Unearned share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=immd_PerformanceBasedStockOptionsMember', window );">Performance Based Stock Options [Member] | Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price stock option issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NumberOfConsultant', window );">Number of consultant | Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_AnnualSalesRevenueTarget', window );">Annual sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Company cancelled service-based options, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Company cancelled service-based options, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_FairValueOfPerformanceBasedStockOptions', window );">Fair value stock options, stock warrants embedded conversion features</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=immd_PerformanceBasedStockOptionsMember', window );">Performance Based Stock Options [Member] | Unvested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NumberOfConsultant', window );">Number of consultant | Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Company cancelled service-based options, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Company cancelled service-based options, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Sale of common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Warrants fully vested and expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Consulting services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Warrants fully vested and expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Issuance of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Warrants fully vested and expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=immd_WarrantOneMember', window );">Warrant One [Member] | Issuance of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,407,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Warrants fully vested and expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Performance Based Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_AnnualSalesRevenueTarget', window );">Annual sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Performance Based Stock Options [Member] | Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock options, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Performance Based Stock Options [Member] | Unvested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price stock option issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock options, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_AnnualSalesRevenueTarget', window );">Annual sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Warrant [Member] | Consulting services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Performance Based Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_AnnualSalesRevenueTarget', window );">Annual sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Performance Based Stock Options [Member] | Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock options, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Performance Based Stock Options [Member] | Unvested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price stock option issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock options, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_AnnualSalesRevenueTarget', window );">Annual sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Warrant [Member] | Consulting services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember', window );">Immudyne PR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services as per agreement</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,183,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority interest rate</a></td>
<td class="nump">78.1667%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Charge to noncontrolling interest</a></td>
<td class="nump">$ 91,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,730<span></span>
</td>
<td class="nump">$ 46,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember', window );">Immudyne PR [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority interest rate</a></td>
<td class="nump">21.8333%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember', window );">Immudyne PR [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority interest rate</a></td>
<td class="nump">66.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ConsultantMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services as per agreement, shares | shares</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services as per agreement</a></td>
<td class="nump">$ 690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NumberOfConsultant', window );">Number of consultant | Consultants</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ConsultantMember', window );">Consultants [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Number of options granted, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,397<span></span>
</td>
<td class="nump">$ 40,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price stock option issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options fully vested and expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NumberOfConsultant', window );">Number of consultant | Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_AggregateOfFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate of fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_AggregateOfFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_AnnualSalesRevenueTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock options exercisable upon the Company achieving annual sales revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_AnnualSalesRevenueTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_FairValueOfPerformanceBasedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of performance-based stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_FairValueOfPerformanceBasedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_NumberOfConsultant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of consultant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_NumberOfConsultant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_PurchaseOfCommonStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents about purchase price of common stock description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_PurchaseOfCommonStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_StockholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_StockholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_UnamortizedOfServiceAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unamortized of service agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_UnamortizedOfServiceAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_WarrantsToPurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants topurchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_WarrantsToPurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeitures, of stock or other type of equity granted of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of forfeitures of stock or other type of equity issued of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=immd_PerformanceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=immd_PerformanceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=immd_VestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=immd_VestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=immd_UnvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=immd_UnvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=immd_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=immd_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=immd_IssuanceOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=immd_IssuanceOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=immd_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=immd_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=immd_ImmudynePrLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753141600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalties (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RoyaltiesTextualAbstract', window );"><strong>Royalties (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_PercentageOfRoyaltyBasedUponSales', window );">Percentage of royalty based upon sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RoyaltyBasedUponSalesAmount', window );">Royalty based upon sales amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PresidentMember', window );">President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RoyaltiesTextualAbstract', window );"><strong>Royalties (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_InterestInRoyalty', window );">Interest in royalties</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalties payable</a></td>
<td class="nump">$ 84,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued</a></td>
<td class="nump">499,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock price per share</a></td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_InterestInRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of interest in royalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_InterestInRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_PercentageOfRoyaltyBasedUponSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalty based upon sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_PercentageOfRoyaltyBasedUponSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_RoyaltiesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_RoyaltiesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_RoyaltyBasedUponSalesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of royalty based upon sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_RoyaltyBasedUponSalesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771931712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 01, 2016</div></th>
<th class="th">
<div>Apr. 01, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>Thresholds </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease expired date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Monthly base lease rental payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating leases, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,061<span></span>
</td>
<td class="nump">$ 16,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Annual compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock option exercise prices lower range limit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock option exercise prices upper range limit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock', window );">Stock issued during period performance based options to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Annual revenue base</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SalesRevenueIncreased', window );">Annual revenue exceeding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_BonusPercentageOfCompensationForPretaxIncome', window );">Percentage of bonus compensation for pretax income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_PertaxIncomePercentage', window );">Pretax income percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services as per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock options, Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase common stock option | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NumerOfThresholds', window );">Number of thresholds | Thresholds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember', window );">Mr. McLaughlin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating leases, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember', window );">Immudyne PR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Office space subleased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services as per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted shares value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyAgreementsDescription', window );">Agreements of performance fees, Description</a></td>
<td class="text">In addition, Immudyne PR share pay Pilaris a performance fee of $50,000 on the 180-day anniversary of the agreement and an additional $50,000 performance fee on the 365-day anniversary of the agreement. As of March 31, 2017, the Company has accrued $58,333 expense related to this agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PremiumsPercentageAssumedToNet', window );">Percentage of net income</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ConsultantMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services as per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_DebtLongTermAndShortTermCombinedAmountShares', window );">Combined capped | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock and Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services as per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_DebtLongTermAndShortTermCombinedAmountShares', window );">Combined capped | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted stock expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 690,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=immd_RestrictedStockOneMember', window );">Restricted Stock One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services as per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted shares value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_BonusShares', window );">Additional bonus shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_OptionToBuyShares', window );">Option to buy shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=immd_RestrictedStockTwoMember', window );">Restricted Stock Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted shares value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=immd_RestrictedStockThreeMember', window );">Restricted Stock Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted shares value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_BonusPercentageOfCompensationForPretaxIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of bonus agreement compensation for pretax income during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_BonusPercentageOfCompensationForPretaxIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_BonusShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents bonus of an additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_BonusShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_CommitmentsAndContingenciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_CommitmentsAndContingenciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_DebtLongTermAndShortTermCombinedAmountShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt long term and short term combined amount shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_DebtLongTermAndShortTermCombinedAmountShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_NumerOfThresholds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numer of thresholds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_NumerOfThresholds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_OptionToBuyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contracts conveying rights, but not obligations, to buy or sell a specific quantity of a security at a specified price during a specified period or at a specified date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_OptionToBuyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_PertaxIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pertax income percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_PertaxIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_SalesRevenueIncreased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales revenue increased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_SalesRevenueIncreased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the performance based options issued by the company to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntercompanyAgreementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of product support, consulting, business, or other advisory service agreements entered into between the managing member or general partner and the LLC or LP, affiliate of the managing member or general partner, or affiliate of the LLC or LP. Includes a description of the key provisions of such agreements and the amount of compensation for such services during the accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntercompanyAgreementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=7661868&amp;loc=d3e34039-112682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsPercentageAssumedToNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of assumed premiums earned by the entity to net premiums earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17)<br> -URI http://asc.fasb.org/extlink&amp;oid=34713774&amp;loc=d3e574992-122915<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsPercentageAssumedToNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for salaries for officers and non-officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=immd_ImmudynePrLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=immd_RestrictedStockOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=immd_RestrictedStockOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=immd_RestrictedStockTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=immd_RestrictedStockTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=immd_RestrictedStockThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=immd_RestrictedStockThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753211184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CompensationForLegalServices', window );">Compensation for legal and business advisory services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Accountant charges per month</a></td>
<td class="nump">$ 99,632<span></span>
</td>
<td class="nump">69,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember', window );">Immudyne PR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CompensationForLegalServices', window );">Compensation for legal and business advisory services</a></td>
<td class="nump">10,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Accountant charges per month</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_AnnualIncentiveBonusAwardPercentage', window );">Annual incentive bonus award percentage</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Office space subleased</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember', window );">President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ReimbursementOfHomeOfficeExpenditures', window );">Reimbursement of home office expenditures</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_AnnualIncentiveBonusAwardPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual incentive bonus award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_AnnualIncentiveBonusAwardPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_CompensationForLegalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation for legal services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_CompensationForLegalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ReimbursementOfHomeOfficeExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of home office expenditures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ReimbursementOfHomeOfficeExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_RelatedPartyTransactionsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_RelatedPartyTransactionsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=immd_ImmudynePrLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751890368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 24, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Subscriptions shares received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,817,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Subscriptions shares received</a></td>
<td class="nump">217,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued of warrants</a></td>
<td class="nump">108,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Satisfaction of obligation to pay amount</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_SubsequentEventsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_SubsequentEventsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>46
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MX7<5=M[8O?W'QA=!V<&O?R&_ %!+ P04    " #,AN=*F5R<(Q &  "<)P
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MD\M5]C[DF23/HX3-)/2FR'SR6P6&57AF()S=%]A"1:[P"ASM@8=X/H_7>+Q
MXT6(%_/X(IJ#4:*"I T2P820<2=01J6@A"W@Y"A.#G DB7!&23ZKPPCG\9W;
M0AGE7!6"X3@2Q9$0AT8X$N(P2DF, V6<<*(E3J-0&@7NM5SH1J/Q&G;#HVXT
MQ,RUT#KJ!LJ8("+/<9H"I2D@C8AH"E"F*"2/%QY4R8+3!19*<"L@D":/O8#
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M?]G8_P;1@4\EN?$CU/D/MAH*&A>.[_W9S&,V&PZ'Y0>Q]1N7?P!02P,$%
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M\ &F>@Z43,5_@BNH$!Z5A!PE*I=64O;.HYY8@A0MWL9=FK0/XPT_3+!U )\
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M:'TXOL.SG<=L-KP9EA_$UF]<_0902P,$%     @ S(;G2G[F4*VT 0  T@,
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MA&<[C=ED>-///X@MW[CX U!+ P04    " #,AN=*.^/!9[0!  #2 P  &0
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M_Q5N0!5<.U%[5(P*\^M45R%9OZ@H*SUYF\=N,.,TK\1XH=D)P4((5H(?_I>
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MF^%,,CQ8<Q[/6\GMT+?Z#U!+ P04    " #,AN=*TQAJX^L#  #1$@  &0
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M/QLX**6E(1I_,11/LMA/#Z4\Z.XV-??-<,@R/&AU&0^0HND4:_4O4$L#!!0
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M!?'>-9@ (0*DS:ZJ5FJE:*NVSPX, :W!U';"]N]K&X(2</H2>^P[]\R8V.G
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MT*9373\U0F@PJ41WIN#./!BK0:'1=KLW>SF/S6QH,2PO EJ?I?(O4$L#!!0
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MLNYBM4)H,'ZB.V.E-R_'NJ#0:CO-S5S._3,OM!B7IP&M[U/U#U!+ P04
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M HN(C'T\*J* '<2@@]@XB(85%CGL( $=)/<9).&DC9TF,9JF"X(4;SB+)NT
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M*/5MINYY-]IU"\E:.[8&_>R\_ =02P,$%     @ S(;G2I6#V&=$ @  %0<
M !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&UL=97=CILP$(5?!?$ ,>8W
M1 0IV:IJI5:*MFI[[1 GH#68VD[8OGUMPU("PTVPS9GSS9AXG'5<O,F24N6\
MUZR1>[=4JMTA)(N2UD1N>$L;_>;*14V4GHH;DJV@Y&*#:H9\SXM13:K&S3.[
M=A)YQN^*50T]"4?>ZYJ(OT?*>+=WL?NQ\%K=2F464)ZUY$9_4/6S/0D]0Z/+
MI:II(RO>.()>]^X![X[8-P%6\:NBG9R,'5/*F?,W,_EZV;N>R8@R6BAC0?3C
M05\H8\9)Y_%G,'5'I@F<CC_</]OB=3%G(ND+9[^KBRKW[M9U+O1*[DR]\NX+
M'0J*7&>H_AM]4*;E)A/-*#B3]M<I[E+Q>G#1J=3DO7]6C7UV_9LD'<+@ '\(
M\,> P')0#[*9?R**Y)G@G2/ZS6^)^<9XY^N]*<RBW0K[3B<O]>HC#V(O0P]C
M-&B.O<:?:/"H0-I]1/@0XN@OPH-XQ2  <PRL03#EIPEL$((&H34(GS+P9T7V
MFLAJF@$2A>EV)=,(!$4 *)B!H@7(#ST_3E9 ,0B* 5 X \4+4!A$232I_ F4
M@* $ $4S4*_93D#>!J<P90M2M@ EGE%Z3?I$"6%("D)2 )+,("E02K#R9; '
MGR@/X&SG1PH2K6P97CFY>&F1+(XN7O[;O+5O@\'S>\ ^ ,)S$"!:%(0F7:FF
MXF;[L70*?F_L93!9'7O^P;9\]%_>7QC?B;A5C73.7.G>:#O8E7-%=2[>1I=;
MZCMJG#!Z56:8Z+'H&W4_4;P=+B$TWH3Y/U!+ P04    " #,AN=*=.L"HDT"
M   4"   &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6R-5MN.FS 0_17$
M!RS8$$)6!"G9JFJE5HJV:OOLD$E :S"UG;#]^]J&T"P9I+S$%\Z<,V//>))U
M0KZI$D![[S5OU-HOM6Z?@T 5)=1,/8D6&O/E*&3-M%G*4Z!:">S@C&H>T#!,
M@II5C9]G;F\G\TR<-:\:V$E/G>N:R;];X*);^\2_;KQ6IU+;C2#/6G:"'Z!_
MMCMI5L'(<JAJ:%0E&D_"<>UOR/.6)-; (7Y5T*F;N6=#V0OQ9A=?#VL_M!X!
MAT);"F:&"[P YY;)^/%G(/5'36MX.[^R?W;!FV#V3,&+X+^K@R[7?NI[!SBR
M,]>OHOL"0T +WQNB_P87X 9N/3$:A>#*_7K%66E1#RS&E9J]]V/5N+$;^*]F
MN $=#.AH0&,72R_D//_$-,LS*3I/]H??,GO'Y)F:LRGLICL*]\TXK\SN)8^6
M- LNEFC ;'L,O<&0$1$8]E&"8A);>F<>14N<($)]C!Q!],''"">(48+8$<0?
M".))D @FQ#46J,8"T5C@! E*D#P>Y1(E6"(>)),H,<S,7:2H2(H0I!,1#+/"
M15:HR.J>( TG(AAF)BU)B*=^>$\1+Z:YWX-2!VH<*'R:N5<R4V($<97.4* E
MM"'T\>0@>!&1Z('TP$#IG Y>:P0KMFF&8* TGM'!ZXT@!7>7)"AH[O;PLB3)
M(UF2(%ER]\@%-X]R#?+DVI'R"G%N7"^\V1U;WH:Z1_T_O.^7WYD\58WR]D*;
MUN >\*,0&HPS)CU]KS0M>EQP.&H[79JY[/M4O]"B'7IP,/X1R/\!4$L#!!0
M   ( ,R&YTKR*QI%_ @  ,TY   9    >&PO=V]R:W-H965T<R]S:&5E=#,R
M+GAM;)5;77,;N1'\*RR^YXC!QP)P2:J*9<NFF*MR72K),VVM+-61HD+2UN7?
M9TDN:2VF>[5\D42J 0QVIAL#8/;B9;7^<_-0U]O17\O%T^9R_+#=/K^;3#;?
M'NKE?//;ZKE^:OYSOUHOY]OFX_K[9/.\KN=W^T;+Q<0:4TV6\\>G\=7%_KLO
MZZN+U8_MXO&I_K(>;7XLE_/U_][7B]7+Y5C&QR_^>/S^L-U],;FZ>)Y_K_]9
M;__U_&7=?)J<>KE[7-9/F\?5TVA=WU^._R[O9N+,KL4>\N_'^F7SZN_1;BY?
M5ZL_=Q^F=Y=CLS.I7M3?MKL^YLVOG_5UO5CLNFH,^6_;Z_@TZ*[AZ[^/O=_L
M9]_,YNM\4U^O%O]YO-L^7([3>'17W\]_++9_K%X^U^V,PGC43O\?]<]ZT<!W
MEC1C?%LM-ON?HV\_-MO5LNVE,64Y_^OP^_%I__NE[?_8##>P;0-[:N!2;P/7
M-G"_&L3>!KYMX(<V"&V#,+1!U3:HAC:(;8,XM$%J&Z13 ]_?(+<-\JE!\+T-
MQ!P]9TY-K/0W.3G[E[?C?I3)(4KV8?=AOIU?7:Q7+Z/U@3K/\QU#Y5W3JNE\
M]^T^D/?_;$)OTWS[\\JEZF+R<]=3BWE_P-@.)G8QUPB3NI@/").[F(\ DTT7
M<X,PTL5\0AC;Q7Q&&-?%3!'&=S&W"!.ZF!G"_'K.D\9))T]9["F[[\%U>HBX
M!X=[</L>?*>'PD?3 R;N,4][3*RJBHSC\3@>C%/X>7K A%?CB$VF\/1,HYP-
MYA6L8T[ Y@1ECB\'FB),$5(SA+'8D@I;4H$>RH"KE .RL:8(N9E&I6B"P]9$
M;$T$UA3C3*-V@(O:3P#6XZ>$[4G GH)&'Y(:R$I4[)]J6-.5;TPOGO9, UT(
MT4@@$9^QZ1F87JCH=58NZSZBPP0!2HR"W6A8T*BI1OF<$PO:W?(#EP@#9A=+
MG33G"(>PU4C 4*5$M:"N=XVAX29$4,6"P4J=:D'IU6#F-TN()D1X12NOE])9
M+:@3V[W3(NHK6GZ]E 01K:PV291 UB0AVBI %,66@P4M]HU;0TQD,"*? O13
MU(*MI;'R,7M/QB+B*$ =I51'T;H70Y"8R5A$^$0KGQCU$).:U]_$1!M<H9&W
M&)DD,+.(J(E6-=&!E+5OLY$R][L%N"9!9/I@B119($52S']JM10Y6TD*!;=G
M !C-+E:(442T+! MJ4JC$(C-GF6 0+"D5,<6]'I2DDQ.918]:X%=SUD;V.R)
MMEFD;:6*6IU66J<7K!G .<.7$4LDT ()M$1&+5$V&X;GVY8(E@6"94L&M:#7
M?@@]LF^)8%DM6)JM+:@3'.*"+<3FUFIA8^803;,@F[,D\;!$@&P^8\M#%,,!
MQ2A=<-V"AKK $2%P@./6E6/)6R[HCD6TP $ML+X<"R8O9""V:03\MJ$<"(%(
M*N$(:1TB+?,V(:T[@[2.D-9ITFHB.4W:_;)7"-\MP/4L>XYPVX%DQ*J=N^9L
M"I4A.98CO'6(MZ6<.YUA] U%Z.W KLD1RGE";V^&.]P3VGI$V]+A7F\Z;.[9
MXWK"6S^ MU./>$O694]XZP$E77FDX<&>@PS#SGHT:Q5;;CTXQ^$L\(3<'NPU
M7)DFMR"U,Z9^(BK@P=+MRM,#K]EM4PQT+$)O#^CMRA,?#Y9NZ]DYA2?T]H#>
M*H7TFMYB#?<7X;='_ ZXCT#X'<[@=R#\#D/X'32_10*/FT#X'0"_%>V"3KT)
M[0)A=T#L+L,S ';WA&<@% ]@85;AV8(ZO N>S8J=U&J&.T/.6@(A;JC.B!A"
MR( (694SCD"DA>RQ ^%C 'QTS%K"LW!&FEP1GE4@37:%+MQ4.DT6 W9Q .=X
MV%6$MA6@;>F$FQ;4=4)Y]_(&J&L-X76%>)U+:P#(JZ?3#^I:0^A? ?I[(7T0
M6E?^C+ AA*W0DJS"!AS_]:S(%;L\02NR\H &V<P>#&%_!=C/E*PBO*[2&0^7
M\+I"ZV=YIUKI<[60)?KR4 S@O''.IS(Z-:ZX8>E>+1$]B4A/"O)^:$$LS6UO
MH : 9F^ NB83O8E(;W)I,@"5#)\. <W> '5-)J(4D92P2T B)=$-C]1(I"2B
M#*',*B.X\O4FTEN 2#0G(LTICUM;T+" (((3!PC.%(&H&]E%+!(<9BP1G'B&
MX$0B.!$)3KG!BN3JD5[V$H5(0"$\6903H6R2X9-.A$,)':J7X81 GIQO)4*T
MA-9L9BPA6CICS4Z$/PGP1YU I#/XDPA_$KJN4T\6\8<]6<*?A-+U,FZ3WC_W
MQRVK4@ 9NR<2E@C1TAD9>R;\R0-6V)N,UD62RF1"LHP6*K+-R81D^8SBI4SX
MD]&6M_1RUA=(AUR3N3D3IF6PI 76!V%:/N,T.A,2Y2$D0J! ,K9,2)0!B0(+
M%<*-?,8BE%DI#5B$E#RUH&Y<LVH"0^M:T&UR^6PABE5:B6&%+09EE^J.WX#+
MH=[P%<.*6PQ8LMC=KAA6N&+.R [%L(H4@_+#4JN.J$';=#&L(,6 Y2W07EBE
MB3GC%$D,JR$QFE.JXO+]$:57)C8<*R,Q0RKHCJCN26=R/M/Q6'V( 50-Y2;O
MB.K<_4=KV;F>T#(T5(<68ODT <H*JVKB=6B KD%Y3C1=LU3"ZNMH(1JH1 ,%
M0*(K.VR,KMA8WB*<KT28>VG1&JI:HS5$M!I-SDA9A9:9H3HSX'N-LHY:S+B/
MRLPJ^O08]]O:L('S9I0&I6%HW@!5D?5?:+D7J/?R%8ME5J$E]HP;&V$E58+*
MI2I7SMN"2UG76PE*2T$U X%2@]JJ*O<-QZB%BJ;*6Z+W1]2 :R)AE5""2J$J
ME@:P6B@YIQA*6#64#"F'^BBL'JJ+^S00]QGA)/*+>V$%5@(JK%1YST<!)5:[
MFFME/;K.??U,C]9KG#?),E%CY5@"Z[&\,C[UIF!'VQ%*O5SS!JJPFXF21=N!
MH.P&J/+$]1/NJU)V]Z.*@F\F@ZCNK&3X9P&%9^43FKQZE6OWHN/O\_7WQZ?-
MZ.MJNUTM+W>O;MVO5MNZZ:]QU7CT4,_O3A\6]?UV]^?N.'1]>+_P\&&[>KX\
MO#PY.;W!>?5_4$L#!!0    ( ,R&YTJLO]F.A@(  *\(   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;(U6V8Z;,!3]%<0'#)B=*(F4K6JE5HJFFO;9
M29P$#6!J.\GT[^N%8<#<I/,"V)S-%R],;Y2]\C,APGFKRIK/W+,0S<3S^/Y,
M*LR?:$-J^>9(686%;+*3QQM&\$&3JM(+?#_Q*ES4[GRJ^[9L/J47418UV3*'
M7ZH*L[]+4M+;S$7N>\=S<3H+U>'-IPT^D9]$O#1;)EM>IW(H*E+S@M8.(\>9
MNT"3#0H502-^%>3&>\^.&LJ.TE?5^':8N;Y*1$JR%TH"R]N5K$A9*B69XT\K
MZG:>BMA_?E?_H@<O![/#G*QH^;LXB//,S5SG0([X4HIG>OM*V@'%KM.._CNY
MDE+"51+IL:<EUU=G?^&"5JV*C%+A-W,O:GV_F3=AWM)@0M 2@HX@O1\1PI80
M?I80M83H@Q ]),0M(;8(GAF[+N8:"SR?,GISF)D/#5;3#DUB^;GVJE-_'?U.
MUI/+WNL\2N*I=U5"+69I,,$ DPPQJS$&=0A/)NAB!%",93"B!WYN60"8(6(]
M1L3I$+(!1&(X: C6*]3\<%"+%!:(0(%("T0#@<P:*83)89,8-(G' JEOF1A,
MJC&UJ420HO1.-1+0)P%\D.4SQH16E/5#R"!&"L9(Q_S(2I&.1ALG<6I-L<W_
M4(,L&9@E TH2P (Y*)!_?H8A'U[3/I AM!<U!(KN^-S9.Q @,=H\T*BF693U
MIOS0"=P>%B@ G!+;R8#BGE.4Y\&]]8W@!8Y"P"JUK0PHZUGY3\C^2EYO$ZX(
M.^D3D3M[>JF%VH-ZO=VINPC4)F[UK]!D;<[.#QESE/_ [%34W-E1(8\(O9$?
M*15$AO2?9"7.\N^A:Y3D*-1C*I^9.4)-0]"F_3WPNG^4^3]02P,$%     @
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M)O=94BD*.5&QPE)40&5D=@?0S6U>83DJ=+1VSU$#R'>.&O-@.2HJ1\W=H]@
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M@. U0#, DYF6^@D)5.2,]@XS7ZM#ZE# ^T 6LU1&73O]3JKETGHK(ICFX*:
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MM@7JO-5NC28ISJ@'E(@:Q"2VYX_CK(&\DNCO0+_;"$4-DM6R6&<HQ^DR7NV
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M6/*'XH&';O;UX&)DF+DTD+[)X@S!F" &_H&85U0T1*L\<KE]3A_SG1JVT6#
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M!X.6HFLD[:48@"BA0L\>IEP_)"'AF8AR^8:H=_*VB5F-^_%\>*XQ.:N(80^
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M::@U^C4Z'57P:_?KC>".PUYU*@;6I3>:TYJ/+D."Q;@>OO4N#.+!?FS9GKO
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M6]E+U]+S@<*O"Q=;:S9\J#_0U&)&DQ88W++8<$.$RG]@PQ\0\=+00Q(*O*]
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M80TSJQ\E/)3$^5DAB!VT1]ZF G1D:<6U.:#S*]ON_+O:V7(K#J%PT5Q4 ^R
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M?VT!R9[XGT\C);.S5ER>%&/Y@Q;0[=I!ARWYS_?$+!KM-JY-O#H(IU^8WMU
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M+(R'T.@SW R,WQ4L#"@;-BN^5TR(R2(CML6\65KQW 1#W+Z$R8S!,$%DQ(9
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M4<PJ+VC6KDUKI9N_2#Z,61[JL^X7^.P+4$L! A0#%     @ S(;G2A\CSP/
M    $P(   L              ( !     %]R96QS+RYR96QS4$L! A0#%
M  @ S(;G2F;S"V""    L0   !               ( !Z0   &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " #,AN=*D$+DD>X    K @  $0
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M=#(N>&UL4$L! A0#%     @ S(;G2MA_O%44 @  $P8  !@
M ( !20\  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ,R&
MYTK[>!DH>@,  /<-   8              "  9,1  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " #,AN=*JJ%^1(X$   9%P  &
M        @ %#%0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ S(;G2HQ?W-=7!   %!0  !@              ( !!QH  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ,R&YTI'$VD/M $  -(#   8
M              "  90>  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " #,AN=*\*NC9[0!  #2 P  &               @ %^(   >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ S(;G2I\^'6RT 0
MT@,  !@              ( !:"(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( ,R&YTI7UQPUM0$  -(#   9              "  5(D
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ S(;G2M1^
M.7*S 0  T@,  !D              ( !/B8  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " #,AN=*?N90K;0!  #2 P  &0
M    @ $H*   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M ,R&YTH[X\%GM $  -(#   9              "  1,J  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ S(;G2K\4]T:S 0  T@,  !D
M             ( !_BL  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " #,AN=*64F;<;0!  #2 P  &0              @ 'H+0  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ,R&YTHTU>+EB0(
M -P)   9              "  =,O  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ S(;G2F/!S@S& 0  -P0  !D              ( !
MDS(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #,AN=*
MG(GE-[4!  #2 P  &0              @ &0-   >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,R&YTJKQ^L2 @(  # &   9
M      "  7PV  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ S(;G2AHXI2PY @  K <  !D              ( !M3@  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #,AN=*"#_? .H!  #Q!
M&0              @ $E.P  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( ,R&YTJ$?XW2< ,    .   9              "  48]  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ S(;G2M,8:N/K
M P  T1(  !D              ( ![4   'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " #,AN=*\37E\EP%   J'0  &0
M@ $/10  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( ,R&
MYTHV$B=Y^@$  ,D%   9              "  :)*  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ S(;G2@"!S;[= 0  H@0  !D
M         ( !TTP  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " #,AN=*1 !34>,!  "K!   &0              @ 'G3@  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ,R&YTH0!^9B P(  ,T%
M   9              "  0%1  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ S(;G2I3A9HK$ @  1PL  !D              ( !.U,
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #,AN=*E8/8
M9T0"   5!P  &0              @ $V5@  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( ,R&YTITZP*B30(  !0(   9
M  "  ;%8  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
MS(;G2O(K&D7\"   S3D  !D              ( !-5L  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " #,AN=*K+_9CH8"  "O"   &0
M            @ %H9   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( ,R&YTI&:+XU< 0   T8   9              "  25G  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ S(;G2O+ODYIH @
M!0@  !D              ( !S&L  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " #,AN=*9-:9GSX"  #=!@  &0              @ %K
M;@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( ,R&YTHN
MH]D:OF,  -1^ 0 4              "  >!P  !X;"]S:&%R9613=')I;F=S
M+GAM;%!+ 0(4 Q0    ( ,R&YTIN6+5_,P(  "$*   -              "
M =#4  !X;"]S='EL97,N>&UL4$L! A0#%     @ S(;G2JWESN ! P  OQ<
M  \              ( !+M<  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M ,R&YTKLED50C0$  )$6   :              "  5S:  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,R&YTI<#0.:G $   H7   3
M              "  2'<  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     M
- "T +0P  .[=      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>154</ContextCount>
  <ElementCount>251</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/Consolidatedbalancesheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/ConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/ConsolidatedStatementOfStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Organization and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/OrganizationAndGoingConcern</Role>
      <ShortName>Organization and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.immudyne.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/Royalties</Role>
      <ShortName>Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/IncomeTaxes</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquity</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Organization and Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/OrganizationAndGoingConcernDetails</Role>
      <ShortName>Organization and Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/OrganizationAndGoingConcern</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/Summaryofsignificantaccountingpoliciesdetailstextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.immudyne.com/role/NotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/NotesPayable</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/IncomeTaxesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/IncomeTaxesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquityTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Stockholders' Equity (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityDetails1</Role>
      <ShortName>Stockholders' Equity (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquityTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Stockholders' Equity (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityDetails2</Role>
      <ShortName>Stockholders' Equity (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquityTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Stockholders' Equity (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityDetails4</Role>
      <ShortName>Stockholders' Equity (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquityTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Stockholders' Equity (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityDetails5</Role>
      <ShortName>Stockholders' Equity (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquityTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityDetailsTextual</Role>
      <ShortName>Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquityTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/RoyaltiesDetails</Role>
      <ShortName>Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/Royalties</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/RelatedPartyTransactions</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="immd-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/SubsequentEvents</ParentRole>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>immd-20170331.xml</File>
    <File>immd-20170331.xsd</File>
    <File>immd-20170331_cal.xml</File>
    <File>immd-20170331_def.xml</File>
    <File>immd-20170331_lab.xml</File>
    <File>immd-20170331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>52
<FILENAME>0001213900-17-007275-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-17-007275-xbrl.zip
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MCA=&IF=E8'&6P)Y_WPG]CM'J+_N"OR$_\'S/BR?%[]M1\"*:3=D+>*D!;['
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MER+BHS]74CK_O+J7Z5AXLR)(J@O5ED7Y5=K4NO##H6Y=JK3KM2?T$7I"]T:
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MWP.D%0!Q$$;1:QI]!6/J_-O!50[UM=J]87NP&J[+,&11>$ "ZP^& T.1=AD
MMH2L))0U^^U^TU@'-'&4K\T9$CRP4W@"I&B_=\R1XSJ1PPZ*TJXQ;#?G.<T:
MX.UE527Q3U EC-U7]0:4ZGLS<N[9<3:G-026JM#[,GC*@;NDTS!H#@?#YN:
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M#0A-O)W'$> ,?&.T*C:&@> WV-P[9KK1G85[#H".61A21#^@V7:P_^THCOR
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M:"ZW3-EW[J 3%SXHP.>@*^"J)+=(& (#B%V*2F+>':([PQN$*U"@1)?F;2H
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M>#*'$JGO+S#PB(:E#-+>H@7L'+,0V6GCO";0C?Q:15($Y$<#_F=T&^T^%QS
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MF90/2DLG8;H0_&.XI!1>"I*9U@T!.F@9&".]"7Q+8>E(6'J2'2$0>=XGRZG
MS^UV7P4 AQHQG/N.N4D=*0E'6NK0PAZ%3J@]!9%B-#L\=#U@F4(90!)F& <S
M 7=1T]Q,5]^:;]5\ZW$@OD9W9<I5B2I!+;TU:.N=X<)ZHFK%V$P5/7A1;28N
M6IA3WW#L)4Y]OZ@(1M\ 3MGF1H-L=)Y^JVM7GG4A&>Z"SN,UAZP/ZCFCNQ9(
MU>60*\K9@79'92]$E^EL.3E5IRTH)<<50UG'CY+Z#U$UK2: JIR\'W]XO*A/
M^I\%893SH,T5:RQJQP"'+62NJ\53_&<'3]#2NNA18CQF*O]R*S)30%&MR,M'
M-U:-#@:S$_+V:@ P4@/.Y0>2)838K=XV*4; <U"%4I(ND='P@O+HT$S X(7_
MG4 V@>"Q!CB;8!PC$QL0BU+!LIPP6LD,)IB1,S8%-]'FN#6>\6*NL0<\I8A1
M3_K0"IPI5_!DVG52E!2L>OBTU>VII2D37;/3'.C=_D!9HR>:V3&[8+"GO4Y?
M'W8ZM?KWJ+CBXT7\DHJUX@SUN]UE)61EN86LG89/%A;QQHH^F7)"2M^2SG"H
M#YJ&]BR$ES!<1VL_KP_C>1_&.G1@L]"!CUF7A2RD=[PH@GH#JW2<:L2O%5I
MK<_HFL@!M3"-\ :=4/4R@CK='URT>KW^3QK,AY]()7;BP&K0N9B6Y\5(UU[O
M MY%';YU,6BWVS\IH; 8>(XQN,$MQ>,N<#[R.Y[TY@I+T<->-60U7E%1K]<R
M:M%8G^7'@?@:W8=$][LMRF]&(C6'=VC(WM68$;^C2=JG+69]:F%0HZ_WVR(
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M?6*#4J66Y0(O)3NM-9<3H]N3)E%5<T$Y3M'JY)P!<7%O NN-%<^)J"# .7@
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MNU,+-67>.79CR&_PCXUE)KG(Q66%:GESX[2]$UHOM*)D4!T-74X68M Y 8%
MP4L2KO1W6;&M*.YL?S;ON1SPY6EEM<&[F<%;-M:^)__OG+&62Y_S1<C9V^_
M?T,4&>]!'P)U2==X&!AHM?C[I7WOA'XP2P71H;P(CV!;:A5I751]4AM:22^!
MJ@]DW NF%DKZ9@E]NY*^DZASC+B4Y)W>Z9/OX=IQS0"$W'MSA"E@?D"1R._?
MO\YDY(NW,KGXO'0P:AJ^EON]U?]9/OI@?D<A/)GZ/JH5D]A-LZ1 J>/J&@NX
MS42%GH0FH\+)K5M\ZCIC6:! ^_-&NP8;!Z,3F$MVLIB3M +4&$&)Y$E5I-&0
M:$> ,T8Z2O@$8Q(;-*54,>%S48N91SLX@*!6\R<)AL<BX1.G^I>\9)4PVL7
M=A+(GY8HR&IK C4OM8\PVA4?[5>A@8G!$^2VD,1#\A?<^GAM#C1@9WZ&S<9
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M78&\V6R@;@"5'/2\/<H.4KP836(65UY$_L(3HSFP40?OY+ZZ^-SZP=OR2;S
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M.M![3PM/\HO/7LB"CYY%@N,#F'\N%EDDCP=O0&&: JK\)> 0?\+\!44J)*-
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M.KIU[ G<'X9T5#9A;TB[4<#/#=J**YB*6T'TX?;+2H[.PUNV6^'IO:V N9F
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M2C!O Z8LB&L(H1J=+HY.S;\EWO/QTD7^ >R:%"Q2?4IV>A_(^FA(9"?VC.>
M>F4BJIPR<G7KV'>;0\+UEC5EN?92(U/7H89MP<;^U]F9]L'S0M<+F7;#^/SU
MLS/<LV.[/U[/Q'<?X1_:3_HH!+C^]@+V"!>135^(3WW/@4_OPW#Q^H\_'A\?
MSW_>^LZYY]_]878ZW3_PZS_PP1?XZC_6WDV?XD_LU_A_X9__'U!+ P04
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M4!WGM"1SY2J'_,<=YOKT+<1&6N,ZM$X/TQB2- %V2+8TJ+1-OV:50WQ_T0?
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MF,@3UAY.GV:R3E2-H-V9M<K/\=9=V%@ ^2W'9#MY'.OC]]_]#U!+ P04
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MV>G!? 10[+HY:-&<.VR;4_54[BI^IM4S@_%+3-/L,7RZ8?L[^[<W5<%1QF/
MX,0MU*-:)@WY1+-F?@GC)"WSWU4OE03TGLV9M5<HF$S'#4:!R31G3<L-.<4S
ME;?S[)[Z?C$KRL5L47%#B5KH.L.DH+.F5C,&\;@,M\VP>D^Z?&9X0:O_-YBQ
MX@%@DL\YFZQR)J%]; WKX^W[&,"HR.??PX#>TF<:%_2+]W])>EYD>3*CJ8G;
MS7 $4._;#HUG\PTJ2P3BB:>'C:=WE6,H,_?%M1X=P#-GKBVM@ZX+V_UVUZT*
M7C&B2WEI(#IQ!U1NN$[:%)N*E&LT1^1="K4XD*P+M#-.+FQ3Y>!SOUE5#Q*D
MSIZ>]N!\^UKP8Q@M<G9JB<IJC-F,LG^HO47J7J N.975"[ =+2?N1+_\U&])
M$LB+Q<B:@OKE&@I93#Z>ZW5YQ5B</RZC<!;&ZIHF1OU Z_B8*\B4%SS7Y],L
MH\HLLU4#V*<170_A-0]X9LF"$W6 6M4$UN_25?9K7."Q^J;)<$!+^735P 8?
M#LM7E?F1OK&ARDXT.)UQT";3NKO4W6!CYEL+WY0U&X4?I$>BE%U V7<O?_ X
M?'FJL9V&D)X) Y$)#T4"%M!<S$JFOB9Q\D09C64V/)_9SX)6Q1*D[@CI:6BL
M)G.6\&S2;52F8 W.@]!:6TIN-/OYOEP%R21;N0J\VE7PM' 5!)6K(*]<)?MV
M&%3/FZX89S]H<)^4Z967B>%,W 5&_0&<!2JZ=*X ;5\ H-]4SK)5S8"E?H/X
M2@[UZ<Q,NB, ^(WTV,($$"8UT]&KQ8[-!H &^DW5TDZI^)P >U,K$@?!?O2+
M+\3W]:3[,I]C8AV^)?#JYX;YEI@+T<N4M\1<.+:SM\1<@G9OB;GL1(?PL.RT
MJG<09G^<S<]H[#_.O/0/?3R6LJL;#]6^]B$#[O!XKG:)79)J$NNC[.K(R]4D
M)$NK!U,-[G"&>!I:5""23<RE)O%M:7=>1.4A1X)6L"Y-D\DB.;!OLH!& 8OG
M =DM]6GXS!=[_4-721<8SV=WU:CXL7&/DKJ8MPC^6O"OCB=U&+3D9-&@MR,O
MI^O314,.'<9EZ(F0[CR-^KMR<&H/$$U%W4I1*QY=!K'N35/ )X7]JFP/H=_C
MF"Z_JXX^WFE(!A#@:W.K%ZA R(L[&=]1/XD#,S&+VI(!1)BW%4G+V,&#D=IZ
MY#6 S\#4#4N0,&4CT _?,Z$!<+HEA;Q-%;3B!,V%QJZ&\( "UE35U[=< \A0
M?J7I"_8</2]HGW,-( /VF\I9P@">K7T)+GQ-<II=)U[,JR%_#F,O]L-XNH(<
MLK,YVS39&86G;SCG76CZ5*:'TL>'6?L&&3H!U_9U@+ JAZ4)=:FA;NM1H(A6
M[:ZFZD:&;J Z\Y*65E4E-@>= - <6=PH&,G1!8&F]P1AI#0(\W,O#6[2Q*=9
MEJ2:W5?9B0PA'J@8SQT)HJ%DQYWX[U^2YN)7=B)#B!<G7<2O9<>A+\,L\91A
M#L]6@Y$AUC#,:\U#Q];L.M3G=LJS6R\7/4J1MB5#,+2PO3@%NI'QANCH\$QC
M-O;\^NKS^)9F-'U6O1X2-2=#B/P05G6E8P_/=; , [@(LZ7'.2_2\D!T&D7)
M"SL2T:R\R>IB(?0CD"%$W)\3K3;@&$^LV2EC-@BC(@^?Z1WU"[:*,*8O?_A1
M$=#@,Y,8CXHL\A+H&$^6&4-O:%J6>ZM>F:KN_#;&)T,(3,V)D5B3AXU@ D?1
M;JODP .%9:BZD2$$N.=$X3HV\?B,FJ2K&8$E+[>MGW66\&!IN[%>7ZERF16U
M)R.P%!_6ETT9?TN5G3CP#B4QF[PYXSDJ,R-41^L+FOEI6'Y$ZB#2=20CL*0>
M5J\=1HPN-?03^*0J#VBMS[+R ]T(+.F'DR.LDM&E-G\&U^;O7AKRA6!I=E4:
M)[[=1@6'?.^3E9-.===L- X9@05RV=9U8[Z7JO^$5_5+<H-S+TWG3"S5>5F;
M +'=@&34>_2HNP!6F$7OS.*:M0ZC\@)FT3;61B6C5P-9=91";27PT):8DU.?
MW<C9_\]H_D)I_/O5)=O_JC\9W(M:CTE&KP;^ZB2#VC[@$;'&?(PWDZ>-4TW.
M43L?(*-7@XG9$TAM1@Z>V+#+CK][V<G,[H.:GF34>[RK :>UEN QK\J [KT?
MES^\90;OZ_ /&H6/[,8SGGR+)]YSDG+KO*-Y7F5M4SJN6HQ'CEX-FM::_]HF
M)-B;\T239=S/C3?GI"TJ3^T[C^0%?<BO8B;C@DOEVB!SI*0'0*[(34ITV2$%
MK0'R0<JE)[%N,=G]SOEX'GE9-IX((MUX0-MX<I:D:?)"4]U+GP;#(,@!*=&D
MQ(73C#<T01>F=.L?GC0:"#H;9%-U=5,ZONR08&I'$LD+H_\]!.^>)[,96^)"
M+[KFIQO-ZUAQ:]A24XWGE.".(>4+S02\#W->/O J#M@%-N '9_7>*6R/(.]C
MHTU2Q@2>F+8="K^'^6-9X9[1PXM:WR<5O*!=&!N.!)T54JH:0TUJN<,[\_:G
M8B2;GVM=XTO--9Y,0E^Q&0K;@6:;;#'!Q-K;9@F-3LZ][)&_)F;_XX\+GKW(
M( VRO!."W)/-+HPJ3O#$_MY2QD_HE[X[$<'BWVHG6I=AP?-3*C4GUG9'?M%,
M6I3F@&1;W;]=X-MH5Q>O&^_)8,,5MH?-B]EUJDJ6>QFC^X "RD^.8WDZ3&5[
MV%R8=M6A9=1IDLR-S]Z_)(WT4;>'*?>W/WUL,(KG)'17/&3TSX*GY.<O\PQR
MF4AZ.,J/Z>ZHJN #SPLC 9':"[RTCZM<C.9%.A0B-U;2BA<TYP/;6D)R]+.K
M+GS'NBUJ]4G.1>UATFZ:S0\C)>VFVX17S&.2YO<TG?$%W61+$K7'D&NSV88D
MXP+/0\D=$O7+G+@'>&I-N; -E8,PL:9-[6#9@JRI:1])-=<"Z32)-'=:PB;/
M5%FWX&HC)A_//'!2C=!-UDV'VXF.&SQOONT4N7.3&M-6"<*!%$23<H-F0MG2
M#Y9-Q;*B\-UL./:4Q&7)6".P>J.MJ]2C70H2RC-+"LE'HXAV!2%!$TLV5< .
MZ0[!YO6#AV&N0D47V R2QC'X)FS@B34K\UK2(.,)G=:)5AB_K M,QD@C<8NG
M@HH1-$O2IMVMYTTL]\5@E:5)H3+S00 33;938C/6\$R\3;J_>#G/L#:_4*<
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MVZ:4?0$S!K;7I)8C71:X+HO=FHN\@G*J"WWY[IKR0G2SD!>BFW/V9&MADS$
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M1#?([R;L0$;]!%7T7-6Z0H"5]*9NXZCGV(P],=3FXP#4*2_-ZJUPK0D9]1C
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M[#T'8KRC28L7=+=79\:R\8#T# HC=RXNCW0^E,NC0$@M7KZY/"Z(Z!HF@_A
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MRU,RZ7RP6R@Y0L.<RWHHXF-]M"JZ#5)?.ZEW!X[-W"^8I("@+80*10/.\_4
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MVR'D!7_?[I0BK <(;H0-4)9TH:PFT4>6?-J?"E15P/ UA==X@\W,E^'N>L+
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MC**L7A%VL/$DPJ 2;WE@02'; +UX+LX_7-W@ N=/UB\#A3#@0]I"Q!1=>>A
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M'98?<$36G]#6SSMZ1]@;;&M$I_@DM+6=AFR#-AQ-*?76*^3=9?N05XC5[V'
M40/]<-*J+LCNU7W\/)1K"Y/3K&8:S\Z!=,GLK&_C&TPG:LMI)/$=WA%]^/?
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MX).-FV[QX/$L,3,9Q:.$G+2<&/R*BS).'VR*?G>G0+TGZB_[D&&JO_I65UM
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M\J\13YS6R=BP)@W/9 ,(=!K2XFOPRY;;R)C>KEL(V$P!9H=72A;@O LZ:Y\
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M"OWQ5_(S^0\M"TO^\/\#4$L#!!0    ( ,R&YTJ?+S9J_SP  !MA!  5
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M4>[K?"Q4M](<MV3(29P@[_TR>OG@(TQ(/3FE?Z'S/WWW<;+U<_X+^<DIOOR
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MFAG;3,V[^?-<W>)>P$=!(1<8_F\IF!%$&E$=@Y(DG_8U$IY;FDV!7TYJ<%.
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M4UG.(TYXT^Z1%B7 /L%33IY9CCAY0(1 Y *.MN:]8BD]("]:%B<M87C8468
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MCHM.%:2B"N!U@<Y(T!OSFR"AW2V<IW.[YWU46LMB%N0RM7LCQ7O-)NL'G1_
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MY&AAUN,P<#?=_&0NYAJC*7#PE2:KV #&$'R5&P^38K>X"O :ASE)I)$:PG[
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MB?O+@@4H <K;7\Y *WF_H!= !O_].UL:&53PG,RMJ*I&U'VE I8"MA:C 5<
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ME)5S23:1>D,'T&C+(AO74-*8M-WI^/-2652KQF3Y[E,=).>;ZK](ZG2H#^(
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M8:_C0.G-SLVT=WZ@DWLB.HS\S_\'4$L! A0#%     @ S(;G2I .-\[ O
M \D( !$              ( !     &EM;60M,C Q-S S,S$N>&UL4$L! A0#
M%     @ S(;G2O#MXCD[#@  J)$  !$              ( ![[P  &EM;60M
M,C Q-S S,S$N>'-D4$L! A0#%     @ S(;G2K*@5F^/"   =FL  !4
M         ( !6<L  &EM;60M,C Q-S S,S%?8V%L+GAM;%!+ 0(4 Q0    (
M ,R&YTI^[Z0(ZRL   ,$ P 5              "  1O4  !I;6UD+3(P,3<P
M,S,Q7V1E9BYX;6Q02P$"% ,4    " #,AN=*JL^7J,5C  "6" 8 %0
M        @ $Y  $ :6UM9"TR,#$W,#,S,5]L86(N>&UL4$L! A0#%     @
MS(;G2I\O-FK_/   &V$$ !4              ( !,60! &EM;60M,C Q-S S
@,S%?<')E+GAM;%!+!08     !@ & (H!  !CH0$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
